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Abstract

Molecular imaging is a non-invasive way to diagnose disease. Molecular imaging
probes consist of a targeting entity that has a high affinity for a biological target
and a signaling source for external detection. Multimodality imaging combines the
advantages of different imaging modalities, at the same time eliminating their
shortcomings, thereby providing more accurate results. This thesis focuses on
the development of novel dual PET/fluorescence imaging agents based on
peptides as targeting entities.
Porphyrins are suitable for multimodality imaging applications due to their innate
characteristics such as an ability to fluoresce and to coordinate metals. A galliumprotoporphyrin IX(PPIX)-ghrelin based analogue was designed as a potential
dual PET/fluorescence imaging probe for detection of growth hormone
secretagogue receptor 1a (GHS-R1a) and it was found that fluorescence was not
quenched upon coordination to Ga. The PPIX-ghrelin analogue was also
successfully radiolabeled with 68Ga. The specific uptake of this analogue by the
receptor target, GHS-R1a, was demonstrated through confocal fluorescence
microscopy using OVCAR-8 cells transfected with GHS-R1a. Thus, these dual
modality probes can aid in bridging the gap and extend research from in vitro
fluorescence imaging to in vivo PET imaging.

69/71Ga-hematoporphyrin-bombesin

analogues were synthesized as potential PET/fluorescence imaging probes for
the gastrin releasing peptide receptor (GRP-R), but the reaction yields were low
and all the components of the hematoporphyrin-bombesin mixture could not be
coordinated with gallium and this mixture of coordinated and the uncoordinated
analogues could not be analyzed by optical methods. Nonetheless, the ability of
hematoporphyrin to act as a chelator for Ga and to couple to peptides was
demonstrated.
BODIPY dyes are widely used for fluorescence imaging but suffer from
drawbacks such as complicated synthesis and small Stokes shifts. However,
i

novel BF2-formazanate dyes have favourable properties such as convenient
synthesis and optical properties that can be tuned by modifying the structure.
BF2-formazanate- peptide based analogues were developed as fluorescence
imaging agents for GHS-R1a and GRP-R. Use of a modified ghrelin sequence
led to an improvement in the IC50 value. Specific uptake of the probes could be
visualized through fluorescence microscopy.

Keywords
Optical imaging, positron emission tomography, protoporphyrin,
hematoporphyrin, GHS-R1a, GRP-R, BF2-formazanate
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Chapter 1

1 Introduction

1.1 Molecular Imaging
There has been a tremendous growth in the field of medical imaging over the
past few decades. The main goal of medical imaging is the construction of a
visual account of the body’s interior for clinical evaluation. Structural or
conventional imaging involves the detection of anatomical abnormalities, while on
the other hand, functional imaging reveals the physiological activities within a
tissue.
Molecular imaging, which is defined as the visualization, characterization and
quantification of biological processes at cellular and subcellular levels1, unveils
the clinical biology of the disease process and plays a significant role in the early
assessment and analysis of the disease.2 Molecular imaging also helps in
diagnosing, staging, evaluating therapeutic targets, providing personalized
patient care and monitoring therapy. Molecular imaging can be used for patient
stratification into those with the probability to respond and others who will not
respond to therapy. These kind of personalized treatment plans will not only lead
to improved patient outcome but will also result in the judicious use of the
resources, hence the cost of health care can be controlled.3 Perhaps the most
impressive feature of molecular imaging is that it is non-invasive and does not
involve the use of more invasive procedures such as surgery or biopsy.
Moreover, the biological processes can be examined with good temporal and
spatial resolution.4 The role of molecular imaging has become more significant
since the development of imaging instrumentation that is capable of higher
resolution.
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In particular, molecular imaging has become a vital component of cancer care
since it leads to the early detection and determination of the precise location of a
tumour before the appearance of the symptoms and before the other diagnostic
methods can detect abnormalities.4 The extent to which the disease has spread
to other organs of the body can also be determined. The most effective therapy
can be determined depending upon the molecular characteristics of the tumour
and the individual traits of the patient. Molecular imaging can help in monitoring
the progression of the disease as well as diagnosing the recurrence of cancer.5

1.2 Imaging Modalities
The choice of the imaging modality is governed by the kind of application that is
desired and the nature of the imaging probe that is available. For example,
certain imaging modalities such as magnetic resonance imaging (MRI) and
computed tomography (CT) provide anatomical information but do not provide
functional information. Due to the small size of the early lymph nodes, they may
not be characterized by CT. Nuclear imaging modalities can provide information
related to the functional or metabolic activity of the tissues leading to the early
detection of the disease. Nuclear medicine imaging employs a tiny quantity of
radioactive substance, which is administered to the subject. Special cameras are
utilized to detect the gamma radiation that is emitted by the radioisotope and
computer created images provide accurate illustration of the region being
scanned.6
The two most widely used nuclear medicine imaging modalities are positron
emission tomography (PET) and Single photon emission tomography (SPECT).
PET is a technique in which the detector identifies pairs of gamma rays that are
emitted indirectly from a positron emitting radioisotope.7 Receptor targeted PET
imaging is directed towards imaging the molecular markers that are
overexpressed in various types of cancers and therefore is a useful way for
imaging cancer. PET imaging is discussed in detail in section 1.4. Another related
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imaging modality is SPECT. Here, a gamma emitting radionuclide is introduced
into the body and the SPECT scanner detects the gamma ray emission. The
detector rotates and collects multiple two-dimensional images at several angles
around the patient.7 This way three dimensional images of the accumulation of
the radiotracer are obtained. PET involves the detection of pairs of oppositely
emitted photons in coincidence whereas in SPECT, the emitted photons are
unidirectional, causing the determination of the exact region of emission of the
gamma rays to be a more difficult task and therefore, leading to lower resolution
and decreased sensitivity.7 The most commonly used radionuclide for SPECT is
99mTc,

which is a generator produced radioisotope with a half life of 6 hours,

which is optimal duration allowing for radiosynthesis and acquisition of images.
Other radioisotopes used for SPECT imaging are 111In8 and 67Ga.9
Another widely used imaging modality is MRI and is based on nuclear magnetic
resonance. The hydrogen atoms from the water present in the body, when
exposed to the external magnetic field, become aligned. The scanner produces
radiofrequency pulses, creating a variable magnetic field. The absorption of
energy by the protons flips their spin. On removing the variable magnetic field,
the protons return to their normal spins through relaxation.10 This produces a
radio signal which can be detected and an image can be created. The rate at
which the protons return to the normal state varies for the different tissues in the
body. Therefore, contrast can be generated among the different tissues
depending on the relaxation characteristics of the protons in that tissue. MRI aids
in visualization of the anatomical and functional aspects of the cancer tissues
with high resolution. The contrast agents typically utilized for MRI can either
produce negative image contrast or positive image contrast. Gadolinium (Gd)
based contrast agents produce T1- weighted tumour images. On the other hand
superparamagnetic nanoparticles provide T2- weighted contrast images.11
Recently the application of MRI for the detection of breast cancer micro
metastases was demonstrated using a peptide-Gd-DOTA (1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid) based contrast agent.12
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The field of X-ray CT (computed tomography) came into being with the arrival of
digital computers that could reconstruct objects from projections. Since then, it
has come a long way owing to the use of numerous parallel detectors that aid in
three-dimensional scanning of large regions in shortened time durations.13
Tomographic images of certain areas of the scanned object are created by
obtaining X-ray images from various angles. A computer processed combination
of these X-ray images produces a CT scan.13 Recently the use of CT in the field
of nuclear medicine imaging has increased as it is being used in combination with
PET or SPECT. In fact, there are quite a few similarities between the concepts,
such as image reconstruction from projections, that form the basis of both CT and
PET or SPECT.
Optical imaging is yet another commonly used imaging modality. It makes use of
light to derive the information regarding the cellular and molecular processes in
the living system. Fluorescence imaging employs certain fluorophores which
upon being excited by the light sources e.g. lasers, fluoresce to release light of
higher wavelength. A wide variety of fluorophores such as quantum dots 14 and
dyes like cyanine15, fluorescein16, IR-78017 and have been analysed for
applications in optical imaging with promising results.
The different imaging modalities have their own strengths and weaknesses.
Some modalities such as MRI provide more anatomical information than other
modalities. Some imaging modalities have a high sensitivity and low resolution
e.g. PET and some modalities such as MRI on the other hand have low
sensitivity but higher resolution.18 Therefore, combining two or more modalities
through multimodality imaging can provide more accurate results. Multimodality
imaging is discussed in detail later in this chapter. Table 1.1 provides a
comparison between the various imaging modalities.
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Imaging Modality

Sensitivity

Resolution

Nuclear (PET)

10-15M

1-2 mm

MRI

10-9M-10-6M

25-100 µm

CT

10-6M

50-200 µm

Optical (in vitro)

10-12M

Sub-µm

Table 1.1 Comparison between different imaging modalities.18

1.3 Imaging Probes
The characteristics of an imaging probe greatly influence the outcome of the
imaging analysis. The imaging probe is an agent that aids in visualizing,
characterizing, and quantifying the biological processes taking place within a
living system.19 The imaging probe may be injected into the blood stream,
inhaled, or swallowed by the patient followed by an external detection which can
help in the diagnosis of the disease, monitoring the progression of the disease as
well as following the response to therapy. An imaging probe that is not specific
and selective for the biological target is not very effective as it will also be taken
up by other tissues and hence there will be a poor contrast between the diseased
and the healthy tissue, invalidating the results obtained from the imaging study.
Therefore, an optimal imaging probe should have high affinity and high specificity
for the biological target, as well as have good in vivo stability, an optimal rate of
clearance from the body and possess minimal potential toxicity.20 A targeted
imaging probe is composed of a signaling source, a targeting entity and often but
not always, a linker joining the signaling source and the targeting entity. The
signaling source is responsible for the generation of the signal for imaging. The
characteristics of the ‘label’ decide the applicability of the imaging probe for the
imaging modality e.g. fluorescent molecules are required as a ‘label’ for optical
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imaging, positron emitting radioisotopes for PET, gamma emitting radioisotope
for SPECT and magnetic molecules are desired as ‘labels’ for application in
MRI.19 The targeting entity, as the name suggests is accountable for binding to
the biological target. The biological target could be a receptor that is
overexpressed in some type of cancer. The targeting entity can be a small
molecule, peptide, protein, or an antibody. The linker not only connects the
signaling source and the targeting entity but also helps in improving the
pharmacokinetics of the imaging probe depending on the hydrophilic or
hydrophobic characteristics of the linker. The linker may also help to increase the
distance between the targeting entity and the signaling source such that the
presence of the signaling source does not affect the affinity of the targeting entity
for the biological target. The linker can be comprised of a polyethylene glycol
chain or poly amino acids, as examples. The main criteria to be considered while
choosing a linker are the length of the linker, the presence of any charges, the
hydrophilicity and the flexibility associated with the linker.19

Figure 1.1 General design of the imaging probe.

Before advancing with the development of the imaging probe, it is essential to
recognize a relevant target related to the biological process under investigation.20
The identification of suitable targets has become more straightforward owing to
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the increasing availability of a variety of biological data mining tools. Moreover,
the location and the distribution of the biological target can also be analyzed.
Despite all the recent developments in the field of molecular imaging, there
remain many aspects related to the imaging probe development that require
improvement. It is sometimes seen that the imaging probe shows good binding
for the receptor in vitro but the results from in vivo analysis are not very
promising. One of the main hurdles is the arduous process of developing an ideal
imaging probe with excellent affinity for the biological target and having the least
possible non-specific uptake.21 All this has led to a constant need for the
development of novel biomarkers appropriate for cancer imaging as well as for
the advancement of chemistry and biology techniques for the design of imaging
probes with improved pharmacokinetics.5 The development of more advanced
instruments will also help in contributing towards improved spatial and temporal
resolution.
The two imaging modalities that form the basis of this thesis are PET and optical
imaging and are discussed in detail below.

1.4 PET Imaging
PET is a non-invasive technique that facilitates the evaluation of the functional
and metabolic processes in tissues, typically much before the structural or
anatomical changes can be detected. Initially PET was used only for research but
gradually it made its way into clinics and hospitals notably in the field of oncology
for diagnosis, cancer staging, and monitoring response to treatment.22
PET requires the use of a positron emitting radioisotope that decays by emitting a
positron, which is the antimatter of an electron and has the same mass as an
electron but possesses a positive charge. After emission, the positron travels
through the surrounding tissue until it collides with a nearby electron. This
distance that the positron travels is known as the positron range. 7 The positron
range travelled depends on the energy of the emitted positron and is unique for
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every radioisotope. The greater the positron energy, the longer the distance
travelled before annihilation with the electron, causing a larger loss in spatial
resolution.23 The annihilation process generates two 511 keV gamma rays
approximately 1800 from each other. The simultaneous detection of these pairs of
gamma rays by an array of surrounding detectors aids in determining the location
of the annihilation.7 Figure 1.2 depicts a pictorial representation of the annihilation
process. Despite the fact that it is hard to determine the precise location of
annihilation, acquiring multiple coincidence events along all the lines affords
sufficient information to reconstruct various events which have been recorded
into an image and hence giving adequate information about the spatial
distribution of radioactivity.23

Figure 1.2 Pictorial representation of an annihilation event. Positron upon
annihilation with electron, emits two gamma rays at 1800. The array of
surrounding detectors detects the pairs of gamma rays.
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1.4.1 Radioisotopes for PET
1.4.1.1 Fluorine-18
There are several positron emitting radioisotopes e.g. carbon-11, nitrogen-13,
fluorine-18, copper-64, gallium-68 and iodine-124 etc. that have been utilized to
label diagnostically relevant compounds. Table 1.2 depicts some of the
commonly used PET radionuclides.

Radionuclide

Half life

Method of production

F-18

109.7 minutes

Cyclotron 18O(p,n)18F

Ga-68

68 minutes

68Ge/68Ga

Cu-64

12.7 hours

Cyclotron 64Ni(p,n)64Cu

C-11

20.4 minutes

Cyclotron 14N(p,ɑ)11C

Y-86

14.7 minutes

Cyclotron 86Sr(p,n)86Y

Zr-89

3.27 days

Cyclotron 89Y(p,n)89Zr

generator

Table 1.2 Radionuclides commonly used in PET, their half life and method of
production.23,24

Among all the radioisotopes employed for PET,

18F

is most commonly used,

essentially due to the role of 2-deoxy-2’-fluoro-D-glucose (18F-FDG) as a
successful commercial radiopharmaceutical for cancer imaging. There is an
increased uptake of FDG by the tumour due to the increased metabolism of
glucose by tumour cells.23 Although it has been approved by the FDA and is
considered the gold standard in PET imaging,

18F-FDG

also has uptake in

regions of high natural glucose metabolism such as the kidneys and the brain.
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This has led to the need for the development of novel targeted PET radiotracers
that will have high specificity for the biological target and will not be taken up by
the healthy tissue. 18F possesses some of the most appropriate physical
properties for applications as a PET radionuclide. It has high positron decay ratio
(97%), low positron energy, half-life of 110 minutes that provides sufficient time
for more complicated radiosynthesis, lengthy in vivo evaluation and easy
transportation to clinical centers that do not have radiochemistry facilities. 25 18F is
synthesized in a cyclotron where oxygen-18 enriched water is used as a target.
The hydride ions produced in the ion chamber are passed through an electron
stripper and form protons, which are then bombarded onto the target to convert
18O

to 18F.26

In spite of being a strong nucleophile, fluoride ion undergoes hydrogen bond
formation with the surrounding water and the nucleophilicity is hampered. The
nucleophilicity can be improved by employing a phase transfer catalyst such as
Kryptofix222 or tetrabutylammonium bicarbonate.26
The tremendous increase in the demand of

18F

based PET imaging probes

emphasizes the necessity of straightforward and effective

18F

labeling

procedures.

1.4.1.1.1 Methods for 18F Labeling
Nucleophilic Substitution
The positron emitter 18F has been introduced into many molecules through
nucleophilic substitution reactions. To carry out aliphatic nucleophilic fluorination,
the leaving group in the precursor undergoes SN2 substitution with 18F-fluoride.
The selection of an appropriate leaving group is important for the success of such
reactions. The commonly employed leaving groups are tosylate,27 sulfonate28,
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triflate29 and mesylate.30 Nucleophilic aliphatic fluorination reactions usually result
in decent radiochemical yields, require mild reaction conditions such as moderate
reaction temperature and shorter reaction duration. A variety of PET
radiopharmaceuticals used in clinics including 18F-FDG, 18F-choline31 are
synthesized using this methodology.
The presence of an electron withdrawing group, such as NO2 or CN positioned
ortho or para relative to the leaving group, activates the phenyl ring and makes it
able to undergo aromatic nucleophilic substitution reactions with F-.26 Usually
these reactions require heating at higher temperatures which limits their
application in the case of more sensitive molecules such as peptides and
proteins. The frequently employed leaving groups for such type of reactions are
nitro32 and trimethyl-ammonium.33 Several 18F PET radiotracers have been
reported to be synthesized using this methodology, e.g.

18F-fluorodopamine34

and

18F-altanserin35.

Isotope exchange reactions involving the exchange of

18F

with 19F, can also be

carried out using nucleophilic substitution reactions.36,37 However, it is difficult to
separate 18F labeled compound from the 19F precursor, therefore isotope
exchange reactions typically result in low specific activity (activity per quantity of
molecule).
Boron can also act as a fluoride binding site for labeling of biomolecules. This
approach involves the reaction of aryl boronic ester with nucleophilic

18F

and

potassium hydrogen fluoride (KHF2) resulting in the formation of [18F]organotrifluoroborates.25 This approach involves just a single radiochemistry step
and the step involving the azeotropic drying of 18F-fluoride can be eliminated
since this reaction is carried out under partial aqueous conditions. Using this
strategy, a biotinylated 18F-aminophenyltrifluoroborate was synthesized.38 Aryl
hydroxyl or alkoxy silanes react with 18F-fluoride leading to the formation of
triorganofluorosilane.
Nucleophilic substitution reactions are used for most of the reported 18F labeling
procedures.
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Electrophilic Fluorination
For the generation of the electrophilic 18F-F2, the addition of 19F-F2 is required to
extract 18F-F2 from the target.39 This leads to a lower specific activity and
decreases the yield of production from the cyclotron.26 High yield of production
from the cyclotron and high specific activity are critical factors for PET imaging.
Therefore, most methods of
18F-fluoride

18F

labeling in nuclear medicine focus on the use of

using nucleophilic substitution reactions. Several improved

methodologies have been utilized to achieve a higher specific activity using
electrophilic fluorination and there are many reports depicting synthesis of
compounds through electrophilic radiofluorination.40,41 Recently, 18F-labeled
derivatives of resazurin were synthesized as potential PET imaging probes using
this methodology.42

Direct Labeling of Biomolecules
In the direct labeling method, the molecule is reacted directly with

18F-fluoride

(Figure 1.3). The molecule may be altered previously in order to be made suitable
for the radiolabeling procedure.43 There are a few reports of introduction of 18F
directly to peptides. One of the drawbacks of this technique is that it is quite
challenging to label directly without effecting the functional groups on the side
chains of the peptides. Direct 18F labeling of monomeric and dimeric cyclic RGD
peptides modified with 4-NO2-3-CF3 arenes was reported, demonstrating one
step radiofluorination of a peptide with good yield, and high specific activity.44 The
labeled peptides were evaluated in vitro and in vivo for specific binding to
integrins. One step 18F fluorination was also achieved for a bombesin peptide
modified with tetramethylammonium leaving group under mild radiolabeling
conditions.45 In another report Al18F was coordinated to a chelator 1,4,7triazacyclononane-1,4,7-trisacetic acid (NOTA), bound to a bombesin peptide in a
one pot synthesis.46
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Figure 1.3 Schematic for the direct labeling approach for 18F labeling.

Indirect Labeling of Biomolecules
The indirect labeling method is often referred to as the prosthetic group approach
for radiofluorination (Figure 1.4). A prosthetic group is a small molecule that can
be radiolabeled with ease and is subsequently attached to the more sensitive
biomolecule (such as a targeting peptide) using mild reaction conditions. The
synthetic methodologies that are commonly used to conjugate the prosthetic
group to the peptide include acylation, alkylation or amidation reactions. 43
Synthesis of 18F-labeled prosthetic group is usually carried out in 2-3 steps,
followed by the purification steps. To obtain a high radiochemical yield, the focus
should be on using synthetic steps that are less time consuming and high
yielding.43 The selection of an appropriate prosthetic group is essential for the
development of 18F labeled biomolecules. Several prosthetic groups have been
established using nucleophilic approaches. The development of 3-18Ffluoropropanesulfonyl chloride as prosthetic group for radiofluorination of amines
has been reported.47 Recently, novel thiol reactive, fluorobenzaldehyde-O-[6-(2,5-
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dioxo-pyrrol-1-yl)-hexyl]oxime (FBAM) prosthetic group was developed for
conjugation to small peptides and other biomolecules.48

Figure 1.4 Schematic for the prosthetic group approach for 18F labeling.

Bioorthogonal Approach / Click Chemistry
Bioorthogonal reactions refer to the chemical reactions that can occur inside the
living systems without interacting with the biological system.43 These reactions
are very selective and can be performed in biological media. Therefore, several
bioorthogonal reaction approaches have been utilized to introduce

18F

into

biomolecules. One such approach makes use of azide-alkyne click chemistry.
The orthogonal nature of these reactions prevents the need for protecting the
other functional groups. This strategy involves the development of

18F-labeled

small molecules having azide or alkyne functional groups and clicking them onto
peptides or other biomolecules containing the analogous reactive component.43
Several examples utilizing this approach are seen in the literature e.g.

18F-fluoro-

N-methyl-N-propargyl benzene sulphonamide was developed as a novel click
chemistry building block for labeling of peptides, protein and oligonucleotides. 49

15

More recently, the scientific community has become more interested in the
development of approaches that do not involve the use of toxic copper in
biological systems. This has led to the rise in the application of strain promoted
azide alkyne cycloaddition reactions (SPAAC). The bent geometry of triple bond
of the eight-membered ring in cyclooctyne, causes the activation barrier to
decrease resulting in fast reaction rates.50 SPAAC reactions have been utilized to
convert azide acceptors such as azadibenzocyclooctyne (ADIBO) into
azadibenzocyclooctatriazoles (ADIBOT). Recently, RGD-PEG-ADIBOT-18F
analogues were synthesized and high tumour uptake was demonstrated in
U87MG tumour bearing mice.51 This methodology holds potential for 18F labeling
of biomolecules for clinical applications.

1.4.1.2 Gallium-68
Another commonly used radioisotope for PET imaging is

68Ga.

It is a generator

eluted radioisotope with a half-life of 68 minutes. It decays into the stable

68Zn

through 89% positron emission.52 The parent isotope 68Ge has a half-life of 271
days, permitting the use of a 68Ge/68Ga generator for up to one year. This
eliminated the requirement of having a cyclotron on site for isotope production,
making 68Ga a convenient and economical PET isotope. 68Ge/68Ga generators
employ an inorganic matrix such as TiO2 or SnO2 to immobilize 68Ge, which
decays into 68Ga (+3) and is eluted with a mobile phase such as dilute HCl.53 The
energy associated with the positron emitted from

68Ga

is more than that from 18F,

which can result in a lower resolution.
Over the last few years, several bifunctional chelating agents (BFC) have been
developed to coordinate radiometals such as 68Ga. Chelating agents contain
atoms such as N, O, S that can form bonds with metal ions by donating lone pair
of electrons. Bifunctional chelators can coordinate to the radiometal, at the same
time possess functional groups that are suitable for the attachment of a
biomolecule e.g. peptide. Several factors affect the stability of the metal-chelator
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complex such as size of the cavity of the chelator and the ionic radius of the
radiometal, number of donor atoms provided by the chelator, the coordination
geometry preference of the radiometal.54 Figure 1.5 depicts some of the
bifunctional chelators commonly used for 68Ga coordination. Target specific 68Ga
PET agents are developed using this bifunctional chelating approach.52 A
bifunctional chelator on one end is attached to a targeting entity that has a high
affinity for the receptor leading to the accumulation in the target tissue. And on
the other end, it forms a complex with the radiometal, leading to stabilization of
the radiometal in vivo.

Figure 1.5 Chelators commonly used for 68Ga coordination.
A lot of attention has been given to the development of

68Ga

based

radiopharmaceuticals targeting the somatostatin receptor. Lately, peptide
conjugates based on 68Ga-DOTA-TOC((D)-Phe1-Thy3-octreotide),55 68Ga-DOTANOC(Nal3-octreotide),56 68Ga-DOTA-TATE(Tyr3-octreotide)57 have shown
potential as efficient PET imaging agents for this receptor target. More recently,
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68Ga-NOTA-bombesin

was evaluated for PET imaging of prostate cancer.58 68Ga-

DOTA-trastuzumab has also been evaluated as a PET imaging agent for
targeting the human epidermal growth factor.59
68Ge/68Ga

68Ga

is easily available through

generators, therefore is a highly desired PET isotope. But there is a

need of developing novel chelators that will permit the use of a variety of
biomolecules and receptor analogues.

1.5 Optical Imaging
Optical imaging is an economical, sensitive, fast, and proficient technique for the
non-invasive detection of cancer. It makes use of light to investigate the cellular
and molecular changes associated with the tumour. The lower limits of detection
for optical imaging probes are expected to extend to picomolar or femtomolar
concentrations in the near future.60 For in vivo optical imaging, when the
excitation light penetrates the tissue, it undergoes scattering. The degree of
scattering for biological tissues varies inversely with the wavelength such that the
degree of scattering is greater when the excitation light is in the UV and visible
range. Furthermore, the absorption of light by biological molecules such as
hemoglobin, melanins and flavins is also greater in the visible region. 61 These
biological molecules dissipate the excitation photons as heat and reduce the
emission signal intensity of a fluorophore significantly.62 Tissue autofluorescence
is another limiting factor, with several biological tissues such as NADH
(nicotineamide adenine dinucleotide) and flavins causing background tissue
autofluorescence.61
To overcome these challenges and to be able to image at greater depths, light in
the first near infrared region window (NIR-I) with emission ranging between 650900 nm is being employed. At these wavelengths, the absorption by hemoglobin,
lipids and water is very low.63 Tissue scattering and autofluorescence are also
reduced. A targeted optical imaging agent consists of a targeting entity and an
optically active probe.64 The targeting entity plays a crucial role in determining the
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specificity and selectivity of the optical imaging agent. While designing the optical
probe, stability, contrast and toxicity are some of the important criteria to be
considered.

1.5.1 Fluorescence Imaging
Fluorescence imaging involves the application of external light of suitable
wavelength to excite a fluorescent molecule. After absorbing light, the fluorophore
is excited to a higher energy level. The excited molecule relaxes by emitting light
of lower energy and longer wavelength, which is recorded by the detector. The
excited fluorophore may also undergo intersystem crossing to triplet state and
relax through phosphorescence. Figure 1.6 shows a simplified depiction of the
fluorescence process.

Figure 1.6 Simplified depiction of the Jablonski diagram
A number of organic fluorescent dyes such as cyanine,15 porphyrin,65
phthalocyanine,66 and BODIPY67 have been used as fluorophores for
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fluorescence imaging. The choice of the dye as the fluorophore is guided by its
optical properties such as absorption/emission wavelengths, extinction
coefficient, fluorescence quantum yield and Stokes shift.68 Additionally, the ease
of synthesis, stability, resistance to photobleaching and solubility are also
important factors to be considered.
Recently, the focus has shifted to the development of NIR dyes with tumour
targeting properties.69 NIR dyes that have been approved by the FDA are
indocyanine green (ICG) and methylene blue. Their emission range lies in the
first NIR window (NIR-I). There are various examples of the application of ICG for
fluorescence imaging of cancer.69 Analysis of ICG for detecting sentinel lymph
node in breast cancer patients was reported by Chi and coworkers.70 Despite the
fact that the imaging results using NIR-I imaging probes are superior to those
obtained from traditional fluorophores, there is a better improvement in the image
quality obtained from fluorophores emitting in the second NIR window (NIR-II)
(1000-1700nm). More recently, the synthesis and evaluation of NIR-II small
molecule (CH1055) for in vivo imaging and image guided surgery was described
by Antaris and coworkers.71 Other fluorescent probes based on quantum dots14
and nanoparticles72 have also been reported.
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Figure 1.7 a) Fluorescence image using traditional fluorophore © Wiley, b)
Fluorescence image using NIR-I fluorophore © American Association for Cancer
Research, c) and d) comparison between images obtained using NIR-I and NIR-II
fluorophores respectively © Nature Publishing Group. Adapted with permission
from a) ref 73 (Wiley) , b) ref 74 (American Association for Cancer Research), c)
and d) ref 75 (Nature Publishing Group).

1.6 Multimodality Imaging
Cancer is a complicated phenomenon; therefore, a single imaging modality might
not be adequate to comprehend the many processes associated with cancer. The
advantages of various imaging modalities can be combined to achieve a more
exhaustive analysis of physiological and structural events occurring in the tumour
tissue.76 Of all the imaging modalities that are currently available, each has its
own strengths and shortcomings. Researchers always encounter issues such as
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high cost, low resolution, poor sensitivity, and exposure to ionizing radiations,
which need to be mitigated in order to enhance the efficacy of the imaging
technique.25 Multimodality imaging aims at combining two or more imaging
techniques, thereby bringing together their advantages, and at the same time
eliminating the weaknesses associated with each imaging modality
independently. Consequently, more useful data can be acquired than can be
obtained using a single modality.
The preliminary attempts towards achieving multimodality imaging were made by
combining the functional and anatomical data obtained from fusing nuclear
techniques such as PET and SPECT with X-ray CT.77 Since then a lot of
progress has been made in this field. More recently, focus has shifted towards
combining PET and MRI, due to the development of fused PET/MRI scanners.78
Owing to a better soft tissue contrast, multidimensional functional, structural and
morphological information, this is considered superior to PET/CT. PET/MRI
affords exceptional structural, functional and metabolic information that aids in
understanding the pathophysiological processes associated with cancer.79 Some
challenges can emerge while combining PET or SPECT with MRI due to mutual
interference between the two systems e.g. PET and SPECT might interfere with
the magnetic field and the radiofrequency from the MRI system.80 Several
methodologies have been developed to overcome these challenges such as use
of optic fibers,81 APD based detectors82 etc. Dual PET/MRI nanoparticle 89Zrferumoxytol was used for the non-invasive mapping of the lymph nodes by
Thorek and coworkers.83 In another recent study, 67Ga or 64Cu labelled
superparamagnetic iron oxide nanoparticles were analyzed as PET/SPECT-MRI
single probe imaging agents.84
Dual MRI/optical imaging combines the advantages of optical imaging such as
high sensitivity, operational simplicity with high spatial resolution and high soft
tissue contrast from MRI.77 Further both the techniques do not employ harmful
ionizing radiations as is the case with PET and SPECT. Anatomical and
physiological information from deep lying tissues can be obtained using MRI/NIR
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optical imaging probes. The use of nanoprobes for dual modality MRI/optical
imaging is widely known. The first example of application of paramagnetic
quantum dots coupled to RGD peptide targeted to human endothelial cells in vitro
was shown by Mulder and coworkers.85 In another example Mn3[Co(CN)6]2
nanocubes were developed as contrast agents for MRI and two photon
fluorescence imaging.86 More recently, Qiao and coworkers demonstrated the
application of Fe2O3 nanoparticles based osteopontin targeted MRI/optical probe
for imaging of atherosclerotic plaque.87
Development of combined nuclear/optical methods for imaging cancer has
gained a lot of interest lately. Nuclear methods such as PET and SPECT have
high sensitivity and are valuable tools for whole body imaging.88 Due to low
spatial resolution, PET/SPECT may not be able to analyze the heterogeneity of
the tissues at cellular levels. On the other hand, optical imaging is characterized
by high spatial resolution, but can be disadvantageous owing to the low
penetration depths. Therefore, integrating the two modalities will aid in imaging
from the whole body down to cellular level and successive surgical intervention. 88
Although not usually preferred, but the use of a separate biomarker for PET and
optical imaging respectively is feasible. The drawback of this strategy is that the
bio distribution and pharmacokinetics of the two biomarkers will be different and
the results from the two techniques will not be compatible. 89 For instance, if a
targeting peptide is conjugated to a fluorophore for application in fluorescence
imaging in one case. But for application in PET imaging the same targeting
peptide is radiolabeled with 18F through a prosthetic group, then the two imaging
probes might have different in vivo pharmacokinetics owing to the different
lipophilicity of the fluorophore and the

18F

prosthetic group. In one literature report

the in vivo pharmacokinetics of imaging probes comprised of the same targeting
peptide, but with different radioisotopes (64Cu-DOTA-RGD, 18F-FB-RGD and 125IRGD), were compared.90 The 125I compound demonstrated higher tumour uptake
as compared to the 18F and 64Cu imaging probes. 18F-FB-RGD showed rapid
tumour clearance and higher retention in gall bladder and intestines. 64Cu-DOTA-
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RGD on the other hand, showed prolonged tumour retention and higher liver
uptake. This demonstrates that the structural differences in the imaging entity can
lead to different behaviour in vivo even though it uses the same targeting entity.
Therefore, in order to have more accurate results, a hybrid marker with minimal
structural modifications is needed.
Fluorescent proteins e.g. green fluorescent protein or red fluorescent protein,
fluorescent small molecule dyes, quantum dots are some of the reporter probes
that can be used in a combined PET/optical imaging agent. 64 These types of dual
modality PET/optical imaging probes will aid in narrowing the gap between in
vitro optical imaging and in vivo PET imaging as the results obtained from in vitro
optical imaging can be carried forward to the next level i.e. in vivo PET imaging.
The combined findings from both the modalities will provide more useful results.
A recent example of the application of photo click chemistry for the synthesis of
dual PET/optical imaging probe targeted for urokinase-type plasminogen
activator receptor (uPAR) was demonstrated by Sun and coworkers. 91 In this
study, targeting peptide AE105 functionalized with alkene was photo clicked with
68Ga-NOTA

attached tetrazole. The diazole photo-click linker between the

targeting peptide and PET chelator NOTA acted as the fluorescent entity for
optical imaging. The results from fluorescent imaging depicted the specificity of
this imaging probe for uPAR receptors on U87MG cells. This probe was used for
fluorescence imaging of U87MG cells. Further this dual modality probe was also
investigated in vivo PET imaging done using mice bearing U87MG xenografts.
PET imaging results were consistent with the optical imaging results and
confirmed the in vivo specificity of the probe for the receptor.
Another 124I labeled pyropheophorbide derivative was synthesized and the
specificity for benzodiazepine receptor (PBR) was demonstrated through in vitro
optical imaging using RIF cells. Further a high tumour uptake was also
demonstrated through in vivo PET imaging in mice injected with the RIF tumour.92
The development of multimodal instrumentation has aided in the application of
different modalities in conjunction, providing a better understanding of the
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disease. Several multimodal imaging probes have been developed so far. But the
field of multimodality imaging is still progressing rapidly necessitating the
development of novel multimodality imaging probes with superior properties such
as ease of synthesis, elimination of structural modifications and improved
pharmacokinetic properties etc.

1.7 Targeted Imaging Probes Based on Peptides
The targeted imaging probes have the potential to show improved signal due to
increased target uptake as compared to the traditional non-targeted imaging
probes. Therefore, there is a need for designing targeted imaging probes that
have high affinity, specificity for the target, high accumulation in the target tissue
and fast clearance from the non-target tissues, high stability in vivo and are safe
to use.93 Due to their advantages over small molecules and antibodies, peptides
are considered ideal candidates for targeted imaging. Peptide based probes can
contain up to 50 amino acids. Peptides possess favourable pharmacokinetics,
such as fast clearance from blood and non-target tissues. They have good target
tissue uptake, and low cellular toxicity.94 Moreover, the solid phase peptide
synthesis approach allows easy, convenient, and reproducible synthesis of
peptides.
Recent development in the field of molecular biology has introduced several
disease targets including peptide receptors e.g. somatostatin (SST), integrin,
gastrin releasing peptide receptor (GRP-R), growth hormone secretagogue
receptor (GHS-R), that are overexpressed in various carcinomas.95,96,97,98 Peptide
based probes are constructed based on naturally occurring peptides. The
peptides in their natural forms are prone to degradation due to peptidases and
proteases found in vivo.99 In order to improve the in vivo stability, the peptide
sequence that is essential for binding to the target is determined and the peptide
is modified to increase the biological half-life. The peptides can be modified by
introducing unnatural amino acids and D-amino acids which will not be easily
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recognized by the enzymes in vivo.99 Furthermore, acetylation of the N-terminus
or amidation of the C-terminus can also be carried out to prevent degradation by
exopeptidases. Cyclization of the peptide can restrain the 3-D conformation and
can also enhance the stability of the peptide. Much care should be taken while
modifying the peptide sequence so as not to hamper its binding affinity for the
target.100 For example, cyclic somatostatin peptides required extensive structure
activity analysis prior to determining a sequence that was effective for in vivo
application.101 A stable cyclic somatostatin derivative was designed by the
introduction of disulfide bridge between Cys3 and Cys14 residues. 102 Another
research group developed improved somatostatin analogue by the replacement
of phenylalanine with unnatural amino acids such as difluorophenylalanine. 103
Several peptides have been labeled with appropriate imaging tags leading to the
development of novel targeted imaging probes. Recently, a short peptide
sequence CAQK that selectively binds to injured brain in mouse and humans was
identified by in vivo phage display. CAQK coated nanoparticles containing
silencing oligonucleotides helped in delivery of siRNA to injured brain tissue. This
example demonstrated a useful methodology for the delivery of therapeutics to
regions of acute brain injury.104

1.8 Growth Hormone Secretagogue Receptor and Ghrelin
Growth hormone secretagogue receptor (GHS-R) has been found to be highly
expressed in variety of cancer types such as prostate cancer, breast cancer and
ovarian cancer.98,105,106 Therefore, GHS-R1a has the potential to act as a
promising target for cancer imaging. GHS-R1a is a G-protein coupled receptor
comprising of 366 amino acids and has seven transmembrane domains. GHSR1a is present in the hypothalamus and pituitary of various mammalian
species.107 The receptor is responsible for various physiological functions such as
release of growth hormone, regulation of appetite and food intake, modulation of
gastrointestinal motility and secretion, managing cell proliferation and survival,
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regulation of pancreatic secretion and energy homeostasis.107 Two isoforms,
GHS-R1a and GHS-R1b, have been discovered. GHS-R1a is considered to be
the active form and has been the center of interest for researchers.
Peptide ghrelin was discovered as the endogenous ligand for the receptor.108
Ghrelin is a 28 amino acid peptide that was originally purified from the rat
stomach.109 Figure 1.8 depicts the structure of ghrelin. It has a N-octanoyl
modification at the third serine residue which is catalyzed by ghrelin O-acyl
transferase. It is mainly produced in the stomach, but is also found in other
tissues such as duodenum, lung, heart, pancreas, pituitary and hypothalamus.

Figure 1.8 Structure of natural ghrelin (1-28).

The structural activity relationship of ghrelin peptides has been a subject of
research for many groups. The octanoyl modification at the Ser-3 position is
necessary for the biological activities of ghrelin. The desoctanoyl version of the
peptide has been found to be less potent than the original peptide.108 The
replacement of Ser-3 with aromatic amino acid such as tryptophan did not affect
the activity but the replacement with aliphatic amino acids hindered the activity
drastically.110
In another study Ser-3 was replaced by diaminopropionic acid (Dpr) and then
coupled to octanoic acid, thereby substituting the ester linkage with amide
linkage. The presence of this amide bond enhanced the potency of the peptide
fragment.111 The ester linkage in the parent peptide is prone to enzymatic
degradation by esterases and proteases therefore, the amide linkage plays a key
role in the in vivo stability. The presence of a positive charge at the N-terminus is
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essential for identification by GHS-R1a. Table 1.3 summarizes some of the
modified ghrelin analogues and their literature IC50 values. The N-terminal
pentapeptide was found to be the minimal sequence essential for activity. 111

Ghrelin analogue

Residue 3

Reported IC50
(nM)

Ghrelin (1-28)

Ser(CO(CH2)6CH3)

0.25

Ghrelin (1-28)

Ser(-)

>10000

Ghrelin (1-28)

Ser(CO-CH3)

>2000

Ghrelin (1-28)

Dpr(CO(CH2)6CH3)

0.42

Ghrelin (1-18)

Ser(CO(CH2)6CH3)

0.77

Ghrelin (1-14)

Ser(CO(CH2)6CH3)

7.1

Ghrelin (1-5)

Ser(CO(CH2)6CH3)

55

Ghrelin (1-4)

Ser(CO(CH2)6CH3)

889

Table 1.3 Reported modified ghrelin analogues and their IC50 values.98

Previously, in order to develop potential imaging probes for GHS-R1a, fluorine
and rhenium containing ghrelin (1-5) and ghrelin (1-14) analogues were
synthesized by modifying the octanoyl group at the Ser-3 position. The most
promising of these analogues had IC50 values as low as 28.0 nM.112 Fluoresceinghrelin (1-18) analogue was synthesized by coupling the fluorescent dye
fluorescein to C-terminus of ghrelin through a lysine residue that was added to
the C-terminus.113 This demonstrated the possibility of modifying ghrelin (through
lysine) at the C-terminus for conjugating it to a number of useful molecules.
Recently, ghrelin agonists and antagonists were attached to bifunctional chelator
1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid (NODAGA) which was
radiolabeled with 68Ga and evaluated in vitro and the bio distribution was
analyzed in rodents.114 These compounds demonstrated the ability to act as
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potential PET imaging agents. Since ghrelin is a relatively new ligand for
targeting GHS-R1a, a lot of research is still being conducted to develop ghrelin
based imaging probes with increasing binding affinity for the receptor.

1.9 Click Chemistry

Figure1.9 Depiction of Cu(I)-catalyzed azide-alkyne click reaction.

Click chemistry is one of the most common approach that is employed for
attaching the imaging tag to the targeting entity e.g. for coupling a fluorophore to
a targeting peptide. Owing to the orthogonal nature of these reactions the need
for protecting the other functional groups can be eliminated. Click chemistry is
defined as a reaction that involves coupling of molecular fragments in an
effective, chemoselective, high yielding manner with little or no byproducts. 115
The most commonly studied among these types of reactions is the azide-alkyne
[3+2] cycloaddition reaction often referred to as ‘click reaction’ (Figure 1.9). Other
kinds of click reactions include thio-ene click reaction, Diels-Alder, and Michael
addition reaction.116 The uncatalyzed azide-alkyne cycloaddition, also known as
Huisgen reaction, requires high temperature and produces a mixture of 1,4 and
1,5-disubstitution products.117 The Cu(I) catalyzed azide-alkyne cycloaddition was
first described by Meldal118 and Sharpless119 independently. This reaction
converts azides and terminal alkynes exclusively into 1,4-disubstituted 1,2,3triazoles. The synthesis of 1,5-disubstituted triazole starting from azide and
terminal alkyne using ruthenium cyclopentadienyl complexes has also been
described in literature.120
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Several experimental conditions have been utilized for copper catalyzed azidealkyne cycloaddition reactions (CuAAC). Different copper catalysts that act as a
source of Cu(I) species have been used. Cu(II) salt such as CuSO4 can be used
as a pre-catalyst in the presence of reducing agent such as sodium ascorbate.
Cu(I) compounds such as CuI or CuBr can also be used but the reaction has to
be performed under anaerobic conditions so as to eliminate the chances of
oxidation of Cu(I) to Cu(II).117
While the use of ligands is not necessary for the click reaction to proceed, the
presence of the ligand can certainly improve the rate of reaction as well as
protect the Cu(I) species from oxidation.116 Polydentate N-donors and amines are
the commonly employed accelerating ligands. Examples of some of the ligands
used for CuAAC are tris(2-aminoethyl)amine (Tren),121
tris(benzyltrizolylmethyl)amine (TBTA),122 bathophenanthroline disulphonate
(BPDS),123 and pentamethyldiethylenetriamine (PMDETA).124
The stability of natural peptides is an issue that could restrict their application as
drug candidates and imaging agents. When an unnatural component is
introduced in the peptide to enhance the stability, the resulting structure needs to
still maintain the biological activity of the natural peptide. The structural studies of
the amide bond and the triazole have shown similarities in terms of the size and
the dipole moment and the replacement of amide by triazole does not disrupt the
helical structure of the peptide.125 Therefore, triazole is considered as an isostere
of the amide bond and can act as potential surrogate for the modification of the
peptide. Bock and coworkers modified a naturally occurring tyrosinase inhibitor
cyclo-[Pro-Val-Pro-Tyr] with triazole moiety which was shown to maintain the
enzyme inhibitory acivity.126 Daumar and coworkers employed CuAAC reaction to
attach a 18F prosthetic group to pHLIP peptide.127
The use of CuAAC reactions can be ideal for several applications but can be
problematic specifically for the applications involving biological systems as Cu(I)
can be cytotoxic.128,129,130,131 Therefore, a lot of interest has been generated
towards the development of copper free versions of azide-alkyne cycloaddition
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reactions.50 Strain-promoted azide-alkyne cycloaddition reaction (SPAAC), is a
copper free variant of the traditional CuAAC reaction.

Figure 1.10 Depiction of strain promoted azide-alkyne cycloaddition reaction
using cyclooctyne.

The release of ring strain in a cycloalkyne, usually cyclooctyne, lowers the energy
of activation for the cycloaddition step, increasing the efficacy of the reaction and
eliminating the need of the Cu(I) catalyst. Subramanian and coworkers
synthesized a novel EpCAM aptamer-fluorescent conjugate for imaging prostate
cancer.132 Recently, 18F-labeled RGD analogues synthesized using SPAAC were
evaluated as PET imaging probes.51

1.10 Porphyrins
Porphyrins are heterocyclic macromolecules composed of four pyrrole rings
interconnected by methine bridges at the alpha C atoms.133 (Figure 1.11) This
ring system possesses aromatic characteristics.
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Figure 1.11 Structure of porphine.
There are a variety of porphyrin and related compounds that are necessary for
the proper functioning of biological processes that sustain life. For instance,
porphyrin heme forms the fundamental part of hemoglobin that is responsible for
oxygen transport. While porphyrin is a vital bio molecule, so is its metabolism.
Failure in the metabolism of porphyrin can cause diseases such as porphyrias.134
Other porphyrin related molecules are also found in the nature. These types of
molecules are biologically very important. For example, chlorin systems such as
chlorophyll are important for photosynthesis in plants. Bacteriochlorins such as
bacteriochlorophylls are photosynthetic pigments found in certain bacteria.
Chlorins and bacteriochlorins can be obtained by reduction of one or two double
bonds respectively. Other porphyrin related compounds are phthalocyanines and
naphthalocyanines which have one or two more benzo rings connected to pyrrole
subunits respectively. Structure of porphyrin and related compounds are shown
in Figure 1.12.
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Figure 1.12 Structure of porphyrin related compounds.

The central cavity of the porphyrin ring is suitable for chelating to a metal ion. A
large number of examples can be seen in the literature where a vast range of
metal ions can be chelated into the central cavity of the macrocycle (e.g. Mn, Cu,
Zn, Pd, Pt, Fe, Ni, Co).135–140
The electronic absorption spectrum of a typical free base porphyrin contains one
intense Soret or B band around 400 nm and multiple weak Q bands between
450-700 nm.133 The Soret band arises due to the transition from the ground
singlet state to the second excited singlet state (S0

S2) and the Q-bands arise

due to transition from the ground singlet state to the first excited singlet state
(S0

S1).141 The number of Q-bands in the absorption spectra of free base

porphyrins is reduced from four to two upon metalation. Another important
characteristic of porphyrins is the tendency to exhibit fluorescence. In the case of
certain metalloporphyrins that are coordinated to paramagnetic metal ions such
as Cu(II) the fluorescence has been found to be quenched due to intersystem
crossing to triplet state and non-radiative processes. Certain other
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metalloporphyrins such as Pt(II)-porphyrins and porphyrins with heavy atoms
such as halogens exhibit phosphorescence due to heavy atom effect that
promotes intersystem crossing to triplet state.142
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Representative (a) absorption spectrum (showing Soret and Q

bands) and (b) emission spectrum for free base porphyrin (Protoporphyrin IX)
(λex=405 nm). (UV absorption and emission spectrum were acquired in DMSO
using Varian Carry 300 Bio UV-Vis spectrophotometer and Photon Technology
International QM-4 SE spectrometer respectively).

One of the features seen among porphyrins is pi-pi stacking between 2 or more
units, which is a non-covalent attractive interaction between aromatic rings.
These interactions between porphyrins result in aggregation in solution 143 and will
tend to lower their solubility. Aggregation can be followed and monitored by the
changes in spectral properties. In general, aggregation leads to broadening and a
blue shift of the Soret band.141
The two important properties of porphyrins i.e. the ability to coordinate to metal
ions and the tendency to exhibit fluorescence will be explored in this thesis for
developing the porphyrins into PET/fluorescence imaging probes.
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1.11 Summary
This thesis focuses on the development of peptide based dual modality imaging
probes as potential candidates for PET/fluorescence imaging.
Chapters 2 and 3 focus on the application of porphyrins in the development of
such probes. In chapter 2 the synthesis, in vitro fluorescence imaging and 68Ga
labeling of PPIX-ghrelin based probe targeted for GHS-R1a is described. Here,
PPIX was attached to the peptide ghrelin through a linker and then coordinated to
Ga3+. Chapter 3 describes the design and attempted synthesis of an
hematoporphyrin-bombesin based probe targeted for the GRP-R. The ability of
hematoporphyrin to act as a chelator for gallium was demonstrated and
hematoporphyrin was also radiolabeled with

68Ga.

BF2-formazanates are new class of compounds that have interesting properties
such as ease of synthesis, high molar extinction coefficient, good quantum yields,
large Stokes shift and emission and absorption spectra that can be tuned based
on structural modifications. Chapter 4 discusses the application of azide-alkyne
click chemistry catalyzed by Cu(I) for the synthesis of fluorescent imaging probes
based on BF2-formazanate-peptide conjugates. The uptake of these probes by
the receptor targets GHS-R1a and GRP-R, is also shown through fluorescence
microscopy.
Chapter 5 presents the conclusions drawn from all the chapters and discusses
the future directions of these research projects.
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Chapter 2

2 The Development of a Ga-Ghrelin-Protoporphyrin IX
Analogue for Imaging of GHSR-1a Receptor

2.1 Introduction
Imaging technologies have experienced a tremendous growth in clinical
applications over the last few years. A number of imaging technologies are
complementary and their advantages can be coupled together to afford a better
depiction of tumours and their environment.1 The application of a single unique
probe for multimodality imaging is not mandatory for all purposes, but it certainly
has benefits. A single probe will demonstrate the same pharmacokinetics and
colocalization of signal for the individual imaging modalities.2 This becomes more
evident in clinical diagnostics, where the modalities with high sensitivity typically
have low resolution, such as PET and the modalities possessing high resolution
have low sensitivity such as MRI. Therefore, bringing together PET and MRI can
lead to a more accurate diagnosis.
The first stage of multimodal imaging was the development of software tools for
image co-registration, the second stage is the continuing development of
multimodality instrumentation. The final stage is the development of appropriate
multimodality imaging agents.3 A variety of biomolecules provide suitable ground
for the construction of imaging agents that can afford contrast for multiple
imaging modalities. For instance, the use of a fluorescent multimodality agent for
imaging in vitro, followed by the utilization of the same agent to conduct
PET/SPECT/MRI in larger animals or patients.4
Since the introduction of this concept, research has shown a significant
advancement in the design of multimodal agents which includes the development
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of novel chelators, superior fluorophores and more in vivo compatible modes of
bio conjugation.5 One approach for the synthesis of multimodal agents is to
couple all imaging tags to a central scaffold, but this method may necessitate a
great deal of structural modifications from the single agent.6 Another approach is
to use the same central molecule armed with various imaging tags but
synthesized exclusively for different imaging modalities.7 The shortcoming of this
method is the structural variance that could not only modify the characteristics of
the central molecule but may also generate incongruity in results obtained from
various imaging modalities. Therefore, there is a need for having a single imaging
agent that would retain the characteristics of the central molecule and at the
same time would reduce the incongruity in imaging results from various
modalities.
In recent times, a lot of interest has been generated in the development of
porphyrins and associated compounds as useful agents for medical imaging and
therapy owing to the suitable optical properties associated with them. 8
Several metalloporphyrins have been found to be successful in affording imaging
contrast for near infrared fluorescence (NIR),9 and magnetic resonance imaging
(MRI).10 Due to their high singlet oxygen quantum yields, Pt(II) and Pd(II)
coordinated porphyrins form appealing candidates for photodyanamic therapy
(PDT).11,12 Metal ions like Mn(III) coordinated to porphyrins have been studied as
MRI contrast agents.13
Protoporphyrin IX (PPIX) is one of the most common naturally occurring
porphyrin. It is the iron free form of hemin, which can be synthesized from
fundamental precursors such as glycine and succinyl coenzyme A or glutamate. 14
PPIX has a large number of applications in medicine but its most practical
application is as a photosensitizer in PDT.15,16 PDT involves the introduction of
tumour localizing photosensitizer (possessing minimum dark toxicity) into the
body. Upon maximum photosensitizer uptake, the tumour is irradiated with light of
appropriate wavelength. This eventually generates singlet oxygen which is
considered to be responsible for the irreversible destruction of the tumour.17,18
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Photofrin which is a hematoporphyrin (HP) derivative has been approved by the
FDA as a sensitizer for PDT.19 Other first generation porphyrin based
photosensitizers such as Photogem and Photosan-3 have been approved for
clinical use in Russia and Brazil.20,21 5-Aminolaevulinic acid (ALA) generates
endogenous photosensitizer PPIX through the heme biosynthetic pathway, upon
being internalized by the cells.14,22 Porphyrin complexes labeled with positron
emitting radioisotopes have been used in analysing the efficiency of targeted
PDT agents. For example, a 18F labeled porphyrin complex has been evaluated
as a potential PDT/PET single theranostic agent for cancer.23 However, this
strategy is difficult to execute due to multiple synthetic steps involved. To this
point the ability of porphyrins to chelate metal ions becomes instrumental in
developing PET imaging agents. Recently, a 64Cu-PPIX-bombesin peptide analog
has been evaluated as a targeted PET imaging and PDT agent. 24 In their
research PPIX was used as a photosensitizer and the bombesin peptide was
used for targeting gastrin releasing peptide receptor. The 64Cu-PPIX-PEG6-BBN
analogue was studied as a targeted PDT agent and evaluated for cellular uptake
in a PC-3 cell line and for PET imaging in the PC-3 tumour bearing mice.
Taking into account the two most interesting features of porphyrins i.e.
fluorescence and metal coordinating capability, this study will focus on the
development of porphyrin-peptide based PET/fluorescence imaging agents. The
porphyrin used for this study will be the previously discussed PPIX. Since PPIX
is fluorescent on its own and at the same time can coordinate a metal ion, any
additional structural alterations are not needed. This not only preserves the
innate properties of the porphyrin macrocycle but also decreases any disparity
between the two imaging techniques.
The usefulness of a solid phase strategy for functionalization of porphyrins has
been reported in the literature e.g. the synthesis of 5,15-diphenylporphyrin using
2-chlorotrityl chloride resin.16 Also reported is a scaffold for the synthesis of
photoactive libraries by attaching 5,15-dibromo-10-(4-hydroxyphenyl)-20-(4nitrophenyl) porphyrin to brominated Wang resin.17 Wang resin was utilized as a
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solid support for the synthesis of Fmoc-protected amine derivatives of PPIX.18
These results showed that porphyrins are amenable to resin loading and that a
solid phase strategy can be utilized for synthesizing PPIX-peptide conjugates for
this project.
Detection and treatment of cancer can be achieved using imaging agents
possessing high selectivity for the biological target.5 For this purpose, the imaging
tag is coupled to a targeting entity that is specific for a receptor which is highly
expressed in cancer.
The PET isotope used for this study was 68Ga. The production of 68Ga is by
means of a generator from parent isotope 68Ge. The scope of applications for
68Ga

based agents has expanded over the past few years. This can be attributed

to the advantageous physical properties of

68Ga,

such as E βmax of 1.8 MeV, 89 %

positron emission along with a half life of 68 min. The simplicity, availability and
lower capital cost of 68Ge/68Ga generators has made it more desired for
research.25 Small scale generators have come a long way since their introduction
which in turn has made 68Ga available in facilities that do not possess an on-site
cyclotron.
The introduction of 68Ga for PET imaging, has a considerable role to play in
current and future clinical practice. The most commonly used chelator for

68Ga

is

DOTA. In 2001 Henze and coworkers reported the first breakthrough clinical
work, demonstrating 68Ga-DOTATOC PET imaging in patients with
meningiomas.26 A lot of research has already been done with
conjugates for imaging different receptors e.g.

68Ga-DOTA-peptide

68Ga-DOTA-Tyr1-Phe3-Octreotide

(TOC), 68Ga-DOTA-NaI3-Octreotide (NOC), 68Ga-DOTA-Tyr3-Octreotide (TATE)
are the three main 68Ga-DOTA-peptide that are currently available for imaging
somatostatin receptors.27 More recently interest has been generated in evaluation
of some other chelators for 68Ga including 1,4,7-triazacyclononane-1,4,7trisacetic acid (NOTA),28 1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid
(NODAGA) 29 N,N’-di(2-hydroxybenzyl)ethylenediamine-N,N’-diacetic acid
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(HBED),30 etc. Another class of molecules that can serve as chelators for

68Ga

are porphyrins.
There are a few reports illustrating the development of

68Ga-porphyrin

based

imaging probes. 68Ga labeled 5,10,15,20-tetrakis(pentafluoro-13 phenyl)
porphyrin has been synthesized as a potential PET imaging probe. The complex
was found to be stable in human serum for 5 hours.31 In another report, 68Ga
labeled 5,10,15,20-tetra(4-methylpyridyl) porphyrin was synthesized and the
biodistribution studies showed high tumour uptake within 30 minutes post
injection of the radiotracer.32 Recently, a bimetallic gallium-porphyrin-ruthenium
bipyridine complex with lysosome specific subcellular localization was
synthesized.33
Ga-protoporphyrin IX complex has been previously synthesized and studied as a
soluble diamagnetic model for malaria pigment by Stillman and coworkers.34 In
another study, Ga-PPIX-peptide compounds were synthesized where the
tripeptide sequence RGD was reported as the targeting entity.35 The tripeptide
RGD was selected as a targeting entity as it has been reported to have high
affinity for αvβ3 integrin36 which is over expressed in ovarian37 and breast
cancers.38
In the present study, the peptide ghrelin is selected as the targeting peptide.
Ghrelin has a unique hydrophobic n-octanoyl modification in the Ser-3 residue
that has been found to be essential to bind to the ghrelin receptor, also known as
the growth hormone secretagogue receptor 1a (GHS-R1a).39 GHS-R1a is a cell
surface receptor having seven trans-membrane domain. GHS-R1a is
overexpressed in different tumours such as prostate,40 breast41 and ovarian
cancer.42 Therefore, GHS-R1a can play a vital role in non-invasively
differentiating the cancer tissue from the normal tissue over a range of cancers.
Natural ghrelin (1-28) has a strong affinity for GHSR-1a, yet suffers from in vivo
instability, which can be overcome through truncation and replacing the amino
acids in natural ghrelin with unnatural amino acids.43 Structure activity studies
have found that the N-terminus is essential for binding to the receptor, therefore
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modifications can only be done at C-terminus. It was also found that the Nterminal pentapeptide was sufficient for binding to the receptor.39 To improve the
binding affinity various truncated versions of ghrelin have been studied. The
ghrelin analogue used for this study is [Dpr3(octanoyl)Tyr8]-ghrelin-(1-8), which
has been earlier shown to have IC50 of 65.0nM.44
The goal of this project is to synthesize a

69/71Ga-ghrelin-PPIX

analogue as a

probe for in vitro fluorescence imaging and furthermore, to radiolabel ghrelinPPIX with 68Ga to develop the analogous PET agent for imaging of GHSR-1a in
prostate carcinomas.

2.2 Results and Discussion
The design of the imaging probe consists of PPIX as the fluorescent tag/metal
chelator, connected to the peptide targeting entity through a linker. Since the Nterminus of ghrelin is important for binding to the receptor, PPIX was attached to
ghrelin at the C-terminus, leaving the N-terminus free for binding. Due to the
poor solubility of porphyrins a short polar linker is used to attach PPIX to the Cterminus of ghrelin peptide. This feature will enhance the solubility of PPIX while
serving as an attachment point for the targeting moiety. Our choice of linker is
polyethylene glycol (PEG) chain which has been shown to increase the
hydrophilicity.45 By adding a linker the targeting moiety will also be spatially
removed from the N-terminus of ghrelin and PPIX, decreasing the effect of the
bulky chelator PPIX on the binding affinity of ghrelin. The proposed structure of
the probe is shown in Figure 2.1.
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Figure 2.1 Structure of proposed imaging probe.

2.2.1 Synthesis of PPIX-ghrelin(1-8) Analogue
Optimization of methods to load PPIX on resin

The presence of two free carboxylic acid groups on PPIX, makes it highly
suitable for this study as one carboxylic acid group will act as a point of
attachment to the solid support and the other carboxylic group can be coupled to
the amino acids through the linker 2,2’- (ethylenedioxy)bis(ethylamine). For this,
several attempts were made to first attach PPIX to the Wang resin through one
of the free carboxylates followed by a one pot reaction coupling it to 2,2' (ethylenedioxy)bis(ethylamine). The coupling agents that were used for this step
were PyBrOP or HATU as activating agents. Several trials were carried out,
employing different conditions, varying the reaction temperature and the duration
for which the reaction mixture was heated. The best result that could be obtained
was a 28% yield for product 2.1. However, 43% of the unreacted PPIX (as
determined by HPLC analysis) was remaining. These results were not sufficient
to continue with, since the reactions were carried out on solid support and could
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not be purified before continuing with building the peptide chain. (Scheme 2.1).

2.1

Scheme 2.1 Route for synthesis of 2.1 by the on-resin coupling of 2,2’(ethylenedioxy)bis(ethylamine) to PPIX.

It was thought that the low yield could be due to two reasons. 1) the first step
involving the attachment of one carboxylate of PPIX to the Wang resin could be
problematic, and/or 2) the second carboxylate of PPIX was not activated by the
coupling agent to be able to couple to 2,2’- (ethylenedioxy)bis(ethylamine). To
enhance the attachment of PPIX to the resin we tried 2-chlorotrityl chloride as an
alternative resin. To further rule out any difficulties with the step involving
attachment of PPIX to resin and to validate that the second carboxylate of PPIX
could be actually activated and coupled to 2,2'-(ethylenedioxy)bis(ethylamine), a
comparison was done with a solution phase coupling of PPIX to 2,2'(ethylenedioxy)bis(ethylamine), (i.e. without loading PPIX onto 2-chlorotrityl
chloride resin). (Scheme 2.2)

51

2.2a

2.2b

Scheme 2.2 Route for coupling of PPIX to 2,2' -(ethylenedioxy)bis(ethylamine) in
solution.

From the HPLC chromatogram a large peak corresponding to PPIX (34%),
another peak corresponding to product 2.2a (14%) and a major peak
corresponding to compound 2.2b (43%) was observed.
From these results, it was concluded that during the first step of attachment of
PPIX to 2-chlorotrityl resin, both the carboxylates of PPIX were attaching to the
resin. Therefore, no free carboxylate would be available for the amine to react,
leading to low reaction yield. Apart from that, the ability of 2,2' (ethylenedioxy)bis(ethylamine) to cyclize across the two carboxylic acids of PPIX
was also observed. Therefore compound 2.3 was synthesized, where one of the
free amines of 2,2' -(ethylenedioxy)bis(ethylamine) was protected with an Fmoc
group. In order to prevent PPIX from cyclizing across the resin, it was proposed
to couple one of the carboxylates to compound 2.3 before loading it onto the
resin. Even after all these modifications, the yield of coupling PPIX to compound
2.3 using HATU as a coupling agent was low. The next approach was to form an
anhydride, instead of an active ester and then couple it to compound 2.3.
(scheme 2.3). This approach gave the best results so far where the product was
isolated with the yield of 47%. Now that the linker was attached to one of the
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carboxyl groups of PPIX, it was loaded onto 2-chlorotrityl chloride resin using the
other free carboxyl group and the targeting peptide ghrelin can be build off the
linker.
Natural ghrelin has a unique octanoyl chain connected to the side chain of Ser-3
residue though an ester linkage. In order to avoid the enzymatic hydrolysis of
ester linkage in vivo, the Ser-3 residue was replaced by diaminopropionic acid.
This modification substitutes the labile ester bond by a more stable amide linkage
at the octanoyl chain.39
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Scheme 2.3 Route for synthesis of PPIX-linker-ghrelin analogue 2.8.
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2.2.2 69/71Ga Coordination
Compound 2.8 was first coordinated to 69/71Ga, leading to the synthesis of
compound 2.9 which would be used to demonstrate the affinity for GHS-R1a
through fluorescence microscopy. Before moving into optical imaging, the effects
of 69/71Ga coordination on the photophysical characteristics of analogue 2.8 must
be studied. It would then be incubated with the cells transfected with GHS-R1a
and the uptake by the cells will be analysed through fluorescence microscopy.
One way to confirm the successful synthesis of the radioactive analogue 2.10, is
to compare it to a non-radioactive standard i.e. compound 2.9. The only
difference between the non-radioactive standard i.e. compound 2.9 and the
radioactive analogue i.e. compound 2.10 is that of the Ga isotope, therefore both
appear with the same retention time when analyzed by HPLC chromatography.
Hence, the 69/71Ga coordinated analogue will not only serve as an applicant for in
vitro analysis, it will also act as a non-radioactive standard for 68Ga radiolabeling.
High temperature conditions have been found to be essential for coordination of
some metal ions to the central porphyrin cavity.31 Coordination of 69/71Ga to PPIXRGD analogue was earlier reported using a pH 4.5 sodium acetate/acetic acid
buffer35, utilizing microwave in order to reduce the reaction time. All attempts
made to coordinate 69/71Ga to analogue 2.8 using sodium acetate/acetic acid
buffer and GaCl3 were unsuccessful. This might be due to the poor solubility of
compound 2.8 in sodium acetate/acetic acid buffer. Next, coordination attempts
were carried out in 2,6-lutidine and GaCl3 by conventional heating method
reported previously.34 It could be observed that the coordination was taking place
but the yield was very poor as the peptide was breaking down at high reaction
temperature. In order to decrease the reaction time and temperature such that
degradation of peptide could be minimized, the reaction was carried out using a
microwave at 1200C for 1 hour (Scheme 2.4). This led to an improvement in the
yield. Additional attempts at this reaction by increasing the reaction
time/temperature led to degradation of the peptide.
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Scheme 2.4 Route for coordination to 69/71Ga.

2.2.3 Optical Analysis
To estimate the potential of compound 2.9 for fluorescence microscopy, photophysical data was obtained and compared to PPIX (summarized in table 2.1). It
was observed that there was a blue shift in emission maxima for compound 2.9
as compared to PPIX. The absorbance maxima did not shift notably upon
coupling to ghrelin or upon coordination to 69/71Ga. Additionally, there was a
significant increase in molar extinction coefficient for both compound 2.8 and 2.9
as compared to PPIX. As expected the absorption spectrum of compound 2.8
consisted of one Soret band and four Q-bands. The coordination of 69/71Ga could
be easily confirmed from the absorption spectrum for compound 2.9, as the
formation of metalloporphyrin leads to the disappearance of two Q-bands. (Figure
2.2)
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The fluorescence quantum yields were obtained according to the reported
comparative methods46, using Rhodamine 6G as the standard. The fluorescence
quantum yield study gave some interesting results. It has been seen in the
literature that porphyrin fluorescence generally gets quenched upon coordination
to metals such as Cu2+, leading to a significant decline in fluorescence quantum
yield.47 Fluorescence quenching is the process that involves the reduction in
fluorescence intensity of the substance as it relaxes through non-radiative decay
of the excited singlet state. It was observed that the fluorescence was not only
preserved, the fluorescence quantum yield for compound 2.9 was higher than
compound 2.8, suggesting that fluorescence was not quenched upon Ga3+
coordination. It was postulated that metal ions such as Cu2+ being paramagnetic
cause intersystem crossing to triplet state and loss of energy occurs through nonradiative processes which leads to decrease in fluorescence intensity. On the
other hand, Ga3+ being diamagnetic does not participate in intersystem crossing
therefore fluorescence is not quenched.

λex (nm)

λem (nm)

λabs (nm)

ε (M-1 cm-1)

Φ[a]

(DMSO)

(DMSO)

(DMSO)

(DMSO)

(EtOH)

405

630

408

17377

0.37

Compound 2.8 406

628

408

90706

0.53

Compound 2.9 414

580

415

116653

0.70

Compound

PPIX

Table 2.1 Photophysical data for PPIX and PPIX analogues: excitation, emission,
absorption maxima, molar extinction coefficient, fluorescence quantum yields.
Slit width was 2 nm. Emission collected in the range 415-800 nm for PPIX, 416800 nm for 2.8 and 425-800 nm for 2.9.
[a]: Quantum yields obtained using rhodamine 6G48 as standard in deoxygenated
solution using previously reported procedure.46
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Figure 2.2 Absorption and emission spectra: Absorption for compound 2.8 (blue),
Absorption for compound 2.9 (red), emission for compound 2.8 (pink), emission
for compound 2.9 (orange). Recorded for 10-5 M DMSO solution.

2.2.4 In Vitro Fluorescence Imaging of 69/71Ga-PPIX-ghrelin(1-8)
To validate the potential of 2.9 for in vitro confocal fluorescence microscopy,
OVCAR-8 cells transfected with GHS-R1a were utilized. For this purpose,
OVCAR-8 cells transfected with GHS-R1a were incubated with the analogue 2.9
and fluorescence images were obtained after washing and fixing the cells. The
images depicted the cellular uptake of 2.9 as was evident from the red emission
from 2.9 (around 580nm) (Figure 2.3a). The applicability of 2.9 for orthogonal
imaging was demonstrated by co-staining the cells with nuclear stain 4’,6diamidino-2-phenylindole (DAPI) (in blue), showing that the cytoplasm and nuclei
could be differentiated while being imaged simultaneously (Figure 2.3b). Parental
OVCAR-8 cells (without transfection with GHSR-1a) were used as negative
control for the experiment. The uptake of 2.9 by parental OVCAR-8 cells was
minimal as seen in Figure 2.3c. Further, the specific binding of 2.9 for GHS-R1a
was demonstrated by performing a blocking studies, using a small molecule
antagonist 36 (developed by Bayer Pharmaceutical Corporation) which has very
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high affinity for GHS-R1a.49 In a blocking study the uptake of the imaging probe
for the target is specifically inhibited (blocked) by large excess of a blocking
compound that has a high affinity for the receptor. At a high concentation,
blocking of the target can be detected as a loss of fluorescence signal from the
targeting imaging probe.This confirms the specificity of the targeting imaging
probe for the target. If the targeting imaging probe is not binding specifically to
the desired target and is binding some other target, then the presence of excess
of the blocking compound should not result in the loss of fluorescence signal.
Figure 2.3e demonstrates blocking of GHS-R1a. All this aids in confirming the
specificity of 2.9 for the receptor.
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Figure 2.3 Confocal fluorescence micrographs of OVCAR-8 cells stained with 2.9
(in red) and DAPI (in blue). (a) Using OVCAR-8 cells transfected with GHS-R1a
and image obtained by excitation at 559 nm and emission collected between 575675 nm. (b) Using OVCAR-8 cells transfected with GHS-R1a and overlay of image
obtained by excitation at 405 nm and emission collected between 425-475 nm with
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image 2.3a. (c) Using parental OVCAR-8 cells not transfected with GHS-R1a and
image obtained by excitation at 559 nm and emission collected between 575-675
nm. (d) Using parental OVCAR-8 cells not transfected with GHS-R1a and overlay
of image obtained by excitation at 405 nm and emission collected between 425475 nm with image 2.3c. (e) Using OVCAR-8 cells transfected with GHS-R1a and
blocked with 10X excess of 36 and image obtained by excitation at 559 nm and
emission collected between 575-675 nm. (f) Using OVCAR-8 cells transfected with
GHS-R1a and blocked with 10X excess of 36 and overlay of image obtained by
excitation at 405 nm and emission collected between 425-475 nm with image 2.3e.
(g) Structure of compound 36 used for blocking study.

2.2.5 Optimization of 68Ga Labeling of PPIX-Ghrelin(1-8)
The insertion of a radiometal through chelation is one of the simplest techniques
to introduce a radioisotope into the precursor. This not only avoids the multistep
synthesis associated with other techniques, but also the radiometal conjugates
usually need minimal purification, if any.50
Here, we report the synthesis of

68Ga-PPIX-peptide

based novel imaging probe.

Several conditions were analyzed during the optimization of

68Ga

chelation. The

introduction of 68Ga into porphyrins has been previously shown to require high
temperature31, therefore microwave reactor was employed for labeling compound
2.8 with 68Ga. Sodium acetate/acetic acid (aq) buffer of pH 4.5 was used in order
to prevent hydrolysis of free 68Ga as it has been found that at physiological pH
Ga3+ exists as insoluble hydroxides.51 While using this buffer, no radiolabeled
product was obtained. This could be attributed to the low solubility of compound
2.8 in aqueous media. To improve the solubility, the use of organic solvents like
ethanol and DMF became necessary. Therefore, the ideal solvent system for the
reaction was found to be a mixture of sodium acetate/acetic acid buffer (pH 4.5),
tween 20, ethanol and DMF. Different reaction temperatures and reaction times
were analyzed for the optimization of the reaction conditions. The best result was
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obtained by heating the reaction mixture in a microwave reactor at 1200C for 60
minutes. Comparison with the HPLC trace from the standard compound 2.9,
proved the successful synthesis of compound 2.10. Both the radioactive product
and the non-radioactive standard appeared at the same retention time as is seen
in Figure 2.4.
Even under these conditions the radiolabeling yield was low and insufficient
product was isolated and therefore no PET images were obtained. There could
be a number of reasons behind the low radiolabeling yields. Firstly, the solubility
of compound 2.8 was still not suitable for labeling, even after using a 4-solvent
mixture system. Secondly, as it is seen in various examples in literature, the
yields for metal coordination of porphyrins can be increased by increasing the
reaction time or by increasing the reaction temperature. But in our case any
further extension in reaction time or increase in reaction temperature led to
degradation of the peptide, thus leading to low yields. Further optimization is
required towards improving the yield of the radiolabeling step.
However, since we were successfully able to label compound 2.8 with 68Ga, this
validates the ability of PPIX to act as a 68Ga chelator.
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Scheme 2.5 Route for radiolabeling with 68Ga.
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Solvent
1

Solvent Solvent Solvent
2

3

4

Temp

Time

Yield

(0C)

(min)

(From
HPLC)

2,6-lutidine

120

30

0%

2,6-lutidine

120

45

0%

NaOAc/AcOH

75

40

0%

120

30

0%

120

40

0%

120

40

0%

120

40

2%

120

40

3%

120

60

62%

150

25

10%

(aq)
NaOAc/AcOH
(aq)
NaOAc/AcOH
(aq)
NaOAc/AcOH DMSO
(aq)
NaOAc/AcOH EtOH
(aq)
NaOAc/AcOH DMF
(aq)
NaOAc/AcOH EtOH

DMF

(aq)
NaOAc/AcOH EtOH
(aq)

Tween
20

DMF

Tween
20

Table 2.2 Different conditions for optimization of conditions for radiolabeling with
68Ga

.
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Figure 2.4 UV trace for standard compound 2.9 (blue), AU: 200-800 nm and
radio chromatogram for compound 2.10 (red), obtained using CsI(Tl) scintillating
crystal coupled to silicon PIN diode.

2.2.6 Competitive Binding Assays (IC50) for PPIX-Ghrelin(1-8)
In a competitive binding assay, there is a competition between the nonradioactive competing ligand (the imaging probe) and the radioligand having high
affinity for the receptor. The half maximal inhibitory concentration (IC50) value
obtained from the assay provides the concentration of the competing ligand that
displaces 50% of the specific binding of the radioligand. The effect of the
introduction of the chelator PPIX on the binding affinity of the peptide for GHSR1a, was studied through a competitive binding assay.

65

The IC50 values for compound 2.8 and 2.9 that were obtained from the
competitive binding assay were compared to the parent peptide and compared to
each other to determine the effect of

69/71Ga

coordination on the binding affinity

for the receptor. The IC50 value for the parent sequence [Dpr3,Tyr8] ghrelin(1-8)
was 65.0 nM, the IC50 values for compounds 2.8 and 2.9 were determined to be
4.8 µM and 617.1 nM respectively. It is believed that the reason for the decrease
in binding affinity of peptide upon coupling to PPIX is the presence of the bulky
chelator PPIX close to the N-terminus of the peptide that is essential for binding
to the receptor. The linker used for the present study is not suitable to increase
the distance between PPIX and the N-terminus. Therefore, further optimization is
required to select a more suitable linker. This will not only improve the binding
affinity of the PPIX-ghrelin analogue, but may also provide opportunity to
enhance the solubility by utilizing a more hydrophilic linker. None the less, the
binding affinity for the 69/71Ga coordinated analogue was better than the one
without 69/71Ga, confirming the role of Ga coordination in enhancement of binding
affinity and hence making it a superior targeting entity.
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Figure 2.5 Half-maximal inhibitory concentration curve of (a) compound 2.8 and
(b) compound 2.9 against [125I]-human ghrelin in HEK 293/GHS-R1a cells.
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2.3 Conclusions
With the goal of developing PET/fluorescence based dual imaging probes, we
were able to synthesize a Ga-PPIX-ghrelin (1-8) analogue, which could be
utilized for both PET and fluorescence imaging without the requirement of going
through any additional structural alteration. Here PPIX was attached to the Cterminus of the peptide ghrelin. The synthetic strategy that was developed opens
ways for conjugating porphyrins, such as PPIX, to a variety of peptides and other
biomolecules. Chelation to Ga preserved the fluorescent characteristics of the
imaging agent. Affinity for the GHS-R1a was evident through the fluorescence
images. A radiolabeled analogue was also synthesized; however, the
radiochemical yield still needs to be improved before in vivo images can be
obtained. Once this is achieved this imaging probe will permit in vitro evaluation
via fluorescence microscopy (69/71Ga), as well as in vivo PET imaging (68Ga). This
proof of concept study validates the use of Ga-PPIX, as an imaging tag in peptide
analogues, for simultaneous dual modality optical/PET imaging of biological
targets.

2.4 Experimental
Materials and Methods
All common solvents were purchased from Fischer scientific. All Fmoc protected
amino acids, coupling agents and resins were purchased from Chem Impex,
Peptide Internationals and Novabiochem® and were used without further
purification unless otherwise stated. All reagents were purchased from Sigma
Aldrich except from GaCl3 which was purchased from Strem Chemicals. The
germanium/gallium generator was obtained from Eckert and Ziegler. [ 125I]-ghrelin
was received from Perkin Elmer. RP-C18 Sep-Pak SPE cartridges were
purchased from Waters. Flash column chromatography purification was carried
out with Isolera one using Biotage SNAP Cartridge KP-C18-HS. For analysis of
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samples, an analytical Agilent RP-C18 4.6 X 150 mm, 5 µm column was utilized.
The flow rate was 1.5 mL/min over 25 minutes. For purification of samples, a
reverse phase preparative HPLC column (Agilent RP-C18 19 X 150 mm, 5 µm)
was employed. The flow rate in this case was 20 mL/min over 15 minutes. The
gradient solvent system used were 0.1% TFA in acetonitrile (solvent A) and 0.1%
TFA in water (solvent B). This system was provided with a Waters 600 controller,
Waters Prep degasser, Waters Mass Lynx software (version 4.1). For the studies
on UHPLC-MS, Waters Inc. Acquity UHPLC H-Class system was used. This was
used in combination with Xevo QTof mass spectrometer (ESI +, cone voltage
30V). For analytical studies, a Waters Acquity UHPLC BEH C18 2.1 X 50 mm,
1.7 µm column was utilized. The gradient solvent system employed was 0.1%
formic acid in acetonitrile (solvent C) and 0.1% formic acid in water (solvent D).
For analysing the radioactive samples, analytical SunfireTM RP-C18 4.6 X 150
mm, 5 µm column was used. The system comprised of a Waters 1525 Binary
HPLC pump with a Water 2487 dual λ absorbance detector and Breeze software
(version 3.30).

Synthesis of compound 2.3
In a 1 L, 2-neck round bottom flask, 2,2’- (ethylenedioxy)bis(ethylamine) (3.50 g,
23.6 mmol) was dissolved in anhydrous chloroform (472 mL, 20 mL/mmol) and
cooled to 00 C. In a 500 ml round bottom flask, Fmoc chloride (3.05 g, 11.8 mmol)
was dissolved in anhydrous chloroform (118 mL, 5 mL/mmol). This was added
dropwise to the solution of 2,2’- (ethylenedioxy)bis(ethylamine) in chloroform and
stirred at 00 C for 1 hour. The reaction mixture was allowed to stir at r.t. for 16
hours. The reaction mixture was washed with 5 M sodium chloride (NaCl) (500
mL X 2), followed by 1 M sodium hydroxide (NaOH) (2 X 150 mL). 1%
hydrochloric acid (HCl) (150 mL) was added to the organic layer and allowed to
stir for 30 min. The solution was concentrated in vacuo. The resulting compound
was purified by flash chromatography using Biotage SNAP Cartridge KP-C18-HS
60 g (MeOH in 1% HCl/H2O). Fractions were collected in round bottom flask and
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MeOH was rotary evaporated. Remaining aqueous solution was frozen at 78 0 C
and lyophilized overnight which provided a white solid in 31% yield (3.00 g, 7.38
mmol), purity 95%. HRMS (ESI +): m/z calculated for C21H27N2O4, [M+H]+=
371.1971; observed, [M+H]+= 371.1961

Synthesis of compound 2.4
In a round bottom flask Protoporphyrin IX (PPIX) (500 mg, 0.888 mmol) was
dissolved in anhydrous DCM (45 mL, 50 mL/mmol) and DMF (4.5 mL, 5
mL/mmol). To this solution, acetic anhydride (252 µL, 2.66 mmol) was added and
reaction mixture was refluxed for 3.5 hours under N2. The solvent was removed
using rotary evaporator and left under high vacuum for 2 hours. The brown solid
obtained was dissolved in anhydrous DCM (20 mL). Compound 2.3 (361 mg,
0.888 mmol) and N,N-diisopropylamine (DIPEA) (309 µL, 1.77 mmol) were added
to the reaction mixture and it was allowed to stir at r.t. under nitrogen for 16
hours. The reaction mixture was then washed with deionized H2O (3 X 20 mL),
dried over MgSO4, gravity filtered and concentrated in vacuo. The resulting
compound was purified using flash column chromatography (MeOH (1%
Triethylamine) /DCM). The fractions were collected in round bottom flask and
evaporated to dryness using a rotary evaporator. The brown solid was dissolved
in DCM (150 mL) and washed with H2O (3 X 20 mL). The organic layer was dried
with MgSO4, gravity filtered and evaporated on rotary evaporator. Compound 2.4
was obtained as a brown solid in 46% yield (378 mg, 0.413 mmol), purity 95%.
HRMS (ESI+) : m/z calculated for C55H59N6O7, [M+H]+= 915.4445; observed
[M+H]+ = 915.4456

Synthesis of compound 2.5
2-chlorotrityl chloride resin (90 mg, 0.072 mmol) was swelled in anhydrous DCM
for 15 min. Compound 2.4 (330 mg, 0.360 mmol) was dissolved in anhydrous
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DCM (2 mL), DIPEA (250 µL, 1.44 mmol) was added to this solution and allowed
to shake (using IKA-VIBRAX-VXR shaker from Sigma-Aldrich) for 10 minutes.
The DCM solution of compound 2.4 was added to the resin and was shaken for 3
hours at r.t. The resin was washed with DMF (4 X 2 mL) and DCM (4 X 2 mL)
and used for the next step.

Synthesis of PPIX-linker-[Dpr3,Tyr8]ghrelin(1-8) 2.8
Synthesis of the peptide was carried out using frit bearing peptide synthesis
vessels, employing solid phase peptide synthesis chemistry. Compound 2.5 was
initially swelled in DCM for 15 min. Fmoc deprotection was carried out using 2 mL
of 20% Pip/DMF for two cycles (10 min, 15 min). Activation of amino acids was
carried out using 3 eq. of HCTU, and 6 eq. of N,N-diisopropylethylamine (DIPEA)
in 2 mL of DMF. The mixture was then added to the resin and shaken for 60 min.
These cycles were repeated till all N terminal amino acids were coupled to the
resin. The deprotection of the allyloxycarbonyl group of diaminopropionic acid
was carried out under inert atmosphere N2. To maintain N2 atmosphere, septum
was attached to the open end of the peptide vessel and the solution was flushed
with N2. 2 mL of anhydrous DCM was added to the resin. 24 eq. of phenylsilane
was added. 0.1 eq. of tetrakis(triphenylphosphine) palladium (0) was then added
and solution was allowed to stir under N2 for 5 min. Peptide vessel was removed
from inert conditions and allowed to shake for two cycles (10 min, 20 min). Full
deprotection of peptide was accomplished by adding 3 mL mixture comprising of
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS), 2.5% H2O to the
resin and vortexed for 4 hours. The cleaved peptide was precipitated using ice
cold tert-butyl methyl ether (TBME) and centrifuged at 3000 rpm for 15 min. The
supernatant was removed and peptide pellet was dissolved in 20% ACN in H 2O,
frozen at -780C and lyophilized to obtain a brown solid. The crude peptide was
purified using preparative HPLC-MS and the purity was examined using UHPLC.
The pure product was obtained in 7% yield (24 mg, 0.0136 mmol), purity 93%.
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HRMS (ESI +): m/z calculated for C88H118N15017, [M+H]+ =1656.8830, observed
[M+H]+ =1656.8843

69/71

Ga Coordination

In a glove bag assembly under inert N2 atmosphere, compound 2.8 (50 mg,
0.028 mmol) was dissolved in 2,6-lutidine (2.5 mL) in a microwave vessel.
Gallium trichloride (GaCl3) (164 mg, 0.933 mmol) was dissolved in 2,6-lutidine
(0.5 mL) and was added dropwise to the microwave vessel containing PPIX
solution. The reaction mixture was microwaved at 1200C for 60 min. The reaction
mixture was allowed to cool to r.t. and brine (15 mL) was added. 20% citric acid
was then added to acidify the reaction mixture to pH 4. Vacuum filtration was
carried out and the solid was washed with H2O (3 X 1 mL). The solid was then
dissolved in MeOH and the solution was concentrated in vacuo. Crude compound
was then dissolved in ACN (0.1% TFA) and H2O (0.1% TFA) and purified by
preparative HPLC-MS. The fractions were combined and frozen at -780 C and
lyophilized to yield the pure compound in 42% yield (17 mg, 0.009 mmol), purity
95%. HRMS (ESI +) : m/z calculated for C88H115GaN15O17, [M+H]+ = 1722.7851;
observed [M+H]+ =1722.7805

Optical Analysis
UV absorption data was acquired using Varian Carry 300 Bio UV-Vis
spectrophotometer. Excitation and emission data were acquired using Photon
Technology International QM-4 SE spectrofluorometer. For calculating molar
extinction coefficient seven different concentrations were run for each sample.
Molar extinction coefficient was obtained from the slope of the graph of
absorbance vs concentration. The absorption, excitation and emission
wavelengths were determined using DMSO as a solvent. Fluorescence quantum
yields were determined using the comparative method described by FeryForgues and coworkers.46 Briefly, the absorbance for the solutions of the
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unknown sample and the standard was measured. The emission spectra were
also obtained and the area under the curve was determined. Fluorescence
quantum yields were calculated using Rhodamine 6G as the standard.
Fluorescence quantum yield for Rhodamine 6G has been reported to be 0.95. 48
Fluorescence quantum yields were determined using the equation:
ϕx = ϕst [ gradx/gradst ] [ ƞ2x/ƞ2st ]
where ϕx and ϕst are fluorescence quantum yields for unknown sample and
standard respectively. gradx and gradst are the gradients from the plot of
integrated fluorescence intensity vs absorbance for unknown sample and
standard respectively. ƞ is the refractive index of the solvent used.

Cell Imaging Protocol
Transfection of OVCAR-8 cells
HeyA8 and OVCAR8 human ovarian cancer cell lines were maintained in RPMI
media (Wisent) supplemented with 10% fetal bovine serum (FBS; Wisent). Cells
were seeded into 6-well tissue culture plates (Sarstedt) at 1.5 x 105 cells per 35mm well. The following day, media was changed to OptiMEM (Invitrogen)
containing 10% FBS prior to transfection. Cells were transfected with 0.5
micrograms of pCMV6-GHSR1a-EGFP plasmid using LipofectAMINE 3000
(Invitrogen) as per manufacturer’s instructions. Forty-eight hours later, cells were
trypsinized and expanded into 4 separate 100-mm tissue culture plates in
RPMI/10% FBS media. The following day, G418 Sulphate Solution (Wisent)
treatment at 400 micrograms/mL was started and maintained until colonies were
visible. GFP-positive colonies were visualized by indirect fluorescence using a
Leica DMI 4000B inverted microscope, isolated using cloning rings, and
transferred to 24-well tissue culture plates containing RPMI/10% FBS.
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For compound 2.9
OVCAR-8 cells that were transfected with GHS-R1a were released from the
tissue culture flask by trypsinization and seeded onto coverslips in a 12-well
tissue culture plate at a cell density of 50000 cells/well. The cells were incubated
overnight in Roswell Park Memorial Institute medium (RPMI) containing 10% fetal
bovine serum (FBS) at 370 C with 5% CO2. The serum containing RPMI in each
well was removed and replaced with serum free RPMI containing a concentration
of 0.5 µM of compound 2.9 and incubated at 370 C for 1 hour. Cells were then
washed three times with phosphate buffer saline (PBS), fixed with 4%
paraformaldehyde and mounted onto slides containing Pro-Long Gold Antifade
mounting medium with DAPI. For the control experiments, parental OVCAR-8
cells without GHS-R1a were incubated with compound 2.9. Images were then
obtained using an Olympus FluoView FV 1000 confocal microscope.

Blocking Studies with 36
OVCAR-8 cells with GHS-R1a were released from adhesion to tissue cultured
flask. Cells were resuspended in serum free RPMI. Cells were then incubated
with 0.5 µM of compound 2.9 at 370C for one hour. 10 X excess of compound 36
was used as blocking compound for these studies. Cells were washed with PBS
(3 times), reseeded onto coverslips, cultured in RPMI and allowed to adhere.
Cells were washed with PBS, after being adhered to coverslips. Cells were then
fixed with 4% formaldehyde and mounted onto slides. Images were then obtained
using Olympus FluoView V 1000 confocal microscope.

Synthesis of 68Ga-PPIX-linker-[Dpr3,Tyr8]ghrelin(1-8) compound 2.10
Fresh 68Ga3+ was eluted from 68Ge/68Ga generator using 0.1 M hydrochloric acid
(HCL) and trapped on Strata X C cation exchange column. The column was
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eluted with 0.1 M HCl in acetone. 1 mg of compound 2.8 was dissolved in 1 mL of
DMF. To 100 µl of this solution was added 800 µL of Tween 20 solution in
acetate buffer (pH 4.5). The solution was further diluted with 100 µl of EtOH. This
solution was added to a clean glass microwave vessel to which 522 MBq of
68GaCl
3

freshly eluted from Ge-68/Ga-68 generator was added. The reaction

mixture was heated in a microwave reactor at 1200 C for 35 min. The reaction
mixture was then passed through Sep Pak SPE cartridge and washed with 1 mL
of water. The product was eluted off the Sep Pak SPE cartidges with 1 mL of
EtOH. The activity of EtOH solution was 10 MBq. The reaction progress and
product purity was analyzed using analytical HPLC.

Competitive Binding Assay IC50
The affinity for GHS-R1a was determined using a radioligand binding assay.
Assays were performed using HEK293 cells transfected with GHS-R1a (obtained
from Dr. Savita Dhanvantari) as receptor source. HEK293 cells were grown in
MEM (Minimum Essential Media) supplemented with non-essential amino acids
and 10% fetal bovine serum. For the purpose of transfecting the cells with GHSR1a, cells were grown to 70% confluency in a 75cm flask and transfected with
GHS-R1a-pcDNA 3.1 plasmid (Missouri S and T cDNA Resource Center) using a
modified calcium phosphate transfection protocol.52 Human [125I]-ghrelin(1-28)
(PerkinElmer Inc.) was used as radioligand. Human ghrelin(1-28) was used as
reference to ensure the validity of the results. Compounds 2.8 and 2.9 (at
concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M, 10-9 M, 10-10 M, 10-11 M) and
[125I]-ghrelin (15,000cpm per assay tube) were mixed in binding buffer (25 mM
HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and
0.4% BSA, pH 7.4). A suspension of membrane from GHS-R1a transfected
HEK293S cells (50,000 cells per assay tube) was added to the assay tube
containing test peptides and [125I]-ghrelin(1-28). The resulting suspension was
incubated for 20 minutes under shaking (550 rpm). Unbound [125I]-ghrelin was
removed and the amount of [125I]-ghrelin bound to the membranes was measured
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on a gamma counter. The IC50 was determined by a logistic nonlinear regression
analysis using Origin. All binding assays were performed in triplicates.
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Chapter 3

3 The Development of Ga-peptide-Hematoporphyrin
Derivatives as Imaging Agents

3.1 Introduction
Porphyrin and related compounds have been shown to play a crucial role in
imaging, detecting and treating different types of cancers. Recently, tetra
sulphonatophenyl porphyrin (TSPP)-TiO2 was studied as a novel fluorescence
imaging and photodynamic therapeutic agent for rheumatoid arthritis.1
Porphyrins exhibit some very useful properties including, ability to form stable
metal complexes and demonstrate specificity for cancer tissues.2 This makes
them popular not only as sensitizers for PDT but also makes them suitable
imaging agents. The tendency of porphyrins and metalloporphyrins to accumulate
in neoplastic tissues has been previously shown.3
Various types of imaging applications of porphyrins have been reported in the
literature e.g. macrophages which are known to play an important role in
inflammation were labeled with silica-tetrakis(4-carboxyphenyl) porphyrin hybrid
nanotubes (silica-TCPP HNT), injected into mice and imaged by fluorescence
microscopy. The ex-vivo images showed the accumulation of macrophage
labeled HNT’s in the liver and demonstrated the ability of these systems to act as
NIR probes for in vivo imaging.4
A dinitrotetraphenylporphyrin based probe was studied for MRI and fluorescence
Zn sensing.5 Zn selective binding units were conjugated to the porphyrin
analogue. The fluorescence intensity of this probe was found to increase > 10fold on binding to Zn. The Mn-coordinated analogue of
dinitrotetraphenylporphyrin was also synthesized. The relaxivity of this Mn-
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analogue was drastically changed in the presence of Zn, demonstrating the
potential to act as MRI Zn sensor. Lovell and coworkers utilized mesotetrakis (4carboxyphenyl) porphyrin for synthesizing a novel class of optically active
hydrogels.6 Hydrogels can act as efficient drug delivery systems. The hydrogels
after being implanted in mice were monitored for 2 months and found to be stable
and resistant to bleaching. Further, real time image guided surgical resection of
the implanted hydrogel in vivo was also performed. Novel Mn-porphyrin probes
have been explored as MRI agents for prostate cancer.7 Phantom studies
depicted a higher T1 relaxivity change for these porphyrin probes as compared to
the commercial Gd chelates. High tumour to background contrast was seen after
single injection of these probes in prostate tumour xenografts. Another Gd-DTTA
(diethylenetriamine-N,N,N’’,N’’-tetraacetate)-porphyrin complex was synthesized
for application as MRI contrast agent.8 The relaxivity per gadolinium was found to
remain high at very high magnetic field.
Another emerging field of imaging where porphyrins have been shown to have
played vital role is nuclear imaging. The development of [67Ga]-3,4dimethoxylated porphyrin complex as potential SPECT imaging agent has been
reported.9 Stability tests indicated that 67Ga was still intact in the complex after
incubation in human serum after 24 hours. Biodistribution studies and SPECT
images demonstrated a higher uptake in the myocardium.

99mTc-meso-bisphenyl

porphyrin was evaluated as imaging agent for colorectal adenocarcinoma and
non-small cell lung cancer.10 The effect of temperature on the radiolabeling
efficiency was demonstrated and a labeling efficiency > 90% was obtained by
optimizing the reaction temperature. The complex showed a rapid clearance
through gastrointestinal and urinary pathways. A higher uptake by the H1299 cell
line was confirmed by both in vitro and in vivo analysis. 111In labeled porphyrin
derivatives were analyzed as effective agents for SPECT imaging in wild type
mice.11 The stability of these complexes was tested in human serum for 2 days.
Biodistribution and SPECT studies showed rapid clearance through urinary
excretion depicting that these complexes can act as efficient imaging agents.

80

In another example, 5,10,15,20-tetrakis(pentafluoro-13 phenyl) porphyrin (TFPP)
was radiolabeled with 68Ga in 30-60 minutes. Stability tests indicated no loss of
Ga from the complex after incubation with human serum even after 2 days.
Biodistribution analysis was performed in mice bearing fibrosarcoma tumours and
higher uptake of the radiotracer in the tumour was seen. Hence, the potential of
this 68Ga-porphyrin complex to act as PET imaging agent was depicted.
The porphyrin selected for this project is hematoporphyrin (HP). It has been one
of the most commonly studied porphyrins. In the 1960’s, the tumour localizing
fraction from the hematoporphyrin solution was isolated by Schwartz. 12 Later, this
hematoporphyrin derivative was studied by Dougherty and found to have a high
singlet oxygen quantum yield. The efforts made by Dougherty through
ultrafiltration led to the isolation of the material known as Photofrin II.13 Later,
additional purification performed at QLT Photo Therapeutics resulted in the
isolation of the material which is known as Photofrin® today.14,15 There has been
a lot of debate on the chemical composition of this material. A lot of difficulties
were encountered due to the fact that the hematoporphyrin derivative comprised
of a complex mixture of oligomers and the determination of the exact chain length
was difficult.16 This material comprised of a mixture of porphyrins linked together
by ether and ester linkages.17 Photofrin® shows a broad HPLC profile owing to
the complex nature of this mixture. Nonetheless, due to the selective
accumulation of Photofrin® at tumour sites, it was later approved by FDA for the
treatment of lung and esophageal cancer.18
There are some reports in the literature that demonstrate that HP can be
coordinated to metal ions. For example gold(III)-HP complex was synthesized
and used to study cytotoxicity against leukemia and lymphoma derived cell
lines.19 Pt-HP complexes have also been studied as anticancer agents.20 HP has
also been coordinated to radiometals such as 111In and a comparison of
biodistribution of

111In-hematoporphyrin

and 111In chloride in tumour bearing mice

showed a difference in tumour uptake of both these species.21 Effect of metal
coordination on the fluorescent properties of HP has also been studied in a few
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cases. Coordination of HP to metal ions such as Co2+ and Cu2+ has been found
to quench the fluorescence.22
Besides application as a photosensitizer, hematoporphyrin has also been
analysed as an effective imaging agent. In one of the examples, hematoporphyrin
was used for early detection of the surface tumours in mice through fluorescence
reflectance imaging (FRI).23 The red fluorescence signal from the accumulation of
hematoporphyrin in tumour was observed within 3 days from the injection of
cancer cells into the mice i.e. long before the tumour was apparent to the naked
eye. Recently, HP monomethyl ether (HMEE) loaded poly (lactic-co-glycolic acid)
(PLGA) microcapsules were developed as ultrasound/photoacoustic contrast
agent.24 Ultrasound irradiation of sonosensitizers in appropriate frequency can
lead to permanent damage to tumour cells. HMEE/PGLA microcapsules
effectively destroyed ovarian cancer SKOV3 cells and prevented cell proliferation.
99mTc-HP-albumin

nanoparticles (ANP) were studied for application in radio

imaging of lung cancer.25 Here the surface of albumin nanoparticles was modified
with hematoporphyrin which was then labeled with

99mTc.

HP-ANP showed higher

uptake in the cancer cells and higher accumulation in the mouse lung cancer
model.
The efficiency of the imaging probes can certainly be enhanced by developing
delivery modes that will transport them to the biological site of interest. Therefore,
there is continuous demand for the development of new targeting strategies. One
such targeting strategy is to attach the porphyrin to an entity that has high
specificity and selectivity for a bioreceptor. Several small molecules, peptides,
antibodies have been conjugated to porphyrins to facilitate selective uptake by
cancer. A 64Cu-porphyrin-peptide analogue was developed as a targeted PET
imaging probe for the folate receptor that is expressed in lung, ovarian and breast
cancer.26 Small animal PET images depicted the uptake of the analogue in the
folate receptor positive tumours with high tumour to muscle ratio. Gold
nanoparticles were functionalized with porphyrin through hyaluronic acid that is
known to have a high affinity for CD44 which is overexpressed in many cancers.
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The probe could differentiate between cells with different levels of CD44 and also
demonstrated specific damage to cancer cells such as U-87 overexpressing
CD44.27 68Ga-porphyrin-peptide conjugate was developed as PET/PDT
theranostic agent targeted for ɑ6 β1 integrin.28 Azide bearing porphyrin was
labeled with 68Ga and clicked with the alkyne functionalized peptide specific for ɑ6
β1 integrin. The evaluation of the therapeutic effects depicted the selectivity of the
probe for cell line with high integrin expression.
Bombesin (BN) is a 14-amino acid peptide which was isolated from the skin of
the toad bombina bombina.29 Consequently, two mammalian bombesin like
peptides (BN-LP) were isolated: gastrin releasing peptide (GRP) and
neuromedin-B (NMB). BN and GRP stimulate smooth muscle contraction, play a
role in the release of gastrin, the secretion of pancreatic enzymes, and act as
neurotransmitters in the central nervous system.30 Four receptor subtypes
associated with the BN-LP family have been isolated. These include receptor
subtype-1 (GRP-R) that binds to both BN and GRP, receptor subtype-2 (NMB-R)
that binds to NMB, subtype-3 (BRS-3) that is an orphan receptor because its
natural ligand has not been discovered yet and lastly receptor subtype-4 (BRS-4),
that exhibits higher affinity for BN than GRP30. These receptors belong to the Gprotein receptor superfamily.31
GRP-R is overexpressed in several kinds of cancers such as prostate,32 breast,33
gastrointestinal,34 lung cancer35 etc. Therefore, GRP-R can play a vital role in
imaging of cancer by developing imaging probes by the attachment of an imaging
tag to bombesin peptide that has high affinity for GRP-R. Structure activity
studies demonstrate that the C-terminus is crucial for binding to the receptor
therefore modifications can be made at the N-terminus. A pan bombesin
analogue [D-Tyr6,β-Ala11, Phe13, Nle14]-bombesin (6-14), where amino acids at
position 6,11,13 and 14 are replaced by unnatural amino acids has been found to
bind all bombesin receptor subtypes with a high affinity.36 The replacement with
unnatural amino acids also helps in improving the in vivo peptide stability.
Another report suggested that the presence of D-Tyr6 was not necessary for
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binding to GRP-R.37 Therefore, the truncated sequence BN (7-14) is sufficient for
binding to GRP-R.38
BN (7-14) has been used for the development of various imaging probes. Many
BN (7-14) analogues with modifications have been shown to be radiolabeled with
radioisotopes like 64Cu39, 18F40, 99mTc41. Some BN (7-14) have also been reported
for application in fluorescence imaging of GRR-R with Qdots,42 Alexa Fluor43. In
one of the examples, [β-Ala11, Phe13, Nle14]-bombesin (7-14) analogue was
coupled to superparamagnetic iron oxide nanoparticles using click reaction.
Specific uptake of the probe relative to unfunctionalized nanoparticles was
demonstrated in prostate cancer PC-3 cells.44 This demonstrated the potential of
the probe to act as MRI contrast agent for imaging prostate cancer.
This study will involve the conjugation of hematoporphyrin with [β-Ala11, Phe13,
Nle14]-bombesin (7-14) for the development of fluorescent/PET based imaging
probe for GRP-R.

3.2 Results and Discussion
Earlier, Ga69/71 has been coordinated to PPIX45,46 and the presence of the
coordinated Ga69/71 did not quench the fluorescence of PPIX.46 Owing to the
hydrophobic nature of PPIX, there were problems related to the solubility. Due to
the presence of isopropanol substituents, HP seems more hydrophilic as
compared to PPIX. We aimed to develop a Ga-HP-peptide based dual modal
fluorescence/PET imaging agent for GRP-R. The peptide chosen for this study is
[β-Ala11, Phe13, Nle14]-bombesin (7-14), which has been shown earlier in the
literature to be specifically taken up by PC-3 cells expressing GRP-R.44
HP that is commercially available, consists of not just one species, but is a
mixture of different porphyrin species. These include: 1) hematoporphyrin where
two of the pyrrole rings have iso-propanol groups attached, 2) two
monohydroxyethyl monovinyl deuteroporphyrin derivatives HVD1 and HVD2,
where one of the isopropyl group is replaced by a vinyl group for each of the
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HVDs respectively and 3) PPIX, where both the isopropyl groups are replaced by
vinyl groups. Figure 3.1 shows the structure of the porphyrin species comprising
a hematoporphyrin mixture. This entire hematoporphyrin mixture can be used for
imaging and the separation of the porphyrin species comprising this mixture is
not necessary. The main idea is to be able to conjugate all the porphyrin species
with the targeting peptide, coordinate to

69/71

Ga and radiolabel with 68Ga and use

as such for fluorescence and PET imaging.

Figure 3.1 Structures of various porphyrin species comprising hematoporphyrin
mixture.
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3.2.1 69/71 Ga Coordination of Hematoporphyrin
Coordination of certain metal ions to porphyrins typically requires high reaction
temperature.47 Conventional heating methods often require heating the reaction
mixtures at elevated temperatures and for longer reaction times.47 This can be a
limiting factor for the coordination of Ga3+ to porphyrins particularly if the
porphyrin has a peptide attached to it owing to the instability of peptide at very
high temperature. Use of microwave irradiation to coordinate metal ions to
porphyrins has shown improvement over conventional methods. 46 Before moving
forward with the synthesis of the imaging probe, it was desired to analyze the
ability of hematoporphyrin to coordinate to

69/71Ga.

Hematoporphyrin was first

coordinated to 69/71Ga using GaCl3.
Hematoporphyrin is more hydrophilic as compared to PPIX, therefore it was
possible to perform 69/71Ga coordination under aqueous conditions employing a
mixture of NaOAc/AcOH (aq) buffer and acetone as solvent system. This is in
contrast to what was previously found for the coordination of 69/71Ga to PPIX,
which could not be performed under aqueous conditions and required the use of
2,6-lutidine. A mixture of 69/71Ga coordinated hematoporphyrin species was
obtained. Figure 3.2 depicts the structure of

69/71Ga

coordinated hematoporphyrin

mixture. Compound 3.1 corresponds to Ga coordinated hematoporphyrin
mixture, 3.2 and 3.3 correspond to the two isomers of Ga coordinated HVD
where one of the isopropyl group is replaced by vinyl group respectively and 3.4
corresponds to Ga coordinated PPIX component. The HPLC trace for these
species is also shown in Figure 3.3. The ratio between the different

69/71Ga

coordinated hematoporphyrin species was determined to be 2:2:2:1 for
compounds 3.1:3.2:3.3:3.4 (from the HPLC trace). Compounds 3.2 and 3.3 are
two isomers that have different retention times on the HPLC but show the same
mass on the mass spectrum. The formation of 69/71Ga-hematoporphyrin species
was confirmed from the mass spectrum. The m/z values for these species are
summarized in Table 3.1.
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The fluorescence quantum yield for 69/71 Ga-coordinated HP mixture was
determined to be 0.38, once again confirming that Ga coordination does not
quench the porphyrin fluorescence.

Figure 3.2 Structures of the 69/71Ga coordinated hematoporphyrin species.
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69/71

3.1

1.0

Ga-hematoporphyrin derivatives

3.2 and 3.3

Absorbance

0.8

0.6

3.4

0.4

0.2

0.0
0.0

0.5

1.0

1.5

2.0

2.5

3.0

minutes

Figure 3.3 HPLC chromatogram for 69/71Ga coordinated hematoporphyrin
species. Compound 3.1 (retention time 1.25 minutes), compound 3.2 or 3.3
[isomers not assigned] (retention time 1.58/1.66 minutes) and compound 3.4
(retention time 2.02 minutes). AU: 200-800 nm.

Calculated m/z

Observed m/z

3.1

665.1891

665.1689

3.2

647.1785

647.1469

3.3

647.1785

647.1469

3.4

629.1679

629.1655

Table 3.1 Calculated m/z and observed m/z for 69/71Ga-hematoporphyrin species
3.1, 3.2, 3.3 and 3.4.
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3.2.2 Optical Analysis
Photo-physical data was obtained and compared to HP (summarized in table
3.2). It was observed that upon Ga-coordination there was a blue shift in the
emission maxima as compared to HP. The absorbance maxima did not shift
significantly upon coordination to 69/71Ga. The coordination of 69/71Ga could be
easily confirmed from the absorption spectrum, as the formation of
metalloporphyrin leads to the disappearance of two Q-bands. (Figure 3.4)
The fluorescence quantum yields were obtained according to the reported
comparative methods48, using tetraphenylporphyrin as standard.49 Fluorescence
quantum yield for Ga-coordinated HP mixture was 0.38 as compared to 0.07 for
the uncoordinated parent HP(mixture of porphyrin species) .

λex (nm)

λem (nm)

λabs (nm)

Φ[a]

(DMSO)

(DMSO)

(DMSO)

(EtOH)

Hematoporphyrin

399

628

395

0.07

69/71Ga-Hematoporphyrin

405

579

405

0.38

69/71Ga-HP

analogues.

Compound

species

Table 3.2 Photophysical data for HP and

Slit width was 2 nm. Emission collected in the range 409-800 nm for
hematoporphyrin and 415-800 nm for 69/71 Ga-hematoporphyrin species.
[a]: Quantum yields obtained using tetraphenyl porphyrin49 as standard in
deoxygenated solutions using previously reported procedure.48
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Figure 3.4 Absorption and emission spectra: Absorption for HP mixture (blue),
Absorption for 69/71Ga-HP analogues (green), emission for compound HP mixture
(red), emission for 69/71Ga-HP analogues (black). Recorded for 10-5 M DMSO
solution.

3.2.3 Synthesis of HP-AEEA-[β-Ala11, Phe13, Nle14]-Bombesin(7-14)
Analogues
The design of the dual modality imaging probe consists of using the peptide
analogue [β-Ala11, Phe13, Nle14]-bombesin (7-14) as the targeting entity, a linker
and HP as the fluorescent tag/metal chelator. The C-terminus of bombesin is
crucial for binding to the receptor. Therefore, HP would be coupled to N-terminus
of bombesin through a linker, leaving the C-terminus free for binding to the
receptor. The linker 2-[2-(2-aminoethoxy)ethoxy] acetic acid (AEEA) was selected
in order to improve the hydrophilic character of the imaging probe and also to
increase the distance between the peptide and chelator HP, in order to prevent
the adverse effect of the bulky HP on the binding affinity of the peptide, [β-Ala11,
Phe13, Nle14]-bombesin (7-14) was coupled to the AEEA linker. This was then
coupled to hematoporphyrin on resin. A mixture was obtained, where all the
porphyrin species comprising the hematoporphyrin mixture were coupled to the
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peptide. Figure 3.6 depicts the HPLC trace for coupling bombesin peptide to the
hematoporphyrin analogues through the AEEA linker.
The metal chosen was Ga, where the

69/71Ga

analogue will be used for in vitro

fluorescence analysis as well as a non-radioactive standard. The 68Ga analogue
can be used for PET based imaging analysis. The synthetic route for synthesis of
imaging probe is depicted in Scheme 3.1.

Figure 3.5 General design of the imaging probe.
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Scheme 3.1 Route for synthesis of imaging probe comprising hematoporphyrin
species coupled to bombesin analogue (compounds 3.7, 3.8, 3.9 and 3.10).
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Figure 3.6 HPLC trace for crude mixture of products obtained by coupling [βAla11, Phe13, Nle14]-bombesin (7-14)-AEEA with HP. Compound 3.7 (retention
time 1.63 minutes), compound 3.8 and 3.9 (isomers not assigned) (retention time
2.00-2.13 minutes) compound 3.10 (retention time 2.47 minutes). AU: 200-800
nm.

3.2.4 69/71Ga Coordination of HP-AEEA-[β-Ala11, Phe13, Nle14]Bombesin(7-14) Analogues.
Next the hematoporphyrin-peptide mixture was coordinated to 69/71Ga. The HPLC
chromatogram from this reaction looked quite complicated. It was seen from the
chromatogram that although the HP component, i.e. compound 3.7, and HVD
components, i.e. compounds 3.8 and 3.9, were coordinated to 69/71Ga.
Compound 3.10 could not be coordinated to 69/71Ga. Figure 3.7 depicts the HPLC
trace for 69/71Ga coordination.
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Various attempts were made to coordinate all the components to

69/71

Ga but

these attempts were unsuccessful due to decomposition of HP to PPIX and to
other species and due to decomposition of the peptide. This led to an increase in
the complexity of the mixture. This mixture of Ga-coordinated and uncoordinated
porphyrin species could not be used to obtain the photophysical data. Using this
will not give a correct estimation of the effect of
properties.

69/71Ga

coordination on the optical
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Scheme 3.2 Route for 69/71Ga coordination.
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Figure 3.7 HPLC trace for crude mixture of products obtained by coordinating
69/71Ga

to [β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA-HP. Compound 3.11

(retention time 1.01 minutes), compound 3.12 and 3.13 (retention time 1.18-1.48
minutes). Unreacted compound 3.10 (retention time 1.55 minutes). AU: 200-800
nm.

3.2.5 68Ga Labeling of Hematoporphyrin
In order to confirm the potential of HP to chelate to

68Ga,

attempts were made to

radiolabel HP with 68Ga. The radiochromatogram was compared with the HPLC
trace for the non-radioactive standard (mixture of compounds 3.1, 3.2, 3.3 and
3.4) (Figure 3.8). After several trials, the best results depicted that although HP
and HVD were being labeled with 68Ga, no peak corresponding to the

68Ga-PPIX

component was seen. Any further attempts were leading to the breakdown of HP
into PPIX and this PPIX component was not coordinating with the radiometal.
This might be due to solubility issues related to PPIX. There is a difference in the
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solubility between PPIX and HP and its derivatives HVD. PPIX is more
hydrophobic than HP, leading to incomplete labeling. Nonetheless, the ability of
HP to become radiolabeled with 68Ga was demonstrated.

Scheme 3.3 Synthetic route for radiolabeling of HP with

68Ga.
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Figure 3.8 UV trace for standard compound i.e. mixture of 3.1 (retention time 6
minutes), 3.2, 3.3 (isomers not assigned) (retention time 7-8 minutes) and 3.4
(retention time 9 minutes) (blue), AU: 200-800 nm and radiochromatogram for
68Ga

labeling (red) using CsI(Tl) scintillating crystal coupled to silicon PIN diode.

3.3 Conclusions
Hematoporphyrin (HP) can form metal complexes and possesses fluorescent
characteristics. We aimed to develop hematoporphyrin based fluorescence/PET
imaging agents targeting GRP-R, which is highly expressed in prostate cancer
and can be useful in diagnosis. HP was coordinated to 69/71Ga, where a mixture
of 69/71Ga-coordinated porphyrin species was obtained and the fluorescent
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properties were studied. A fluorescence quantum yield of 0.38 was obtained for
this mixture as compared to the parent uncoordinated hematoporphyrin mixture
for which fluorescence quantum yield was determined to be 0.07.
The peptide [β-Ala11, Phe13, Nle14]-bombesin (7-14) has been earlier shown to be
specifically taken up by the prostate cancer cell line PC-3. HP was first coupled
through an AEEA linker to the peptide [β-Ala11, Phe13, Nle14]-bombesin (7-14) at
its N-terminus leaving the C-terminus free as it is needed for binding to the
receptor. A mixture of porphyrin-peptide species was obtained. This mixture
comprised of peptide coupled to HP, two HVD isomers and PPIX species leading
to the synthesis of compounds 3.7, 3.8, 3.9 and 3.10. Upon coordination of this
mixture to 69/71Ga, a complex mixture of 69/71Ga-HP (3.11) and 69/71Ga-HVD (3.12
and 3.13) was obtained. Also, some of the porphyrin species were left
uncoordinated which led to difficulties in purification of this Ga coordinated and
uncoordinated mixture. In order to maintain consistency, all the porphyrin species
comprising the hematoporphyrin mixture need to be coordinated to

69/71Ga.

To focus on the design of a PET imaging probe, HP was radiolabeled with

68Ga.

Although, we were successful in radiolabeling HP and HVD components, the
radiolabeling did not go to completion and we were not able to radiolabel the
PPIX component of the HP mixture.
The aim of this project was to develop fluorescent Ga-bombesin-hematoporphyrin
analogues and to analyze the specific binding to GRP-R through fluorescence
microscopy. Further, the project focussed to develop this probe into PET imaging
probe

through 68Ga labeling. The ability of hematoporphyrin to coordinate to

69/71Ga

and

act as a useful metal chelator was demonstrated. Fluorescence of
hematoporphyrin species was not quenched upon coordination to

69/71Ga

which

was evident from the fluorescence quantum yield data. Hematoporphyrin was
also successfully radiolabeled with 68Ga and this would facilitate the development
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of 68Ga-hematoporphyrin as a PET imaging probe. Further, the ability of
hematoporphyrin to be coupled with a peptide was demonstrated. But the gallium
coordination could not be carried out to completion possibly due to the poor
solubility of the PPIX component.
Since the isolation of the Ga-coordinated analogues was problematic, other
porphyrins should be investigated for use as fluorescent tags and as Ga
chelators. Structural modifications could be carried out to introduce more
hydrophilic groups to the porphyrin. These approaches have the potential to aid
in increasing the solubility of the porphyrin and could improve yields for the metal
coordination reactions.

3.4 Experimental
Materials and Methods
All common solvents were purchased from Fischer scientific. All Fmoc protected
amino acids, coupling agents and resins were purchased from Chem Impex,
Peptide International and Novabiochem® and were used without further
purification unless otherwise stated. All reagents were purchased from Sigma
Aldrich except for GaCl3 which was purchased from Strem Chemicals. The
germanium/gallium generator was obtained from Eckert and Ziegler. [ 125I]-ghrelin
was received from Perkin Elmer. RP-C18 Sep-Pak SPE cartridges were
purchased from Waters. For analysis of samples, an analytical Agilent RP-C18
4.6 X 150 mm, 5 µm column was utilized. The flow rate was 1.5 mL/min over 25
minutes. For purification of samples, a reverse phase preparative HPLC column
(Agilent RP-C18 19 X 150 mm, 5 µm) was employed with a flow rate of 20
mL/min over 15 minutes. The gradient solvent system used were 0.1% TFA in
acetonitrile (solvent A) and 0.1% TFA in water (solvent B). This system was
provided with a Waters 600 controller, Waters Prep degasser, Waters Mass Lynx
software (version 4.1). For the studies on UHPLC-MS, Waters Inc. Acquity
UHPLC H-Class system was used. This was used in combination with Xevo QTof
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mass spectrometer (ESI +, cone voltage 30V). For analytical studies, a Waters
Acquity UHPLC BEH C18 2.1 X 50 mm, 1.7 µm column was utilized. The gradient
solvent system employed was 0.1% formic acid in acetonitrile (solvent C) and
0.1% formic acid in water (solvent D). For analysing the radioactive samples,
analytical SunfireTM RP-C18 4.6 X 150 mm, 5 µm column was used. The system
comprised of a Waters 1525 Binary HPLC pump with a Water 2487 dual λ
absorbance detector and Breeze software (version 3.30).

Synthesis of compound 3.1, 3.2, 3.3 and 3.4.
Hematoporphyrin (10 mg, 0.0167 mmol) was dissolved in 1 mL acetone and 2 mL
sodium acetate/acetic acid buffer (pH 4.3). GaCl3 (14.7 mg, 0.0836 mmol) was
dissolved in 1 mL sodium acetate/acetic acid buffer and this solution was added
to the hematoporphyrin solution. The reaction mixture was heated in a microwave
reactor at 1200 C for 15 minutes, then cooled to r.t. and passed through RP C-18
Sep Pak SPE cartridge. The RP C-18 Sep Pak SPE cartridge was then washed
with water and the products were eluted with ethanol. Analysis of the products
was carried out by UHPLC-MS with four predominant peaks being identified as
Ga-coordinate porphyrins obtained in the ratio 2:2:2:1 (3.1:3.2:3.3:3.4). HRMS
(ESI +): (For 3.1) m/z calculated for C34H36GaN4O6, 665.1891; observed
665.1689. (For 3.2/3.3) m/z calculated for C34H34GaN4O5, 647.1785; observed
647.1469. (For 3.4) m/z calculated for C34H32GaN4O5, 629.1679; observed
629.1655.

Synthesis of [β-Ala11, Phe13, Nle14]-bombesin (7-14) compound 3.5.
Synthesis of peptide was carried out using peptide synthesis vessel, employing
solid phase peptide synthesis chemistry. Peptides were synthesized at 0.1 mmol
scale using Rink amide resin (0.51 mmol/g). Fmoc deprotection was carried out
using 2 mL of 20% Pip/DMF for two cycles (10 min, 15 min). Activation of amino
acids was carried out using 3 eq. of HCTU, and 6 eq. of N,N-
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diisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was then added to
the resin and shaken (using IKA-VIBRAX-VXR from Sigma-Aldrich) for 60 min.
These cycles were repeated until all N terminal amino acids were coupled to the
resin. A small sample from the crude peptide was cleaved from resin using 0.5
mL of a mixture of 95 % TFA (trifluoroacetic acid), 2.5 % TIPS (triisopropylsilane)
and 2.5 % H2O. The cleaved peptide was precipitated from solution using cold
TBME (tert-butyl methyl ether) and centrifuged (3000 rpm, 10 min) resulting in
crude peptide pellet. The supernatant was discarded and the peptide pellet was
dissolved in 40% ACH/H2O, frozen at -78 0C and lyophilized resulting in a brown
powder. The crude peptide was analysed by analytical UHPLC-MS. HRMS (ESI
+): m/z calculated for C48H67N13O9, [M+H]+ = 970.5965; observed [M+H]+=
970.4868

Synthesis of [β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA compound
3.6.
Fmoc deprotection of peptide 3.5 was carried out using 2 mL of 20% Pip/DMF for
two cycles (10 min, 15 min). Linker AEEA (116 mg, 0.300 mmol) was dissolved in
DMF and HCTU (125 mg, 0.3 mmol) and DIPEA (105 µL, 0.600 mmol). This
solution was then shaken at r.t. for 15 min and then added to the peptide.
Reaction mixture was shaken at r.t. for 2 hours. The crude product was analysed
by UHPLC chromatogram. HRMS (ESI +): m/z calculated for C54H78N14O12,
[M+H]+ = 1115.6704; observed [M+H]1+ = 1115.6001

Synthesis of [β-Ala11, Phe13, Nle14]-bombesin (7-14)-AEEA-HP
compound (3.7, 3.8, 3.9 and 3.10)
Fmoc deprotection of peptide 3.6 was carried out using 2 mL of 20% Pip/DMF for
two cycles (10 min, 15 min). Hematoporphyrin (207 mg, 0.300 mmol) was
dissolved in DMF:DCM:DMSO (1:1:1) and HATU (115 mg, 0.300 mmol) and
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DIPEA (105 µL, 0.600 mmol). This solution was then shaken at r.t. for 15 min and
then added to the peptide solution. Reaction mixture was vortexed at r.t. for 16
hours. Full deprotection of product was accomplished by adding 3 mL mixture
comprising of 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS), 2.5%
H2O to the resin and shaken for 4 hours. The cleaved peptide was precipitated
using ice cold tert-butyl methyl ether (TBME) and centrifuged at 3000 rpm for 15
min. The supernatant was removed and peptide pellet was dissolved in 40% ACN
in H2O, frozen at -780C and lyophilized to obtain a brown solid. The crude peptide
was purified using preparative HPLC-MS and the purity was examined using
UHPLC. HRMS (ESI +): (For 3.7) m/z calculated for C88H114N18O17 , [M+2H]2+ =
848.4382; observed [M+2H]2+ = 848.5945 (For 3.8/3.9) m/z calculated for
C88H112N18O16 , [M+2H]2+ = 839.4330; observed [M+2H]2+ = 839.5709 (For 3.10)
m/z calculated for C88H110N18O15 , [M+2H]2+ = 830.4277; observed [M+2H]2+ =
830.5591.

Synthesis of compounds (3.11, 3.12 and 3.13)
Mixture of compounds 3.7, 3.8, 3.9 and 3.10 (10 mg, 0.00553 mmol) was
dissolved in 1 mL acetone and 1.5 mL sodium acetate/acetic acid buffer (pH 4.3).
GaCl3 (5 mg, 0.0276 mmol) was dissolved in 1 mL buffer and added to the above
solution. The reaction mixture was heated in a microwave reactor at 120 0 C for 15
min. The reaction mixture was passed through RP C-18 Sep Pak SPE cartridge
and the cartridge was eluted with water and ethanol. Ethanol was evaporated and
crude product was analyzed using UHPLC. HRMS (ESI +): (For 3.11) m/z
calculated for C88H112GaN18O17 , [M+2H]2+ = 81.8932; observed [M+2H]2+ =
881.3821. (For 3.12/3.13) m/z calculated for C88H110GaN18O16 , [M+2H]2+ =
872.8879; observed [M+2H]2+ = 872.8879.
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Optical Analysis
UV absorption data was acquired using Varian Carry 300 Bio UV-Vis
spectrophotometer. Excitation and emission data were acquired using Photon
Technology International QM-4 SE spectrofluorometer. The absorption, excitation
and emission wavelengths were determined using DMSO as a solvent.
Fluorescence quantum yields were determined using the comparative method
described by Fery-Forgues and coworkers.48 Briefly, the absorbance for the
solutions of the unknown sample and the standard was measured. The emission
spectra were also obtained and the area under the curve was determined.
Fluorescence quantum yields were estimated using tetraphenylporphyrin as the
standard. Fluorescence quantum yield for tetraphenylporphyrin has been
reported to be 0.11 in toluene.49 Fluorescence quantum yields were determined
using the equation:
ϕx = ϕst [ gradx/gradst ] [ ƞ2x/ƞ2st ]
where ϕx and ϕst are fluorescence quantum yields for unknown sample and
standard respectively. gradx and gradst are the gradients from the plot of
integrated fluorescence intensity vs absorbance for unknown sample and
standard respectively. ƞ is the refractive index of the solvent used.

Radiolabeling hematoporphyrin with Ga-68.
Fresh 68Ga3+ was eluted from 68Ge/68Ga generator using 0.1 M hydrochloric acid
(HCL) and trapped on Strata X C cation exchange column. The column was
eluted with 0.1 M HCl in acetone. Hematoporphyrin (1 mg, 1.67 µmol) was
dissolved in 1 mL of acetone. To 100 µl of this solution was added 900 µl of
sodium acetate/acetic acid buffer (pH 4.3). This solution was added to a clean
glass microwave vessel to which 516 MBq of 68GaCl3 freshly eluted from
68Ge/68Ga

generator was added. The reaction mixture was heated in a microwave

reactor at 1200 C for 20 minutes. The reaction mixture was then passed through
preconditioned RP C-18 Sep Pak SPE cartridge and washed with 1 mL of water.
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The product was eluted off the sep pak with 1ml of EtOH. The activity of EtOH
solution was 20 MBq. The reaction progress and product purity was analyzed
using analytical HPLC.
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Chapter 4

4 The Development of Ghrelin-Formazanate Boron Difluoride
Dyes as Imaging Agents

4.1 Introduction
The extensive interest from chemists, biochemists, and physicists in the use of
fluorescence has accelerated the development of novel fluorescent dye systems.
Fluorescent systems have several applications in biology and biotechnology such
as molecular probes in biomedical analysis, microscopy, cellular imaging, flow
cytometry, and genotyping assays.1 The synthesis of dyes has been carried out
since a very long time, with the focus being on the development of compounds
that have good chemical, photochemical and thermal stability, and excellent
optical properties.2 Classes of dyes that have been devised systematically
comprise of porphyrins,3 coumarins,4 xanthenes,5 and cyanines6. One of the most
common application of these dyes is fluorescence microscopy. Fluorescence
quenching and photobleaching are two of the limitations associated with
conventional dyes, therefore, there is a need for the development of novel dyes
that have better photostability and suitable optical properties. 7,8
Recently, one of the most well studied application of the structurally distinct
fluorescent dyes includes the development of the methodologies where unique
reporter entities can be coupled to the targeting agent.9 Various biomolecules
including DNA, proteins and antibodies are labeled with fluorescent dyes such as
fluorescein and rhodamine.1 Recent developments in chemical biology and
molecular library screening has led to the recognition of new ligands having high
affinity for biological targets as well as identification of novel fluorescent systems.
The structure and physiochemical characteristics of a dye-conjugate are
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important factors to be considered for the conservation of the affinity of the
targeting entity. Most fluorescent dyes are large, consisting of polycyclic rings
and are charged due to the presence of certain functional groups. These features
are an obstacle to the development of new imaging agents when targeting moiety
is a small molecule. Since physiochemical properties of the dye might change the
solubility and physical properties of the dye-targeting moiety conjugate. This can
lead to a decrease in the binding affinity for the biological target. 10 The features
for the ideal signaling dye consist of the ease of attachment to the targeting
entity, effective cellular uptake, and absence of innate activity and toxicity.9 This
has led to a requirement for developing novel neutral, small, and biocompatible
fluorescent cores that demonstrate good solubility, optimal photophysical
characteristics and versatile coupling strategies.1
Over the last decade there has been a tremendous interest in the development of
dyes based on 4,4’-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY). BODIPY
dyes exhibit excellent photophysical properties including narrow absorption and
emission bands, high molar extinction coefficients and good fluorescence
quantum yields.2 Owing to all of these favourable spectral properties, BODIPY
derivatives have a wide range of applications such as chemosensors,11
sensitizers for dye sensitive solar cells,12 and in photodyanamic therapies13. A
BODIPY-NLS (nuclear localization sequences) peptide analogue has been
shown as an effective PDT agent.14 Recently, another group reported the
application of near infra-red aza-BODIPY loaded polymeric nanoparticles for
optical cancer imaging.15 Paulus and coworkers investigated the use of

18F-

BODIPY-bombesin GRP receptor PET/fluorescence imaging agent.16 Despite a
number of favourable characteristics, BODIPY derivatives suffer from some
drawbacks such as difficult synthesis and small Stokes shifts which is an
important criterion for application in fluorescence microscopy.
One class of chelating N-donor ligands that has not been studied very extensively
are the formazanate ligands. These are derived from formazans. Formazans
were first reported as 1,5-diphenyl and 1,3,5-triphenyl derivatives.17 The first
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formazan with pyridine in position 5 was synthesized in 1951 and since then a
variety of heteroarylformazans have been described in literature along with the
analysis of their metal complexation characteristics.17 Formazans can exist in
closed, open, and linear geometric isomers where the meso substituent plays an
important role in determining the conformation.17,18

closed

open

linear

Figure 4.1 Depiction of closed, open, and linear forms of formazans.

Initially, formazans were used in the dye industry and for histochemistry. More
recently some interest has been generated in the coordination chemistry of
formazans.19 A set of transition metal (such as Ni, Fe, Pd) complexes of 3cyanoformazanates and 3-nitroformazanates have been described by the Hicks
group.20 In recent times, Co,21 Zn22 and Na23 complexes of formazans have also
been reported. Lately, BF2 complexes of 3-cyanoformazanates have been
reported to demonstrate optimal optical properties including high molar extinction
coefficients, good fluorescence quantum yields, large Stokes shift, emission in
the NIR region, and absorption and emission spectra that can be tuned based on
structural modifications.18 Moreover, the synthetic route for the preparation of
BF2-formazanate complexes consists of high yielding and convenient steps
involving low cost and readily available starting materials.18
There are several examples in the literature which depict fluorescent peptides
being labeled through radiometalation. On the other hand, there are very few
illustrations of 18F labeled fluorescent tracers, due to the various challenges
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encountered during 18F labeling.24,25,26

18F/19F

isotope exchange reactions are

being explored. In this approach, the targeting molecule is altered only at a single
site that allows both PET and optical labeling. By avoiding increased steric
demand that would occur if two separate labelling sites were added, there is
reduced possibility of negatively affecting the targeting ability of the molecule.16
A significant amount of interest has been generated in the development of dual
modality imaging agents, where targeting peptides are acting as specific ligands
for the receptor. These type of imaging agents provide target accumulation and
rapid clearance from non-target tissues, leading to high contrast images.27 There
are various examples in literature where a dye-peptide conjugate has been used
for targeted cancer imaging such as 64Cu-BaAnSarRGD2-Cy5.5, which was
developed as a PET/optical tumor targeting probe.28 ɑvβ3 integrin targeted tumor
imaging was displayed using a [18F] BODIPY-RGD conjugate.29
Chemically and biologically equivalent dual modal PET/fluorescence imaging
probes provide several advantages including fast screening, direct cellular
validation, and economic analysis of the stable isotope containing compound
before scale up of the precursor and radiotracer labeling.30 Research done by
Perrin and coworkers, and Blower and coworkers, depicted boron as the site for
radiofluorination. 24,31 Keliher and coworkers reported efficient acid catalysed
18F/19F

exchange of BODIPY dyes.30 Paulus and coworkers examined

18F-

BODIPY-BBN as a gastrin releasing peptide (GRP) receptor targeting probe in
PC-3 xenograft mouse model.16 Perrin and coworkers described the application
of rhodamine-cRGD-18F-organotrifluoroborate analogue for in vivo PET and ex
vivo fluorescence imaging.24
One of the most commonly studied click reactions is the azide alkyne cycloaddition.
Copper catalysed azide alkyne cycloaddition reactions have achieved much
popularity since their discovery in 2001. In this reaction, a terminal azide and a
terminal alkyne react to form a 1,4-disubstituted 1,2,3-triazole in the presence of a
Cu(I) catalyst. There are a vast number of applications for these reactions such as
bioconjugation32, drug discovery33, hybrid materials34, and polymerization35. In the

113

past few decades, these have also been used for designing fluorophores and
radioligands for developing novel imaging agents e.g.

18F-BODIPY-azide

was

clicked onto a BBN-alkyne derivative and studied as a PET/fluorescence imaging
tool.16 In another example, rhodamine-PEG azide was coupled to an
ammoniomethyltrifluoroborate alkyne analogue using Cu(I) click chemistry yielding
a dual modal PET/fluorescent imaging probe.16 The application of click chemistry
in synthesizing octreotate based analogues showing high affinity to somatostatin
receptor has also been demonstrated in the literature.36 Lately copper free strain
promoted azide alkyne cycloaddition (SPAAC) is drawing much attention. One
such example depicts the synthesis of an EpCAM aptamer (SYL3C)-DIBO-AF594
fluorescent conjugate.37
BF2-formazanate dyes have optimal optical properties for fluorescence imaging
and can potentially be designed as radioactive analogues through 18F/19F isotope
exchange reactions. Considering these interesting features of the BF 2-formazate
dyes and the usefulness of click chemistry in coupling the targeting peptide to the
fluorescent dye as seen through literature, this study is focussed on the
development of novel BF2-formazate-peptide based PET/fluorescence imaging
probes synthesized using copper(I) catalyzed click chemistry.

4.2 Results and Discussion
4.2.1 Study of Fluorescent Properties of FMZ Dyes Using Fibroblast
Cells.
With the goal of developing BF2-formazanate-peptide based PET/fluorescence
imaging probes, the first step was to study the fluorescent properties of these
dyes in vitro. To study the fluorescence properties of the BF2-formazanate (FMZ)
dyes, mouse fibroblast cells were incubated with the dye 4.1 (previously
synthesized)38 and fluorescence images were obtained using a confocal
fluorescence microscope (Figure 4.2). It was evident from the images that the
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dye 4.1 was internalized by the cells. The cells were co-stained using the nuclear
stain DAPI. Some punctate staining could be noticed during these experiments.
This could be present because of the dye being accumulated in either the
endoplasmic reticulum and/or the vesicles.

e

f

Figure 4.2 Confocal fluorescence micrographs of mouse fibroblast cells stained
with BF2 formazanate complex 4.1 and DAPI. Images (a) and (b) were visualized
with excitation at 559 nm and emission collected between 625725 nm, while
images (c) and (d) are an overlay of images (a) and (b) with those obtained from
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excitation at 405 nm and emission collected between 425475 nm. (e) Depicts
the structure of BF2 formazante complex 4.1. (f) Depicts the structure of BF2
formazante complex 4.2
The alkyne groups present in 4.2 (previously synthesized by the Gilroy lab), can
act as a useful tool for attaching it to a targeting peptide by clicking it onto
terminal azide bearing peptides. The peptides chosen for these studies are
truncated versions of the peptide ghrelin. Ghrelin is known to have high affinity for
the GHS-R1a receptor.39 It is the N terminus of ghrelin that is important for
binding to the receptor, and any modifications here might hamper the binding
affinity significantly.40 The terminal azide on the lysine can be coupled to the
alkyne of the formazanate through click chemistry.

Figure 4.3 General structure of the targeted imaging probe.

4.2.2 Trials for 18F/19F Isotope Exchange reaction
For the synthesis of the radioactive analogue of 4.2, the 18F/19F isotope exchange
reaction was investigated. A noteworthy advantage of this method is that
additional synthesis of a non-radioactive standard is not required, as is typically
the case when developing an 18F-imaging agent. Radiofluorination can be
confirmed by comparing the HPLC radiochromatogram with the HPLC UV-trace
for the precursor 4.2, which is also acting as the non-radioactive standard since
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the only difference is that of the isotope. Purification using semi-preparative
HPLC is also not required in this method since radiofluorination does not alter the
composition of the radiotracer, both precursor and radioactive product appear at
the same retention time and cannot be separated through HPLC. Therefore, C18
Sep Pak cartridge elution should be used instead of HPLC purification. Initially,
the fluoride exchange reaction was studied in H2O/DMF under acidic conditions
at pH 2. These conditions have been found to be successful for radiofluorination
of ammoniomethyltrifluoroborate (AMBF3).2
In our case this method proved unsuccessful and no radiofluorination was evident
from the radio HPLC trace. This may be due to the instability of the dye under
acidic conditions and due to poor solubility under aqueous conditions. Next, the
radiofluorination was studied in acetonitrile (ACN). Triflic anhydride (Tf2O) and
tertiary butanol (t-BuOH) were added to the reaction mixture, generating
trifluoromethanesulfonic acid (TfOH) in situ. This along with the residual water
from the 18F was adequate to develop the acidic conditions essential for

18F

radiofluorination. The reaction was carried out at room temperature and at 60 0C
for 15 minutes. None of these attempts were successful. Next, we explored the
use of trimethylsilyl triflate (TMSOTf) as an activator. It was used to activate the
B-F bond, leading to the formation of triflate which would act as a good leaving
group for 18F to attack. Again, the reaction was studied at room temperature and
at 600C. Once again, the method was ineffective. All of these attempts are
summarized in Table 4.1.
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Precursor

Solvent

Reagent

Reagent

Reagent

Temp

Time

Yield by

(0

(min)

HPLC

85

15

0

C)

50nmol

DMF/H2O

10µmol

ACN

Tf2O

t-BuOH

r.t.

15

0

10µmol

ACN

Tf2O

t-BuOH

60

15

0

0.25µmol

ACN

Tf2O

t-BuOH

TMSOTf

r.t.

15

0

0.25µmol

ACN

Tf2O

t-BuOH

TMSOTf

60

15

0

Table 4.1 Different conditions for optimization of

18F/19F

exchange reaction of 4.2.

The use of Lewis acidic reagents for carrying out 18F/19F exchange reaction has
been shown to avoid the need of activation of B-F through formation of triflate.29
Among the various Lewis acidic reagents investigated are ZnCl2, AlCl3, AlF3, and
SnCl4, it has been seen that SnCl4 acts as a phenomenal Lewis acid activator to
aid 19F/18F isotopic exchange reactions.29
The classical method for preparation of highly nucleophilic ‘naked’

18F-,

involves

trapping [18F]fluoride on a cartridge and elution with Kryptofix [2.2.2] (K2,2,2) in the
presence of K2CO3.41 Although, K2CO3 helps in preserving the nucleophilicity of
[18F]fluoride, it might lead to some side reactions.42 Therefore, this was replaced
by TBAB (tetrabutylammonium bicarbonate) as a phase transfer catalyst. Initially,
125 µL of 0.075 M TBAB solution, 100 µL of 0.1 M SnCl4/DCM were used and the
reaction mixture was heated at 45 0C for 30 minutes. 100 µL of 0.1 M SnCl4/DCM
was added again and reaction mixture was further heated at 65 0C for another 30
minutes (Table 4.2). The reaction was analysed by HPLC (Figure 4.4). Contrary
to earlier attempts, new peaks could be seen on the radiochromatogram. These
were compared to HPLC peak corresponding to non-radioactive standard 4.2.

118

Peak A was found to be very close to the peak corresponding to actual product
but did not match with the product. Therefore, something was getting
radiolabeled but it was not our desired product. Addition of extra SnCl4/DCM and
further heating the reaction mixture led to decrease in peak A and appearance of
peak B.

Precursor

TBAB

SnCl4/DCM

Temp

Time

(µmol)

(µL)

(0.1 M)

(0 C)

(min)

1

0.1

125

100 µL

45-50

30

2

0.1

125

+100 µL

65-70

+30

Table 4.2 Conditions for 18F/19F exchange reaction of 4.2 using 0.1 M SnCl4
solution and 125 µL TBAB.

18
F radiochromatogram
19
F HPLC trace

140

18
19

0.1M SnCl4 (100 microliter) 0.025
125 microliter TBAB
450C, 30 minutes

350

A

650C, (30+30 minutes)

0.020

0.010
60

0.015

B

mV

80

Absorbance

250

0.015

mV

0.025

125 microliter TBAB

0.020

100

0.1M SnCl4(100+100 microliter)

300

200
0.010

A

150

0.005

Absorbance

120

F radiochromatogram

F HPLC trace

0.005

100

40
0.000

0.000

50

20
-2

0

2

4

6

8

10

12

14

16

-2

0

2

4

6

8

minutes

minutes

a

b

10

12

14

16

Figure 4.4 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.1 M
SnCl4 and 125 µL TBAB. Blue represents the HPLC trace for non-radioactive
standard, AU: 200-800 nm and red represents the radiochromatogram obtained
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using CsI(Tl) scintillating crystal coupled to silicon PIN diode. (a) Heating at 450 C
for 30 minutes. (b) Heating at 650 C for 30 minutes after adding extra SnCl4.

Next, we used 80 µl of 0.075 M TBAB, 100 µL of 0.1 M SnCl4/DCM and the
reaction was heated at 45 0C for 40 minutes. Reaction mixture was further heated
for 20 minutes after the addition of more (200µL) of 0.1 M SnCl4. (Table 4.3).
Again, peak A close to the product was observed (Figure 4.5).
Precursor

TBAB

SnCl4/DCM

Temp

(µmol)

(µl)

(0.1 M)

(0 C)

(min)

1

0.1

80

100 µl

45-50

30

2

0.1

80

45-50

+20

+100 µl +100 µl

Time

Table 4.3 Conditions for 18F/19F exchange reaction of 4.2 using 0.1 M SnCl4
solution and 80 µL TBAB.

18
19
1600

18
F radiochromatogram

19

F HPLC trace

A 0.1M SnCl (100 microliter)
4
0.025
80 microliter TBAB

1400

450 C, 20 minutes

1200

1000

F HPLC trace

0.1M SnCl4(100+100 microliter)
80 microliter TBAB
0
45 C, (20+20 minutes)

800

0.020

F radiochromatogram

0.025

0.020

B

400

0.010

0.005

200

0.005

0.000

0

mV

0.010

600
400

mV

0.015

Absorbance

600

0.015

B

800

Absorbance

A

1000

200
0
-2

0

2

4

6

8

minutes

a

10

12

14

16

0.000
-2

0

2

4

6

8

10

12

14

16

minutes

b

Figure 4.5 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.1 M
SnCl4 and 80 µL TBAB. Blue represents the HPLC trace for non-radioactive
standard, AU: 200-800 nm and red represents the radiochromatogram obtained
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using CsI(Tl) scintillating crystal coupled to silicon PIN diode. (a) Heating at 450 C
for 30 minutes. (b) Heating at 450 C for additional 20 minutes after adding more
SnCl4.
Next, we examined the effect of increasing the concentration of SnCl4/DCM on
radiofluorination. 0.25 M SnCl4/DCM was used and the reaction mixture was
heated at 45 0C for 25 minutes (Table 4.4). Again, peaks A and B were observed
on the radiochromatogram (Figure 4.6).

1

Precursor

TBAB

SnCl4/DCM

Temp

Time

(µmol)

(µl)

(0.25 M)

(0C)

(min)

0.25

125

100 µL

45-50

25

Table 4.4 Conditions for 18F/19F exchange reaction of 4.2 using 0.25 M SnCl4
solution and 125 µL TBAB.
18
19
180

F HPLC trace

0.25M SnCl4(100 microliter)

B

160

F radiochromatogram

450C, 25 minutes

0.020

120

0.015

A
100
0.010
80

Absorbance

140

mV

0.025

125 microliter TBAB

0.005
60
0.000

40
-2

0

2

4

6

8

10

12

14

16

minutes

Figure 4.6 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.25 M
SnCl4 and 125 µL TBAB. Blue represents the HPLC trace for non-radioactive
standard, AU: 200-800 nm and red represents the radiochromatogram obtained
using CsI(Tl) scintillating crystal coupled to silicon PIN diode.
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The next attempt was using 0.25 M SnCl4/DCM and reaction mixture was
microwaved at 40 0C for 10 minutes (Table 4.5). Again, multiple peaks were
observed (Figure 4.7).

Precursor

TBAB

SnCl4/DCM

MW

Time

(µmol)

(µL)

(0.25 M)

(0 C)

(min)

0.25

125

100 µL

40

10

1

Table 4.5 Conditions for 18F/19F exchange reaction of 4.2 using 0.25 M SnCl4
solution and 125 µL TBAB and microwave at 400 C.

18
19
450

F radiochromatogram

F HPLC trace

0.25M SnCl4(100 microliter)

400

B

0.025

125 microliter TBAB
400C, MW, 10 minutes

350

0.020

A
0.015

mV

250
0.010

200

Absorbance

300

150
0.005
100
0.000

50
-2

0

2

4

6

8

10

12

14

16

minutes

Figure 4.7 Chromatograms for 18F/19F exchange reaction of 4.2 using 0.25 M
SnCl4 and 125 µL TBAB and microwaving at 400 C. Blue represents the HPLC
trace for non-radioactive standard, AU: 200-800 nm and red represents the
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radiochromatogram obtained using CsI(Tl) scintillating crystal coupled to silicon
PIN diode.
Further 1 M SnCl4/DCM was used and reaction mixture was heated at 50 0C for
20 minutes (Table 4.6). Peak A decreased and peak B appeared as the major
peak (Figure 4.8).

1

Precursor

TBAB

(µmol)

(µL)
125

1

SnCl4/DCM

Temp

Time

(1 M)

(0 C)

(min)

100 µL

50

20

Table 4.6 Conditions for 18F/19F exchange reaction of 4.2 using 1 M SnCl4
solution and 125 µL TBAB.

18
F radiochromatogram
19
F HPLC trace
160

1M SnCl4(100 microliter)

B

0.025

125 microliter TBAB
140

500C, 20 minutes

0.020

mV

0.015
100

A

0.010

80

Absorbance

120

0.005

60

0.000

40
-2

0

2

4

6

8

10

12

14

16

minutes

Figure 4.8 Chromatograms for 18F/19F exchange reaction of 4.2 using 1 M SnCl4
and 125 µL TBAB. Blue represents the HPLC trace for non-radioactive standard,
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AU: 200-800 nm and red represents the radiochromatogram obtained using
CsI(Tl) scintillating crystal coupled to silicon PIN diode.
During most of these attempts, peak A was observed as the major peak on the
radiochromatogram. This peak is very close to the actual product. From all these
trials, it was hypothesized that although one of the

19F-

was getting exchanged

with 18F- (appearance of peak other than the peak for free 18F- on
radiochromatogram), it was possible that the other fluoride is getting replaced
with an OH- group which appeared as peak A very close to the actual F-18
product.
Since all the attempts to radiolabel BF2-FMZ dye 4.2 and develop it into a PET
imaging probe have been unsuccessful, the focus now shifted towards the
development of BF2-FMZ-peptide based targeted fluorescent imaging probes.

4.2.3 Synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ Alkyne
Analogue by Click Chemistry.
The general design of the imaging agent includes the FMZ dye as the
fluorescent/PET tag and the peptide as the targeting entity. The peptide selected
for this study was [Dpr3,Tyr8]ghrelin (1-8). The IC50 of this peptide for GHSR1a is
65.0 nM, indicating a strong affinity for the receptor. The synthesis of this imaging
probe was carried out using the copper catalysed click chemistry approach. The
FMZ dye used for this study was 4.2, which has terminal alkynes to carry out the
click reaction. For this, the peptide was synthesized with a lysine azide at the Cterminus leading to the formation of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9) compound
4.6. Initially, the trials for the click reaction were carried out using copper sulphate
and sodium ascorbate. Literature suggests that the pre catalyst for this reaction
could be Cu(II) salt that can be reduced in situ to Cu(I) species by using it in
conjunction with a reducing agent.43 Table 6 summarizes the conditions for
optimization of this reaction. All these reactions gave very poor yield (as seen by
HPLC).
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CuSO4
(eq)

NaAsc

Solvent

(eq)

Time

Temp

(hr)

(0C)

1

0.1

0.2

DMF:H2O

16

25

2

0.1

0.2

DMF:H2O

2

80

3

0.1

0.2

tBuOH:H2O

2

80

4

0.1

0.2

ACN:H2O

16

25

5

0.1

0.2

DMSO:H2O

16

25

6

0.1

0.2

DMSO:H2O

36

25

7

0.1

0.2

DMSO:H2O

2

80

Table 4.7 Different conditions for optimization of click reaction of 4.2 with
compound 4.6 using CuSO4.

Next copper(I) iodide was investigated as the source of copper for the click
reaction.44 The use of dry solvents and maintaining inert conditions during the
reaction becomes important in order to prevent the oxidation of Cu(I) species into
Cu(II). The reaction progress was analysed through HPLC. Again, the yields were
poor as seen from the HPLC traces.
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CuI

NaAsc

DIPEA

(eq)

(eq)

(eq)

Solvent

Time

Temp

Product

(hr)

(0C)

(%)
(By HPLC)

1

0.3

0.3

0.3

DMF:H2O

16

25

20

2

0.3

0.3

0.035

DMF:H2O

16

25

14

2

0.3

0.45

0.1

DMF:H2O

16

25

3

3

0.45

0.69

0.1

DMF:H2O

16

25

4

4

0.5

0.7

0.1

DMF:H2O

16

25

21

5

0.7

1.1

-

DMF:H2O

16

25

19

Table 4.8 Different conditions for optimization of click reaction of 4.2 with
compound 4.6.
At this stage, the use of a ligand became necessary. pentamethyldiethylene
triamine (PMDETA) has been demonstrated to act as an effective ligand for
copper catalysed click reactions.45,46 Hence the synthesis of
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.5 was done using CuI
and PMDETA. The result from this reaction was the best one so far. Scheme 4.1
shows the route for the synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne
analogue 4.7.
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Scheme 4.1 Route for synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne
analogue 4.7.
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4.2.4 Optical Analysis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ
Alkyne Analogue.
In order to explore the potential of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne
analogue 4.7 for fluorescence microscopy, photophysical data was obtained.
The absorption and emission wavelengths, molar extinction coefficient, Stokes
shift and fluorescence quantum yield were determined. The data is summarized
in Table 4.9. A very interesting feature of the FMZ dyes is the large Stokes shift,
which is an important criterion for application in fluorescence microscopy. The
Stokes shift of the FMZ dye increased after coupling to the peptide. Stokes shift
for the imaging probe was determined to be 138 nm. Both the absorption and
emission maxima for the click product were red shifted as compared to the FMZ
dye 4.2 (Figure 4.9). The quantum yield was also slightly increased upon clicking
the FMZ dye to the peptide.

Compound λabs (nm)

λex (nm)

λem (nm)

ε(M-1 cm-1)

Stokes

(DMSO)

(DMSO)

(DMSO)

(DMSO)

Shift

ΦF [a]
(DMSO)

(nm)

FMZ

526

471

639

33300

113

< 0.01

545

546

683

31582

138

0.04

alkyne
4.2
Analogue
4.7

Table 4.9 Photophysical data for FMZ alkyne 4.2 and
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7 : absorption,
excitation, emission maxima, molar extinction coefficient (ε), Stokes shift and
fluorescence quantum yields (ϕF).
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Slit width was 2 nm. Emission collected in the range 536-800 nm for 4.2 and 555800 nm for 4.7.[a] Quantum yields obtained using [Ru(bpy)3][PF6]2 as standard47
in deoxygenated solutions using previously reported procedure.48

4.0

12000

0.7

10000

0.6

3.5

18000
16000
14000

3.0
0.5

8000

12000

1.5
4000

0.4

10000

0.3

8000

Emission

6000

Absorbance

2.0

Emission

Absorbance

2.5

6000
0.2

1.0

4000

2000
0.5
0.0

0
400

500

600

700

800

0.1

2000

0.0

0
400

500

600

Wavelength (nm)

Wavelength (nm)

a

b

700

800

Figure 4.9 Absorption (blue), emission (red) for (a): FMZ dye 4.2. and (b):
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7. Recorded for 10-5 M
DMSO solution.

4.2.5 In Vitro Fluorescence Imaging Using OVCAR-8 Cells
Transfected With GHS-R1a.
The specific binding of analogue 4.7 for GHS-R1a was demonstrated through
confocal fluorescence microscopy. For this purpose, OVCAR-8 cells transfected
with GHS-R1a were incubated with the analogue 4.7 and fluorescence images
were obtained after washing and fixing the cells. The images depicted the cellular
uptake of 4.7 as was evident from the red emission from 4.7 (around 680nm)
(Figure 4.10a). The nuclear stain DAPI was used to visualize the nuclei (in blue).
In order to get a detailed view of cellular uptake of 4.7, 60X images were also
obtained (Figure 4.10c and 4.10d). From these images, it was evident that 4.7
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was taken up in the cytoplasm and it was possible to distinguish the nuclei
(Figure 4.10d). Parental OVCAR-8 cells (without transfection with GHSR-1a)
were used for negative control for the experiment. These cells were incubated
with 4.7 and imaged. As expected, the parental OVCAR-8 cells that did not
express GHS-R1a showed minimal uptake of 4.7 (Figure 4.10e), as these cells
do not express GHS-R1a. In order to validate the specific binding of 4.7 for GHSR1a, blocking studies were also performed, using a small molecule antagonist 36
(developed by Bayer Pharmaceutical Corporation) which has very high affinity for
GHS-R1a.49 For this purpose OVCAR-8 cells expressing the receptor were
incubated with 4.7 and 10X excess of 36. Figure 4.10g demonstrates the
displacement of 4.7 by the blocking compound.
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Figure 4.10 Confocal fluorescence micrographs of OVCAR-8 cells stained with
4.7.
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DAPI stained nuclei are shown in blue and 4.7 in red. (a) Using OVCAR-8 cells
transfected with GHS-R1a and image obtained by excitation at 559 nm and
emission collected between 598-698 nm. (b) Using OVCAR-8 cells transfected with
GHS-R1a and overlay of image obtained by excitation at 405 nm and emission
collected between 425-475 nm with image 4.10a. (c) Using OVCAR-8 cells
transfected with GHS-R1a and image obtained by excitation at 559 nm and
emission collected between 598-698 nm, using 60X objective. (d) Using OVCAR8 cells transfected with GHS-R1a and overlay of image obtained by excitation at
405 nm and emission collected between 425-475 nm with image 4.10c, using 60X
objective. (e) Using parental OVCAR-8 cells (not transfected with GHS-R1a) and
image obtained by excitation at 559 nm and emission collected between 598-698
nm. (f) Using parental (OVCAR-8 cells not transfected with GHS-R1a) and overlay
of image obtained by excitation at 405 nm and emission collected between 425475 nm with image 4.10e. (g) Using OVCAR-8 cells transfected with GHS-R1a and
blocked with 10X excess of 36 and image obtained by excitation at 559 nm and
emission collected between 598-698 nm. (h) Using OVCAR-8 cells transfected with
GHS-R1a and blocked with 10X excess of 36 and overlay of image obtained by
excitation at 405 nm and emission collected between 425-475 nm with image
4.10g. (i) Structure of compound 36 used for blocking studies.

4.2.6 Competitive Binding Assays (IC50)
In order to determine the binding affinity of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ
alkyne analogue 4.7 for the GHS-R1a receptor, the radioligand competitive
binding assays were performed. The IC50 value for [Dpr3,Tyr8] ghrelin(1-8) has
been previously reported to be 65.0 nM,50 the IC50 for
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7 was determined to be
166.4 nM (Figure 4.11). Although, attachment of FMZ dye 4.2 to the peptide led
to decrease in the binding affinity, this value was deemed acceptable as a
prototype ghrelin-FMZ conjugate for GHS-R1a. But there is certainly scope for
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improvement in the binding affinity. For this purpose, we decided to use an
alternate peptide that would have an even better IC50 value to begin with. So, the
next peptide that was selected for the further experiments was ghrelin (1-18). The
IC50 for this peptide has previously been determined to be 1.3 nM.50
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Figure 4.11 Half-maximal inhibitory concentration curve of ghrelin(1-9)-FMZ
analogue 4.7 against [125I]-human ghrelin in HEK 293/GHS-R1a cells.

4.2.7 Attempted Synthesis of Ghrelin (1-19)-FMZ Analogue 4.11 by
Click Chemistry
The synthesis of ghrelin (1-19)-FMZ analogue 4.11 was attempted following the
same route as followed for the synthesis of [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ
alkyne 4.7 analogue. In this case the click reaction was unsuccessful and did not
yield any product. Scheme 4.2 depicts the synthetic route followed for the
synthesis.
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Scheme 4.2 Route for attempted synthesis of [Dpr3,(Lys(N3))19] ghrelin(1-19)FMZ alkyne analogue 4.11.
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Some of the factors which have been shown to play a crucial role in the success
of click reaction are the choice of solvent, the source of Cu(I) species and the
presence of ligands.43 All these factors were explored and multiple trials were
carried out. Optimization of conditions for synthesis of this imaging probe was
carried out by using different solvents e.g. THF, ACN, DMF, DMF/H2O and using
different sources of copper. Other ligands were evaluated for the reaction, such
as BPDS51 (bathophenanthroline diphenyl sulphonate). But none of the trials
yielded any click product. Therefore, it was decided to discontinue with this
peptide and consider another peptide.

4.2.8 Synthesis of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ Alkyne
Analogue by Click Chemistry.
Several ghrelin (1-8) analogues have been previously synthesized where
glutamic acid at position 8 has been replaced by other amino acids and the
structure activity studies revealed that the presence of threonine at position 8
brings the IC50 value down to 3.2 nM as compared to IC50 valve of 65.0 nM for
ghrelin (1-8) having tyrosine at the 8th position.50 Therefore, using this peptide for
clicking with the BF2-FMZ dye might provide an imaging probe with a better
binding affinity for GHS-R1a. Further, as seen from the unsuccessful attempts
for clicking ghrelin (1-19) to BF2-FMZ dye, it appears that ghrelin (1-8) seems to
be an ideal peptide chain length for the click reactions. Therefore, the next
peptide to be studied was [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9) i.e. compound 4.14.
The imaging probe i.e. [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy analogue
4.16 was synthesized using the same approach as was used for the synthesis of
[Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ alkyne analogue 4.7. Scheme 4.3 shows
the route for the synthesis.
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Scheme 4.3 Route for synthesis of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ
analogue 4.16.
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4.2.9 Optical Analysis
Before moving ahead with the optical imaging using analogue 4.16, it was
important to compare the optical properties of 4.16 with the parent dye 4.15 in
order to determine whether the optical properties of this probe are suitable for
optical imaging. Therefore, photophysical data was obtained for the imaging
probe 4.16 (summarized in Table 4.10). Absorption, excitation and emission
spectra, Stokes shift, molar extinction coefficient and fluorescence quantum yield
were determined. The absorption and emission maxima were red shifted as
compared to dye 4.15 (Figure 4.12). There was a significant increase in the
fluorescence quantum yield for imaging probe 4.16 as compared to the parent
dye.

ε(M-1 cm-1)

ΦF[a]

(DMSO) (DMSO) (DMSO) Shift (nm)

(DMSO)

(DMSO)

4.15

546

467

665

119

34500

0.04

4.16

560

557

688

128

32235

0.21

Compound

λabs(nm) λex(nm)

λem(nm)

Stokes

Table 4.10 Photophysical data for FMZ alkyne 4.15 and
[Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy analogue 4.16 : absorption,
emission maxima, Stokes shift, molar extinction coefficient (ε), fluorescence
quantum yields (ϕF).
Slit width was 2 nm. Emission collected in the range 556-800 nm for 4.15 and
570-800 nm for 4.16. [a] Quantum yields obtained using [Ru(bpy)3][PF6]2 as
standard47 in deoxygenated solutions using previously reported procedure. 48
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Figure 4.12 Absorption (blue), emission (red) for (a): FMZ dye 4.15 and (b):
[Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy analogue 4.16. Recorded for 10-5
M DMSO solution.

4.2.10 In Vitro Fluorescence Imaging Using OVCAR-8 Cells
Transfected with GHS-R1a.
To demonstrate the potential of 4.16 for in vitro confocal fluorescence
microscopy, OVCAR-8 cells transfected with GHS-R1a were used. These cells
were incubated with the analogue 4.16 and fluorescence images were obtained
after washing and fixing the cells. The images depicted the cellular uptake of
4.16, as was evident from the red emission from 4.16 (around 680 nm) (Figure
4.13a). The nuclear stain DAPI was used to visualize the nuclei (in blue). To get a
more detailed view of the cellular uptake of 4.16, 60X images were also obtained
(Figure 4.13c and 4.13d). The images demonstrated the uptake of 4.16 in the
cytoplasm and at the same time the nuclei could be distinguished. Parental
OVCAR-8 cells (without transfection with GHS-R1a) were used as negative
control for the experiment. These cells were incubated with 4.16, and the images
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depicted minimal uptake of 4.16 by the parental OVCAR-8 cells since these cells
do not express GHS-R1a (Figure 4.13e).
Further to validate the specific binding of 4.16 for GHS-R1a, blocking studies
were also performed, using a small molecule antagonist 36 (developed by Bayer
Pharmaceutical Corporation) which has very high affinity for GHS-R1a.49 Figure
4.13g demonstrates the displacement of 4.16 by the blocking compound. All this
aids in confirming the specificity of 4.16 for the receptor.
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Figure 4.13 Confocal fluorescence micrographs of OVCAR-8 cells stained with
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4.16 (in red) and DAPI (in blue). (a) Using OVCAR-8 cells transfected with GHSR1a and image obtained by excitation at 559 nm and emission collected between
575-675 nm. (b) Using OVCAR-8 cells transfected with GHS-R1a and overlay of
image obtained by excitation at 405 nm and emission collected between 425-475
nm with image 4.13a. (c) Using OVCAR-8 cells transfected with GHS-R1a and
image obtained by excitation at 559 nm and emission collected between 575-675
nm, using 60X objective. (d) Using OVCAR-8 cells transfected with GHS-R1a and
overlay of image obtained by excitation at 405 nm and emission collected between
425-475 nm with image 4.13c, using 60X objective. (e) Using OVCAR-8 cells (not
transfected with GHS-R1a) and image obtained by excitation at 559 nm and
emission collected between 575-675 nm. (f) Using OVCAR-8 cells (not transfected
with GHS-R1a) and overlay of image obtained by excitation at 405 nm and
emission collected between 425-475 nm with image 4.13e. (g) Using OVCAR-8
cells transfected with GHS-R1a and blocked with 36 and image obtained by
excitation at 559 nm and emission collected between 575-675 nm. (h) Using
OVCAR-8 cells transfected with GHS-R1a and blocked with 36 and overlay of
image obtained by excitation at 405 nm and emission collected between 425-475
nm with image 4.13g.

4.2.11 Competitive Binding Assays (IC50)
In order to determine the binding affinity of [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ
methoxy analogue 4.16 for the GHS-R1a receptor, the radioligand competitive
binding assays were performed. The IC50 value for [Dpr3,Thr8] ghrelin(1-8) was
previously determined to be 3.2 nM,50 the IC50 for [Dpr3,Thr8,(Lys(N3))9]ghrelin(19)-FMZ alkyne analogue was determined to be 89.9 nM (Figure 4.14). Therefore,
compound 4.16 seems better than compound 4.7, in terms of binding affinity for
GHS-R1a.
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Figure 4.14 Half-maximal inhibitory concentration curve of ghrelin(1-9)-FMZ
analogue 4.16 against [125I]-human ghrelin in HEK 293/GHS-R1a cells.

4.2.12 Alternate Route for Synthesis of Imaging Probe
The click reaction between the FMZ dyes and the peptides were low yielding so
far, which could possibly be due to the low solubility of the peptide in THF. In
order to improve the yield, an alternate strategy was proposed. Since it was
thought that the peptide might be causing difficulties for the click reaction to
occur, the peptide should not be clicked to the FMZ dye directly. Instead, it would
be better to click the FMZ dye to just an azide such as lysine azide (which has
good solubility in THF). The resulting triazole can be loaded onto the solid
support and the peptide chain can then be built using solid-phase peptide
synthesis. Scheme 4.4 shows the proposed synthetic route for this approach.
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Scheme 4.4 Proposed alternate route for synthesis of ghrelin(1-19)-FMZ alkyne
analogue 4.20.
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The first trial for clicking lysine azide and FMZ alkyne dye was carried out using
CuI and PMDETA at room temperature for 4 hours and overnight. The reactions
were analysed through HPLC (Figure 4.15a and 4.15b respectively). The HPLC
chromatogram showed peak C corresponding to the desired product 4.17, along
with peak A, which is the product without the BF2 part i.e. compound 4.17a and
peak B in which both the alkynes on FMZ dye are getting clicked to azide part
from lysine i.e. compound 4.18. More trials were carried out by heating the
reaction at 40 0C for 4 hours and overnight. The reaction was again analysed by
HPLC. The results were quite similar to the trials done at room temperature
(Figure 4.15c and 4.15d respectively).
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Figure 4.15 HPLC chromatograms for click reaction between FMZ alkyne 4.2
and lysine azide. (a) Reaction carried out at r.t. for 4 hours. (b) Reaction carried
out at r.t. overnight. (c) Reaction carried out at 400 C for 4 hours. (d) Reaction
carried out at r.t. overnight. AU: 200-800 nm.
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Figure 4.16 Structure of compounds synthesized during click reaction between
FMZ alkyne 4.2 and lysine azide.

As can be seen by the HPLC chromatograms (Figure 4.15), both the monosubstituted species 4.17 and the di-substituted 4.18 were formed and since it
proved difficult to separate these, it was decided to use FMZ dye 4.15. This dye
would not have two terminal alkynes and instead, one of the alkynes was
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replaced by a methoxy group. Figure 4.17 shows the structure of the new FMZ
methoxy alkyne dye 4.15.

Figure 4.17 Structure of formazanate methoxy dye 4.15.

4.2.13 Stability Analysis of BF2-Formazanate Dyes
Before moving on with the peptide synthesis, the stability of the FMZ dye 4.15
under peptide synthesis conditions was evaluated. First, the stability of the FMZ
dye 4.15 in TFA (trifluoroacetic acid) which is used for the cleavage of the peptide
from the resin, was analysed. For the stability study, 20% TFA was used and the
stability was examined from the HPLC chromatogram (Figure 4.18b). The
chromatogram depicted that along with the peak corresponding to the dye, an
additional peak was also observed, which indicated that the dye is breaking down
in 20% TFA. For cleaving the peptide from the Rink amide resin, 95% TFA is
required and to cleave off the side chain protecting groups from the amino acids
comprising the peptide at least 20-30% of TFA is required. But it is clear from the
stability tests that the dye will not survive under these conditions. One solution to
this problem is to use 2-chlorotrityl chloride resin. The conditions used to cleave
the peptide from this resin are very mild, requiring only 1% TFA. Next, the
stability of the dye in 1% TFA was examined. The chromatogram depicted that
the dye was stable in 1% TFA (Figure 4.18c). Therefore, by choosing 2chlorotrityl chloride resin and carefully selecting the side chain protecting groups,
the problem associated with the stability of the dye in TFA could be overcome.
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Figure 4.18 HPLC chromatogram for stability analysis of FMZ methoxy alkyne
dye 4.15 in TFA. (a) FMZ dye 4.15 in the absence of TFA. (b) In 20% TFA. (c) In
1% TFA. AU: 200-800 nm.
Next, the stability of the dye in 20% piperidine/DMF was determined. 20%
Piperidine/DMF is needed for the removal of Fmoc (fluorenylmethyloxycarbonyl)
protecting groups from the amine during synthesis of the peptide. It was seen
from the HPLC chromatogram that along with the peak from FMZ dye 4.15, an
additional peak was also observed. Although this additional peak was small, as
we carry out peptide synthesis and go through multiple Fmoc deprotection steps
(depending upon the length of the peptide) this will greatly reduce the overall
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yield of the synthesis. Next the stability of the dye in some other bases that could
be used for Fmoc deprotection such as 5% Piperazine/DMF, Morpholine/DCM,
and DBU (1,8-diazabiclclo[5.4.0]undec-7-ene) was examined, and analyzed
through HPLC (Figure 4.19). The dye seemed to be decomposing in these bases
as well. DBU showed better results than other bases. But DBU must be used in
conjuction with piperidine in order to remove the dibenzofulvene that is formed as
a by-product during Fmoc deprotection.
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Figure 4.19 HPLC chromatograms for stability analysis of FMZ dye 4.15.
(a) in 5% Piperazine/DMF. (b) in 50% Morpholine/DCM. (c) in 50% DBU/DCM.
(d) in 2% DBU/DMF. AU: 200-800 nm.

149

The ghrelin peptide analogue used for this project has an octanoyl modification at
the Diaminopropanoic (Dpr) residue at the 3rd position. To synthesize this, we
start with Dpr that has alloc (allyloxycarbonyl) protection. After the removal of the
alloc group, the octanoyl group is coupled. For removal of the alloc group, the
peptide is treated with phenylsilane and tetrakis triphenylphosphine Pd (0) as a
catalyst. Next, the stability of the FMZ dye 4.15 under alloc deprotection
conditions was checked. The HPLC chromatogram showed multiple peaks and a
peak corresponding to FMZ dye 4.15 could not be seen (Figure 4.20). Therefore,
the dye was not stable under these conditions.
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Figure 4.20 HPLC chromatograms for stability analysis of FMZ dye 4.15 in
Phenylsilane and Tetrakis triphenylphosphine Pd(0). AU: 200-800 nm.
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4.2.14 Synthesis of [D-Phe6, β-Ala11, Phe13, Nle14] Bombesin 6-14(PEG)7-FMZ Analogue 4.23.
The results obtained from these stability analyses depict that the FMZ dye would
not be stable under the conditions used for the peptide synthesis and an alternate
strategy is desired.
Keeping all this in mind, an alternate strategy needs to be designed, where the
Fmoc deprotection step can be avoided. As well as choose a peptide which
would not involve an alloc deprotection step. For this, solution phase acid-amine
coupling strategy seemed to be a promising approach. The peptide selected for
this was bombesin analogue 4.22. Peptide bombesin is known to have high
affinity for the gastrin releasing peptide receptor that is highly expressed in a
number of cancers such as prostate,52 and breast cancer.53
The bombesin peptide chosen for this study was [D-Phe6, β-Ala11, Phe13, Nle14]
bombesin 6-14. This pan bombesin analogue is known to bind to all bombesin
receptor subtypes.54,55 To increase the distance between the dye and the
peptide and also to increase the solubility, the spacer (PEG)7N3-OH was
selected. 4.15 was clicked to (PEG)7N3-OH leading to the synthesis of compound
4.21. This was then coupled to the peptide 4.22 in solution, leading to the
synthesis of the imaging agent 4.23.
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Scheme 4.5 Route for synthesis of [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 614-(PEG)7-FMZ analogue 4.23.

4.2.15 Optical Analysis
Again, before evaluating the specific binding of analogue 4.23 for GRP-R through
optical imaging, it was essential to study the optical properties of analogue 4.23
and determine if it was a suitable candidate for optical imaging. Therefore,
photophysical data including absorption, excitation and emission spectra, Stokes
shift, molar extinction coefficient and fluorescence quantum yield were
determined and compared to the parent dye 4.15 (Table 4.11). Once again,
Stokes shift increased slightly upon coupling to the peptide. The absorption and
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emission maxima were also red shifted as compared to dye 4.15 (Figure 4.21).
There was an increase in the fluorescence quantum yield for imaging probe 4.23
as compared to the parent dye.

Compound

λabs(nm) λex(nm)

λem(nm)

Stokes

(DMSO) (DMSO) (DMSO) Shift

ε(M-1 cm-1)

ΦF[a]

(DMSO)

(DMSO)

(nm)
4.15

546

467

658

112

34500

0.04

4.23

555

544

690

135

31890

0.12

Table 4.11 Photophysical data for FMZ alkyne 4.15 and [D-Phe6, β-Ala11, Phe13,
Nle14] bombesin 6-14-(PEG)7-FMZ analogue 4.23 : absorption, emission maxima,
Stokes shift, molar extinction coefficient (ε), fluorescence quantum yields (ϕF).
Slit width was 2 nm. Emission collected in the range 556-800 nm for 4.15 and
565-800 nm for 4.23.
[a] Quantum yields obtained using [Ru(bpy)3][PF6]2 as standard47 in
deoxygenated solutions using previously reported procedure.48
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Figure 4.21 Absorption (blue), emission (red) for (a): FMZ dye 4.15 and (b): [DPhe6, β-Ala11, Phe13, Nle14] bombesin 6-14-(PEG)7-FMZ analogue 4.23.
Recorded for 10-5 M DMSO solution. AU: 200-800 nm.

4.2.16 In Vitro Fluorescence Imaging Using PC-3 Cells.
The specific binding of analogue 4.23 for GRP-R was demonstrated through
confocal fluorescence microscopy. For this purpose, Prostate cancer PC-3 cells
which have natural expression of GRP-R, were incubated with the analogue 4.23
and the fluorescence images were obtained after washing and fixing the cells.
The images depicted that 4.23 was internalized by the cells, evident from the red
emission from 4.23 (around 690 nm) (Figure 4.22a). The nuclear stain DAPI was
used to visualize the nuclei (in blue). The images depicted the uptake of 4.23 in
the cytoplasm (Figure 4.22c and 4.22d). Further, specific binding of 4.23 to GRPR was depicted through blocking studies that were performed using 10 fold
excess of peptide 4.22 which has very high affinity for GRP-R. Figure 4.22e
demonstrates the displacement of 4.23 by the blocking compound 4.22. All this
aids in confirming the specificity of 4.23 for the receptor.
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Figure 4.22 Confocal fluorescence micrographs of PC-3 cells stained with 4.23 (in
red) and DAPI (in blue). (a) Image obtained by excitation at 559 nm and emission
collected between 605-705 nm. (b) Overlay of image obtained by excitation at
405nm and emission collected between 425-475 nm with image 4.22a using 40X
objective. (c) Image obtained by excitation at 559 nm and emission collected
between 605-705 nm, using 60X objective (d) Overlay of image obtained by
excitation at 405nm and emission collected between 425-475 nm with image 4.22c,
using 60X objective. (e) PC-3 cells blocked with 10X excess of 4.22 and image
obtained by excitation at 405 nm and emission collected between 425-475 nm (f)
PC-3 cells blocked with 10X excess of 4.22 and overlay of image obtained by
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excitation at 559 nm and emission collected between 605-705 nm with image
4.22e.

4.2.17 Competitive Binding Assays (IC50)
In order to determine the binding affinity of [D-Phe6, β-Ala11, Phe13, Nle14]
bombesin 6-14-(PEG)7-FMZ analogue 4.20 for GRP-R, radioligand competitive
binding assays were performed. The IC50 value for the parent peptide [D-Phe6, βAla11, Phe13, Nle14] bombesin (6-14) was determined to be 0.7 nM, and the IC50
for [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14-(PEG)7-FMZ analogue 4.23
was determined to be 16.3 nM (Figure 4.23). Although, attachment of Fmz dye
4.15 to the peptide led to decrease in the binding affinity as compared to the
parent peptide, the IC50 value for analogue 4.23 seemed to prove that this
analogue has high binding affinity for GRP-R. The binding affinity for this imaging
probe for GRP-R was also higher than the two previously synthesized imaging
probes (4.7 and 4.16) for GHS-R1a. Analogue 4.23 is the first example of a BF2FMZ-bombesin based fluorescence imaging probe with a good binding affinity for
GRP-R.

Figure 4.23 Half-maximal inhibitory concentration curve of bombesin(7-14)-FMZ
analogue 4.23 against [125I]-bombesin in PC-3 cells.
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4.3 Conclusions
GHS-R1a and GRP-R are highly expressed in a variety of cancer types and have
the potential to be important biomarkers for cancer diagnosis. BF2-Formazanate
complexes possessing optically and electronically tunable properties have been
previously synthesized through a straightforward and high yielding synthesis,56
but have not been reported as conjugates to targeting ligands. In this study, Cu(I)
catalysed click chemistry was used to synthesize BF2-formazanate-peptide based
imaging probes targeting the protein receptors GHS-R1a and GRP-R. The
photophysical data for these novel imaging probes showed red shifted absorption
and emission wavelengths and a slight increase in Stokes shift as compared to
the parent formazanate dyes.There was an increase in fluorescence quantum
yield of imaging probe 4.16 as compared to the parent formazanate dye 4.15.
An alternate strategy involving the combination of both Cu(I) catalyzed click
chemistry and acid-amine solution phase coupling was also demonstrated to give
better yields and this strategy opened the path for improved synthesis of BF 2formazanate-peptide based imaging probes.
Attempts to carry out radiofluorination through

18F/19F

isotope exchange reactions

were unsuccessful. While the use of SnCl4 as an acid catalyst led to the formation
of the 18F labeled species, this radiolabelled material did not correspond to the
desired product. This could possibly be due to the exchange of one of the
fluorides by a hydroxide group. Such species (containing OH- and 18F- groups)
can be used for PET imaging since there is evidence of

18F/19F

exchange, but

this compound will not be identical to the compound (containing two F - groups)
used for fluorescence imaging and there will be inconsistencies between the
results from the two techniques. Nonetheless, all three imaging probes 4.7, 4.16
and 4.23 demonstrated decent fluorescent properties. Attachment of targeting
peptides to the formazanate dyes decreased the binding affinity of the resulting
imaging probes for the receptor target but the imaging probes still maintained
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sub-micromolar IC50 values. IC50 values were determined to be 166.4 nM, 89.9
nM and 16.3 nM for imaging probes 4.7, 4.16 and 4.23 respectively, which are
acceptable considering that these are the first reported examples of BF 2formazanate-peptide based fluorescence imaging agents.
The specificity for the receptors was confirmed through the fluorescence
microscopy studies demonstrating the uptake of the imaging probes by the
OVCAR-8 cells transfected with GHS-R1a for compounds 4.7 and 4.16 and by
PC3 cells for 4.23.

4.4 Experimental
Materials and Methods
All common solvents were purchased from Fischer Scientific. All Fmoc protected
amino acids, coupling agents and resins were purchased from Chem Impex,
Peptides International and Novabiochem® and were used without further
purification unless otherwise stated. All reagents were purchased from Sigma
Aldrich. Compounds 4.1,4.2,4.15 were obtained from Dr. Gilroy’s lab (previously
synthesized).38 Click reactions were performed under a nitrogen atmosphere,
using Schlenk reaction vessels. Reactants along with solvents were added to the
Schlenk vessels and inert conditions were maintained by performing freezepump-thaw cycles by freezing the reactants using liquid nitrogen and evacuating
air and filling nitrogen through the Schlenk line. [125I]-ghrelin was received from
Perkin Elmer. [18F]H218O was obtained from Dr. Mike Kovacs at the Cyclotron and
PET Radiochemistry Facility at St. Joseph’s Hospital in London, Ontario, Canada.
RP-C18 Sep-Pak SPE cartridges were purchased from Waters. For analysis of
samples, an analytical Agilent RP-C18 4.6 X 150 mm, 5 µm column was utilized.
The flow rate was 1.5 mL/min over 25 minutes. For purification of samples, a
reverse phase preparative HPLC column (Agilent RP-C18 19 X 150 mm, 5 µm)
was employed. The flow rate in this case was 20 mL/min over 15 minutes. The
gradient solvent system used were 0.1% TFA in acetonitrile (solvent A) and 0.1%
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TFA in water (solvent B). This system was provided with a Waters 600 controller,
Waters Prep degasser, Waters Mass Lynx software (version 4.1). For the studies
on UHPLC-MS, Waters Inc. Acquity UHPLC H-Class system was used. This was
used in combination with Xevo QTof mass spectrometer (ESI +, cone voltage
30V). For analytical studies, a Waters Acquity UHPLC BEH C18 2.1 X 50 mm,
1.7 µm column was utilized. The gradient solvent system employed was 0.1%
formic acid in acetonitrile (solvent C) and 0.1% formic acid in water (solvent D).
For analysing the radioactive samples, analytical SunfireTM RP-C18 4.6 X 150
mm, 5 µm column was used. The system comprised of a Waters 1525 Binary
HPLC pump with a Water 2487 dual λ absorbance detector and Breeze software
(version 3.30).

Synthesis of 4.3
Rink amide MBHA resin (192 mg, 0.100 mmol) was used as the solid support for
the peptide synthesis. Fmoc deprotection was carried out using 2 mL of 20%
Pip/DMF for two cycles (10 min, 15 min). Fmoc lysine azide (118 mg, 0.300
mmol), HCTU (124mg, 0.300 mmol) and DIPEA (105 µL, 0.600 mmol) were
dissolved in DMF (2mL) and shaken (using IKA-VIBRAX-VXR orbital shaker from
Sigma-Aldrich) for 10 min. This solution was then added to the Rink amide resin
and shaken for 16 hours at r.t. Kaiser test was used to confirm completion of
reaction.

General Synthesis of peptides
Synthesis of peptide was carried out manually employing solid phase peptide
synthesis chemistry. Peptides were synthesized on 0.1 mmol scale using Rink
amide MBHA resin (0.52 mmol/g) in peptide synthesis vessels (20 mL Poly prep
chromatography columns). Fmoc deprotection was carried out using 2 mL of 20%
Pip/DMF for two cycles (10 min, 15 min). Activation of amino acids was carried
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out using 3 eq. of HCTU, and 6 eq. of N,N-diisopropylethylamine (DIPEA) in 2
mL of DMF. The mixture was then added to the resin and shaken for 60 min.
These cycles were repeated until all N-terminal amino acids were coupled to the
resin. The deprotection of the allyloxycarbonyl group of diaminopropionic acid
(DPA) was carried out under N2 atmosphere. For maintaining N2 atmosphere, a
septum was attached to the open end of the peptide vessel and the solution was
flushed with N2. 2 mL of anhydrous DCM (dried over sieves) was added to the
resin. 24 eq. of phenylsilane (PhSiH4) was added. 0.1 eq. of
tetrakis(triphenylphosphine) palladium (0) was then added and the solution was
allowed to stir under N2 for 5 min. The peptide vessel was removed from inert
conditions and allowed to shake for two cycles (10 min, 20 min). Full deprotection
of peptide was accomplished by adding 3 mL of a mixture comprising of 95%
trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIPS), 2.5% H2O to the resin
and shaking for 4 hours. The cleaved peptide was precipitated using ice cold tertbutyl methyl ether (TBME) and centrifuged at 3000 rpm for 15 min. The
supernatant was removed and peptide pellet was dissolved in 40% ACN in H2O,
frozen at -78 0C and lyophilized to obtain a brown solid. The crude peptide was
purified using preparative HPLC-MS giving white solid with yields of 20% (200
mg, 0.159 mmol), purity 98% for 4.6, 14% (253 mg, 0.0970 mmol), purity 96% for
4.10, 17% (205 mg, 0.172 mmol), purity 98% for 4.14, 27% (223 mg, 0.165
mmol), purity 98% for 4.22. HRMS (ESI+): (for 4.6) m/z calculated for
C54H83N14O13, [M+H]+=1135.6186; observed [M+H]+= 1135.6246,(for 4.10) m/z
calculated for C102H171N36O30, [M+3H]3+=793.4320; observed
[M+3H]3+=792.9659, (for 4.14) m/z calculated for C49H81N14O13,
[M+H]+=1073.6029; observed [M+H]+=1073.6096, (for 4.22) m/z calculated for
C57H77N14O10, [M+H]+=1117.5869; observed [M+H]+=1117.5967.

Synthesis of 4.7
Dry THF (2.5 mL) was added to both pentamethyldiethylenetriamine (PMDETA)
(4.5 µL, 0.0208 mmol) and to compound 4.6 (130 mg, 0.104 mmol) in two
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different Schlenk vessels and both the solutions were degassed through three
freeze pump thaw cycles respectively. Dry CuI (4 mg, 0.0208 mmol) was then
added to the PMDETA solution and stirred at r.t. for 20 min. Compound 4.2 (36
mg, 0.104 mmol) and CuI-PMDETA solution were added to THF solution of
compound 4.6 and the reaction mixture was heated at 40 0C for 4 hours. THF
was removed using a rotary evaporator. The crude compound was dissolved in
ACN (0.1% TFA) and H2O (0.1% TFA) and purified by preparative HPLC-MS.
The fractions were combined and frozen at -78 0C and lyophilized to yield the
pure compound 6% (10 mg, 0.00600 mmol), purity 96%. HRMS (ESI+) : m/z
calculated for C72H93BF2N19O13, [M+H]+=1479.7183; observed
[M+H]+=1480.72590

Synthesis of 4.16
Dry THF (2.5 mL) was added to both PMDETA (4.5 µL, 0.0208 mmol) and to
compound 4.14 (125 mg, 0.104 mmol) in two different Schlenk vessels and both
the solutions were degassed through three freeze pump thaw cycles respectively.
Dry CuI (4 mg, 0.0208 mmol) was then added to the PMDETA solution and
stirred at r. t. for 20 minutes. Compound 4.15 (37 mg, 0.104 mmol) and CuIPMDETA solution were added to the THF solution of compound 4.14 and the
reaction mixture was heated at 40 0C for 4 hours. THF was removed using a
rotary evaporator. The crude compound was dissolved in ACN (0.1% TFA) and
H2O (0.1% TFA) and purified by preparative HPLC-MS. The fractions were
combined and frozen at -78 0C and lyophilized to yield the pure compound 7%
(11.7 mg, 0.0076 mmol), purity 98%. HRMS (ESI+) : m/z calculated for
C66H93BF2N19O14, [M+H]+=1424.7132; observed [M+H]+=1424.7237

General synthesis of 4.17 and 4.18
Dry THF (1 mL) was added to both PMDETA (10.5 µL, 0.0506 mmol) and to
Fmoc lysine azide (100 mg, 0.253 mmol) in two different Schlenk vessels and
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both the solutions were degassed through three freeze pump thaw cycles
respectively. Dry CuI (10 mg, 0.0506 mmol) was then added to the PMDETA
solution and stirred at r.t. for 20 min. Compound 4.2 (88 mg, 0.253 mmol) and
CuI-PMDETA solution were added to the THF solution of Fmoc lysine azide and
the reaction mixture was either heated at 40 0C for 4 hours and for 16 hours or
stirred at r. t. for 4 hours and 16 hours. THF was removed using a rotary
evaporator. The crude compound was analysed by analytical reverse phase
HPLC.

Synthesis of 4.21
Dry THF (2.5 mL) was added to both PMDETA (7 µL, 0.0340 mmol) and to
(PEG)7N3-OH (95 mg, 0.170 mmol) in two different Schlenk vessels and both the
solutions were degassed through three freeze pump thaw cycles respectively.
Dry CuI (6.5 mg, 0.0340 mmol) was then added to the PMDETA solution and
stirred at r. t. for 20 min. Compound 4.15 (60 mg, 0.170 mmol) and CuI-PMDETA
solution were added to the THF solution of (PEG)7N3-OH and reaction mixture
was heated at 40 0C for 4 hours. THF was removed using a rotary evaporator.
The crude compound was dissolved in ACN (0.1% TFA) and H2O (0.1% TFA)
and purified by preparative HPLC-MS. The fractions were combined and frozen
at -78 0C and lyophilized to yield the pure compound 35% (54 mg, 0.0410 mmol),
purity 99%. HRMS (ESI+) : m/z calculated for C66H93BF2N19NaO14,
[M+Na]+=928.3800 ; observed [M+Na]+= 928.3817

Synthesis of 4.23
Compound 4.21 (12 mg, 0.0132 mmol) was dissolved in dry DMF (0.5 mL).
Compound 4.22 (17.8 mg, 0.0132 mmol), HOBt hydrate (hydroxybenzotrizole)
(0.35 mg, 0.00264 mmol) and DIPEA (5 µL, 0.029 mmol) were added and the
reaction mixture was cooled to 0 0C in ice bath. After 15 minutes EDC·HCl (N-(3dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride) (3 mg, 0.0026 mmol)
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was added and the reaction mixture for left in ice bath for another 15 min. After
this the reaction mixture was stirred at r.t. for 16 hours. Solvent was removed
using a rotary evaporator. The reaction mixture was diluted with DCM and
washed with deionised water (2 X 5mL). The organic layer was isolated and dried
over sodium sulfate. DCM was evaporated using a rotary evaporator. The crude
compound was then dissolved in ACN (0.1% TFA) and H2O (0.1% TFA) and
purified by preparative HPLC-MS. The fractions were combined and frozen at -78
0C

and lyophilized to yield the pure compound 25% (7 mg, 0.00310 mmol), purity

98%. HRMS (ESI+) : m/z calculated for C96H129BF2N23O22,
[M+2H]2+=1003.4950; observed [M+2H]2+=1003.5022

Optical Analysis
UV absorption data was acquired using a Varian Carry 300 Bio UV-Vis
spectrophotometer. Excitation and emission data were acquired using a Photon
Technology International QM-4 SE spectrofluorometer. For calculating molar
extinction coefficients seven different concentrations were run for each sample.
Molar extinction coefficients were obtained from the slope of the graph of
absorbance versus concentration. The absorption, excitation and emission
wavelengths and fluorescence quantum yields were determined using DMSO as
a solvent. Fluorescence quantum yields were determined using the comparative
method described by Fery-Forgues and coworkers.48 Briefly, the absorbance for
the solutions of the unknown sample and the standard was measured. The
emission spectra were also obtained and the area under the curve was
determined. Fluorescence quantum yields were calculated using [Ru(bpy)3][PF6]2
as the standard. The quantum yield for [Ru(bpy)3][PF6]2 has been reported to be
0.095 in acetonitrile.47
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Cell Imaging Protocol
Transfection of OVCAR-8 cells
HeyA8 and OVCAR-8 human ovarian cancer cell lines were maintained in RPMI
media (Wisent) supplemented with 10% fetal bovine serum (FBS; Wisent). Cells
were seeded into 6-well tissue culture plates (Sarstedt) at 1.5 x 105 cells per 35mm well. The following day, media was changed to OptiMEM (Invitrogen)
containing 10% FBS prior to transfection. Cells were transfected with 0.5 µg of
pCMV6-GHSR1a-EGFP plasmid using LipofectAMINE 3000 (Invitrogen) as per
manufacturer’s instructions. Forty-eight hours later, cells were trypsinized and
expanded into 4 separate 100-mm tissue culture plates in RPMI/10% FBS media.
The following day, G418 Sulphate Solution (Wisent) treatment at 400 µg/mL was
started and maintained until colonies were visible. GFP-positive colonies were
visualized by indirect fluorescence using a Leica DMI 4000B inverted
microscope, isolated using cloning rings, and transferred to 24-well tissue culture
plates containing RPMI/10% FBS.

A) For 4.7 :
OVCAR-8 cells that were transfected with GHS-R1a were released from the
tissue culture flask by trypsinization and seeded onto coverslips in a 12-well
tissue culture plate at a cell density of 50000 cells/well. The cells were incubated
overnight in Roswell Park Memorial Institute medium (RPMI) containing 10% fetal
bovine serum (FBS) at 37 0C with 5% CO2. The serum containing RPMI in each
well was removed and replaced with serum free RPMI containing a concentration
of 0.1 µM of compound 4.7 and incubated at 37 0C for 1 hour. Cells were then
washed three times with phosphate buffered saline (PBS), fixed with 4%
paraformaldehyde in PBS and mounted onto slides containing Pro-Long Gold
Antifade mounting medium with DAPI. For the control experiments, parental
OVCAR-8 cells without GHS-R1a were incubated with compound 4.7. Images
were then obtained using an Olympus FluoView FV 1000 confocal microscope.
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Blocking Studies with 36
OVCAR-8 cells with GHS-R1a were released from adhesion to tissue cultured
flask. Cells were resuspended in serum free RPMI. Cells were then incubated
with 0.1 µM of compound 4.7 at 37 0C for one hour. 10 X excess of compound 36
was used as blocking compound for these studies. Cells were washed with PBS
(3 times), reseeded onto coverslips, cultured in RPMI and allowed to adhere.
Cells were washed with PBS, after being adhered to coverslips. Cells were then
fixed with 4% formaldehyde in PBS and mounted onto slides. Images were then
obtained using Olympus FluoView V 1000 confocal microscope.

B) For 4.16 :
OVCAR-8 cells that were transfected with GHS-R1a were released from the
tissue culture flask by trypsinization and seeded onto coverslips in a 12-well
tissue culture plate at a cell density of 50000 cells/well. The cells were incubated
overnight in Roswell Park Memorial Institute medium (RPMI) containing 10% fetal
bovine serum (FBS) at 37 0C with 5% CO2. The serum containing RPMI in each
well was removed and replaced with serum free RPMI containing a concentration
of 0.1 µM of compound 4.16 and incubated at 37 0C for 1 hour. Cells were then
washed three times with phosphate buffered saline (PBS), fixed with 4%
paraformaldehyde in PBS and mounted onto slides containing Pro-Long Gold
Antifade mounting medium with DAPI. For the control experiments, parental
OVCAR-8 cells without GHS-R1a were incubated with compound 4.16. Images
were then obtained using an Olympus FluoView FV 1000 confocal microscope.

Blocking Studies with 36
OVCAR-8 cells with GHS-R1a were released from adhesion to tissue cultured
flask. Cells were resuspended in serum free RPMI. Cells were then incubated
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with 0.1 µM of compound 4.16 at 37 0C for one hour. 10 X excess of compound
36 was used as blocking compound for these studies. Cells were washed with
PBS (3 times), reseeded onto coverslips, cultured in RPMI and allowed to
adhere. Cells were washed with PBS, after being adhered to coverslips. Cells
were then fixed with 4% formaldehyde in PBS and mounted onto slides. Images
were then obtained using Olympus FluoView V 1000 confocal microscope.

C) For 4.23 :
PC-3 cells were released from the tissue culture flask by trypsinization and
seeded onto coverslips in a 12-well tissue culture plate at a cell density of 50000
cells/well. The cells were incubated overnight in F-12K medium containing 10%
fetal bovine serum (FBS) at 37 0C with 5% CO2. The serum containing F-12K in
each well was removed and replaced with serum free F-12K containing a
concentration of 0.5 µM of compound 4.23 respectively and incubated at 37 0C
for 1 hour. Cells were then washed three times with phosphate buffered saline
(PBS), fixed with 4% paraformaldehyde in PBS and mounted onto slides
containing Pro-Long Gold Antifade mounting medium with DAPI. Images were
then obtained using an Olympus FluoView FV 1000 confocal microscope.

Blocking Studies with [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14.
PC-3 cells were released from adhesion to tissue cultured flask. Cells were
resuspended in serum free F-12K. Cells were then incubated with 0.5 µM of
compound 4.23 respectively at 37 0C for one hour. 10 X excess of [D-Phe6, βAla11, Phe13, Nle14] bombesin 6-14 was used as blocking compound for these
studies. Cells were washed with PBS (3 times), reseeded onto coverslips,
cultured in F-12K and allowed to adhere. Cells were washed with PBS, after
being adhered to coverslips. Cells were then fixed with 4% formaldehyde in PBS
and mounted onto slides. Images were then obtained using Olympus FluoView V
1000 confocal microscope.
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Competitive Binding Assay IC50
For 4.7 and 4.16
The affinity for GHS-R1a was determined using a radioligand binding assay.
Assays were performed using HEK293 cells transfected with GHS-R1a (obtained
from Dr. Savita Dhanvantari) as receptor source. HEK293 cells were grown in
MEM supplemented with non-essential amino acids and 10% fetal bovine serum.
For the purpose of transfecting the cells with GHS-R1a, cells were grown to 70%
confluency in a 75cm flask and transfected with GHS-R1a-pcDNA 3.1 plasmid
(Missouri S and T cDNA Resource Center) using a modified calcium phosphate
transfection protocol.57 Human [125I]-ghrelin(1-28) (PerkinElmer Inc.) as
radioligand. Human ghrelin(1-28) was used as reference to ensure the validity of
the results. Compounds 4.7 and 4.16 (at concentrations of 10-5 M, 10-6 M, 10-7 M,
10-8 M, 10-9 M, 10-10 M, 10-11 M) and [125I]-ghrelin (15,000 cpm per assay tube)
were mixed in binding buffer (25 mM HEPES, 5 mM magnesium chloride, 1 mM
calcium chloride, 2.5 mM EDTA, and 0.4% BSA, pH 7.4). A suspension of
membranes from GHS-R1a transfected HEK293S cells (50,000 cells per assay
tube) was added to the assay tube containing test peptides and [ 125I]-ghrelin(128). The resulting suspension was incubated for 20 minutes under shaking (550
rpm). Unbound [125I]-ghrelin was removed and the amount of [125I]-ghrelin bound
to the membranes was measured on a gamma counter. The IC50 was determined
by a logistic nonlinear regression analysis using Origin. All binding assays were
performed in triplicate.

For 4.23
The affinity for GRP-R was determined using a radioligand binding assay. Assays
were performed using PC-3 cells and [125I]Tyr4-bombesin (PerkinElmer Inc.) as
GRP-R specific radioligand. PC-3 cells were grown in Ham’s F-12K medium
supplemented with 10% fetal bovine serum. Compound 4.23 (30 µL, at
concentrations ranging from 10-12 to 10-6 M) and 20,0000 cpm of [125I]Tyr4-
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bombesin were mixed with the binding buffer (25 mM HEPES, 0.4% BSA, 5 mM
MgCl2, 1 mM CaCl2, 2.5 mM EDTA in H2O, pH 7.4) in 1.5 mL Eppendorf vials. A
suspension of 500,000 PC-3 cells in 50 µL binding buffer was added to each vial
to give a final volume of 300 µL. The vials were shaken at 550 rpm for 1 hour at
37 °C. Immediately after the incubation, the vials were centrifuged at 13,000 xg,
and the supernatant removed. The cell pellet was washed with 500 µL of 50 mM
Tris buffer (pH 7.4), centrifuged again, and the supernatant was removed. The
amount of [125I]Tyr4-bombesin bound to the cells was measured using a gamma
counter (Perkin-Elmer). IC50 values were determined by nonlinear regression
analysis to fit a 4-parameter dose response curve using GraphPad Prism
(Version 6.0c). All data points were obtained in triplicate.
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Chapter 5

5 Conclusions
5.1 Concluding Remarks
Molecular imaging is a rapidly expanding field which can greatly influence clinical
oncology. It not only plays a crucial role in diagnosing cancer at early stages, but
also in determining the extent of the disease, in personalizing treatment and in
studying the response to therapy.1 Despite all the recent advances in this field,
very few molecular imaging probes progress from initial discovery through to
clinical trials. To realize the true potential of molecular imaging, there is a
continuous demand for the development of new imaging probes. Designing
imaging probes with suitable pharmacokinetics is a major challenge. An ideal
imaging probe is expected to have high binding affinity for the target tissue and
minimal non-specific uptake. Combining the advantages of the different imaging
modalities can provide more useful data as compared to a single imaging
modality. The development of dual PET/optical imaging probes is highly desired
since the high sensitivity of PET can be combined with the high spatial resolution
of optical imaging methods resulting in a single probe with excellent sensitivity
and resolution.
The research in this thesis discusses the development of new targeted imaging
probes for PET/optical imaging. The major concern during the development of
multimodality imaging probes is the structural modifications that are required for
making the probe suitable for detection through the different modalities.
Porphyrins, owing to their ability to fluoresce and coordinate to metal ions, are
ideal candidates for this kind of a strategy. In this thesis, porphyrins were
explored as the imaging tag (fluorescent tag or PET isotope chelator). Previously,
a PPIX-RGD based analogue was reported that was radiolabeled with

68Ga

and

developed as a dual PET/optical probe for targeting integrins.2 Using a similar
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concept, the study in chapter 2 focussed on the development of PPIX based
imaging probe for targeting GRP-R1a. Ghrelin is a relatively new peptide being
explored for the synthesis of targeted imaging probes for the detection of cancer
and very few imaging probes have been developed based on it. So far the limited
number of ghrelin based imaging probes that have been reported in literature are
either fluorescent probes or nuclear (PET or SPECT) probes, for example, a
fluorescent ghrelin(1-18) analogue coupled to the dye fluorescein has previously
been developed.3 Other PET imaging probes comprising of ghrelin derivatives
coupled to NODAGA-68Ga, have also been reported previously.4 In another
example, 99mTc labeled ghrelin complexes were developed and were reported to
have IC50 values of around 45.0 nM.5
The ghrelin based imaging probes described in this thesis are the first of their
kind, existing as PET/optical dual imaging probes targeting GHS-R1a. 69/71GaPPIX-ghrelin(1-8) was synthesized and it was observed that Ga-coordination did
not decrease the fluorescence quantum yield of PPIX. This is a significant
achievement especially in the case of porphyrins, where a decrease in
fluorescence quantum yield has been reported in the case of some porphyrins
upon coordination to certain metal ions such as Cu2+.6 The IC50 value for 69/71GaPPIX-ghrelin(1-8) was found to be 617.1 nM, which is very poor as compared to
ghrelin (1-8), but is better than uncoordinated PPIX-ghrelin(1-8). The detrimental
effect of the chelator on the binding affinity of the peptide has been seen in the
literature. For example, the binding affinity of peptide H2 relaxin for receptor
RXFP1, was lowered upon conjugation to the chelator DTPA (diethylenetriamine
pentaacetic acid).7
PPIX, being a bulky molecule, decreases the affinity of the peptide for the protein
receptor. Although a 2,2'-(ethylenedioxy)bis(ethylamine) linker was used for
increasing the distance between PPIX and the N-terminus of ghrelin, this might
not have been sufficient. The length and the position of the linker are important
criteria that determine whether the linker will be able to mitigate the effect of the
chelator on the binding affinity of the peptide. Therefore, more studies focussing
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on the determination of the optimal linker for the conservation of binding affinity of
this peptide are needed. Choosing an appropriate linker will not only help in
improving the binding affinity of our imaging probe, but it will also aid in improving
the solubility, which has been an issue with PPIX due to its hydrophobic nature. 8,9
Nonetheless, the uptake of the imaging probe by GHS-R1a was confirmed
through fluorescence microscopy using OVCAR-8 cells transfected with the
receptor. PPIX-ghrelin (1-8) was successfully radiolabeled with 68Ga, however,
the yield for radiolabeling was low. Poor solubility of the porphyrin and instability
of the peptide at high temperature were responsible for the low radiolabeling
yields. Further optimization of the radiolabeling strategy is needed. The use of a
more appropriate (hydrophilic) linker will definitely play a vital role in improving
the radiolabeling yield. Also, it has been seen in the literature that the introduction
of PEG chains to the porphyrin molecule enhances its solubility.8 In another
report, the synthesis of hydrophilic porphyrins with cationic groups
(methylpyridinium or trimethylammonium) or anionic groups (carboxylate or
sulphonate) was carried out by attachment of polar aromatic groups to meso
positions of porphyrin through two approaches involving (1) Suzuki and (2)
Sonogashira coupling.9 Therefore, there is still scope for improving the
radiolabeling yield by improving the solubility, which likely can be achieved by
modifying the structure of the porphyrin entity by making it more hydrophilic.
In continuation of the research done with PPIX-peptide conjugates, chapter 3
discusses the use of hematoporphyrin (HP) as the fluorescent tag/metal chelator.
HP was selected as it might have better solubility than PPIX, as it is more
hydrophilic due to the presence of two isopropanol groups.

69/71Ga-HP

species

were synthesized and once again the Ga-coordination did not quench the
fluorescence of HP species. 69/71Ga-HP-AEEA-bombesin (7-14) analogues were
synthesized as potential PET/fluorescent probes for GRP-R. The purification of
these compounds was problematic as the Ga-coordination did not proceed to
completion and a mixture of Ga-coordinated and uncoordinated species was
obtained. Any further increase in temperature, led to the decomposition of HP
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into PPIX. 68Ga radiolabeling attempts, demonstrated that although the HP and
the monohydroxyethyl monovinyl deuteroporphyrin (HVD) components of the
mixture were being labeled with 68Ga, there was still unlabeled PPIX that was
present and could not be separated. A mixture of Ga-coordinated and
uncoordinated compounds cannot be used as such for imaging as these might
have different pharmacokinetics and there will be inconsistencies in the imaging
results. Therefore, it will be useful to design an alternate hydrophilic porphyrin.
There are several examples in literature that demonstrate the use of BODIPY
derivatives in the development of dual modality imaging probes. 10,11 This class of
compounds involves complex synthesis and has small Stokes shift. A new class
of compounds known as BF2-formazates can be synthesized in good yields
starting from inexpensive starting materials. Moreover, these have optimal optical
properties such as high extinction coefficients, fluorescence quantum yields and
Stokes shift which make them ideal candidates for fluorescence imaging. 12,13
There are no reports of using BF2-formazanates as imaging agents for cancer.
In order to develop these BF2-formazanate compounds as PET agents, it was
proposed that a 18F-19F exchange reaction could be used to synthesize

18F

version of these compounds. Although there was a radiolabeled compound that
appeared very close to the expected radioproduct on the HPLC
radiochromatogram, it did not match with the non-radioactive standard, indicating
that it was not the desired product. It was hypothesized that one of the fluorine
atoms might be getting exchanged with OH, which would appear at a slightly
different retention time on the radiochromatogram. Therefore, the PET imaging
analogue will consist of

18F

and OH attached to boron whereas the fluorescent

probe will have two F atoms attached to boron. These two probes might have
different pharmacokinetics and the results from fluorescence and PET imaging
might be inconsistent. This kind of compound cannot be used as dual PET/optical
probe since the structure of the probe for PET and optical imaging will be
different and this will lead to inconsistency in results.
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The proposed solution to this problem could be synthesizing new formazanate
compounds that would have one OH and one F attached to boron. This will act as
a non-radioactive standard to confirm that the radiolabeled compound contains
OH- that replaced one of the F-. Also, once this is confirmed, we will have similar
compounds (B-F-OH instead of BF2) for both PET and optical imaging.
Nonetheless, BF2-formazanate compounds were developed into novel targeted
fluorescence imaging probes for GHS-R1a and GRP-R. Two ghrelin based
peptides having an additional lysine residue at the C-terminus were attached to
BF2-formazanate dyes employing CuAAC. The role of the ligand PMDETA in
promoting these reactions was also demonstrated. The two probes that were
designed for targeting GHS-R1a were [Dpr3,Tyr8,(Lys(N3))9]ghrelin(1-9)-FMZ
alkyne compound 4.7 and [Dpr3,Thr8,(Lys(N3))9]ghrelin(1-9)-FMZ methoxy
compound 4.16. The photophysical data depicted that these probes were red
shifted as compared to the parent dyes 4.2 and 4.15 respectively. There was an
increase in the fluorescence quantum yield for probe 4.16 compared to the parent
dye 4.15 (ΦF for 4.16 was 0.21 and for 4.15 was 0.04). Further, it was observed
that the probe 4.16 which had a Thr residue replacing the Tyr residue at position
8, had a better IC50 value (IC50 for 4.16 = 89.9 nM and for 4.7 = 166.4 nM).

4.2

4.15

Figure 5.1 Structures of parent BF2-formazanate dyes 4.2 and 4.15.
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The yield for clicking the ghrelin peptides to BF2-formazanate compounds was
found to be low. Therefore, an alternate strategy, that involved (a) clicking just the
lys(N3) residue to the BF2-formazanate and (b) solution phase acid-amine
coupling reaction, was used and this resulted in an increase in the reaction yield
(35% vs 6%). Using this strategy, [D-Phe6, β-Ala11, Phe13, Nle14] bombesin 6-14(PEG)7-FMZ compound 4.23 was developed as a fluorescent imaging probe for
GRP-R. Once again, the photophysical data showed that the emission
wavelength was red shifted, there was a slight increase in the Stokes shift and an
increase in fluorescence quantum yield as compared to parent dye 4.15. (ΦF for
4.23 was 0.12 and for parent dye 4.15 was 0.04). The IC50 value for this analogue
was 16.3 nM.
Therefore, this new strategy laid the groundwork for developing novel BF 2formazanate based fluorescence imaging probes for different receptors
employing different targeting peptide sequences. The specificity for the receptors
was demonstrated through confocal fluorescence microscopy using OVCAR-8
cells transfected with GHS-R1a for GHS-R1a receptor and PC-3 cells for GRP-R.
In order to improve the IC50 values for these probes, some structural
modifications can be carried out, for example by increasing the distance between
the BF2-formazanate moiety and the N-terminus of the ghrelin peptide by the
introduction of suitable linkers or modification in the peptide sequence to obtain a
peptide with better affinity for the receptor. Structure-activity studies to determine
an ideal ghrelin sequence for binding were done earlier. But there is still potential
to optimize the appropriate ghrelin sequence that will provide better results with
BF2-formazate.
In conclusion, this thesis focussed on the development of new methods for
conjugating fluorophores such as porphyrins and BF2-FMZ dyes to biomolecules
and to radiolabel these probes with 68Ga and 18F respectively. The strategies
used for developing novel PET/fluorescence multimodality imaging probes,
eliminated the need for additional structural modification, as the same molecule
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acted as the fluorescent tag and metal chelator, which will provide consistency in
the imaging results. The methodologies established in this thesis have opened
the way for the development of imaging probes which can be designed using a
variety of peptides for targeting different receptors overexpressed in cancer.
Although there is still a need to develop improved methodology for
radiochemistry, these new classes of probes have the potential to act as effective
imaging agents and contribute to cancer imaging.
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Chapter 6
6 Appendix

6.1 Chapter 2 UPLC Traces
UPLC for 2.3: Analytical 10-70% acetonitrile in water – 4 minutes.
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UPLC for 2.4: Analytical 60-90% acetonitrile in water – 4 minutes.
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UPLC for 2.8: Analytical 35-75% acetonitrile in water – 4 minutes.
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UPLC for 2.9: Analytical 10-70% acetonitrile in water – 4 minutes
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6.2 Chapter 2 ESI+ Mass Spectrums
ESI+ Mass Spectrum for 2.3
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ESI+ Mass Spectrum for 2.4

ESI+ Mass Spectrum for 2.8
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ESI+ Mass Spectrum for 2.9

6.3 Chapter 2 IC50 Curves
IC50 Curve for 2.8
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IC50 Curve for 2.9
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6.4 Chapter 3 UPLC Traces
UPLC for 3.1-3.4: Analytical 10-70% acetonitrile in water - 4 minutes.
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UPLC for 3.7-3.10: Analytical 20-80% acetonitrile in water - 4 minutes.
hematoporphyrin-bombesin species
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UPLC for 3.11-3.13: Analytical 20-80% acetonitrile in water - 4 minutes.
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6.5 Chapter 4 UPLC Traces

UPLC for 4.6: Analytical 10-70% acetonitrile in water - 4 minutes.
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HPLC for 4.7: Analytical 50-90% acetonitrile in water - 4 minutes.
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UPLC for 4.10: Analytical 10-70% acetonitrile in water - 4 minutes.
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UPLC for 4.14: Analytical 10-70% acetonitrile in water - 4 minutes.
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UPLC for 4.16: Analytical 30-70% acetonitrile in water - 4 minutes.
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UPLC for 4.21: Analytical 10-70% acetonitrile in water - 4 minutes.
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UPLC for 4.22: Analytical 10-70% acetonitrile in water - 4 minutes.
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UPLC for 4.23: Analytical 20-80% acetonitrile in water - 4 minutes.
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6.6 Chapter 4 ESI+ Mass Spectrums
ESI+ Mass Spectrum for 4.6
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ESI+ Mass Spectrum for 4.7

ESI+ Mass Spectrum for 4.10
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ESI+ Mass Spectrum for 4.14

ESI+ Mass Spectrum for 4.16
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ESI+ Mass Spectrum for 4.21

ESI+ Mass Spectrum for 4.22
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ESI+ Mass Spectrum for 4.23

6.7 Chapter 4 IC50 Curves
IC50 Curve for 4.7
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IC50 Curve for 4.16
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